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Abstract 
Background:  
 
Amyloidosis is a rare disorder of protein folding in which a variety of 
proteins deposit as fibrils in the extracellular space. The two most commonly 
affected organs are the kidneys and heart. Deposition of amyloid in these two 
critical organs is of major prognostic importance. 
Aims:  
 
To identify the burden of systemic amyloidosis in the English population. To 
characterise the phenotype and diagnostic features of wild type transthyretin 
amyloidosis and identify the type and frequency of arrhythmic activity in cardiac 
amyloidosis. To evaluate outcome in renal amyloidosis, and assess the role of 
renal replacement therapy.  
Results and Conclusions:  
 
Amyloidosis was mentioned in 0.58/1000 deaths in England between 2000 and 
2008. Sensitivity of death certificates in identifying patients with amyloidosis was 
79%. The estimated true incidence of the disease is ~1/100000 population in 
England.  
Wild type transthyretin amyloidosis (ATTRwt) is increasingly diagnosed 
in the UK. Age of the patient at diagnosis and NT-proBNP level can aid in 
distinguishing ATTRwt from cardiac AL amyloidosis. Median survival is 
significantly better in ATTRwt than in cardiac AL amyloidosis. A positive 
troponin T, a pacemaker and NYHA class IV symptoms are all associated with 
worse outcome.  
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Complex ventricular arrhythmias are seen more frequently on Holter 
monitoring in patients with transthyretin cardiac amyloidosis compared to cardiac 
AL which are in turn more frequent than patients without myocardial amyloid 
infiltration. There does not appear to be an association between the frequency of 
complex ventricular arrhythmias and disease severity in cardiac amyloidosis. 
Renal and overall outcome in AL amyloidosis are both strongly associated 
with FLC response and are best among patients who achieve >90% suppression of 
the monoclonal component of the FLC. Survival on dialysis is improving. 
Outcome following renal transplantation is dependent on the amyloid fibril type 
and suppression of the precursor protein. 
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Chapter One: Introduction 
 
Amyloidosis is a disorder of protein folding in which various proteins auto 
aggregate in a highly abnormal fibrillar conformation.  Amyloid fibrils 
accumulate in the extracellular space, the deposits progressively disrupt the 
structure of tissues and this in turn affects organ function throughout the body.
1
 
Amyloid type is classified according to the fibril protein, and some 25 different 
proteins are known to form amyloid fibrils in vivo
2
 (Table 1.1). Deposition of 
amyloid is diverse ranging from localised deposits that can be an incidental 
finding, to a progressive and sometimes rapidly fatal systemic disease. The 
anatomical distribution and natural history vary greatly between, and sometimes 
within, fibril types. Precise pathological diagnosis and comprehensive clinical 
evaluation are imperative for appropriate clinical management.  
 
Fibril Formation and Amyloid Proteins 
 
Fibrillogenesis of amyloid remains poorly understood.  Experiments have shown 
in vitro that given specific conditions nearly any polypeptide chain can be driven 
towards misfolding and aggregation,
3
 but, relatively few proteins are 
amyloidogenic in vivo.  The polypeptides involved in amyloidosis are structurally 
diverse in their normal conformation and may be notably rich in β-sheet, α-helix 
or β-helix.4  During amyloidogenesis, multimeric proteins dissociate to their 
monomeric components, and may further be enzymatically cleaved before or 
during their conversion into amyloid fibrils.
5,6
 There are essentially three 
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circumstances in which amyloid deposition occurs.  The first is a when there is 
sustained abnormally high concentration of ‘normal’ proteins that are usually 
present at low levels, such as serum amyloid A protein (SAA) in chronic 
inflammation, underlying susceptibility to AA amyloidosis.  The second is when 
there is normal abundance of a ‘normal’, but to some extent inherently 
amyloidogenic protein over a very prolonged period, such as transthyretin in 
senile systemic amyloidosis (ATTRwt).  The third situation is the presence of an 
abnormal protein with a markedly amyloidogenic structure, such as monoclonal 
immunoglobulin light chains in AL amyloidosis and genetic variants of 
transthyretin, apolipoprotein AI and fibrinogen Aα chain etc. in hereditary 
amyloidosis.  Despite the heterogeneity of the various precursor proteins, the 
morphological structure and histochemical properties of all amyloid fibrils are 
remarkably similar.  The core structure comprises anti-parallel -strands of 
polypeptide chains lying perpendicular to the long axis of the fibril.
7
 When 
visualised with an electron microscope, amyloid fibrils are characteristically 
straight, non-branching and ~7-10nm in diameter.
8
 Amyloid deposits also contain 
the non-fibrillar normal plasma protein, serum amyloid P component (SAP),
9
 
which is bound in a reversible calcium dependent manner to a ligand present on 
all amyloid fibrils. Binding of SAP stabilizes the amyloid fibril and protects it 
from degradation by proteases and phagocytic cells in vitro.
10
 Amyloid deposits 
also contain several other common constituents such as heparan sulphate and 
dermatan sulphate proteoglycans and glycosaminoglycans (GAGs), 
apolipoprotein E, type IV collagen and laminin. Glycan molecules may also 
contribute to the stabilization of the fibrillar conformation, and may also promote 
fibrillogenesis.
11
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Table 1.1 Classification of Systemic Amyloidosis by Precursor Protein 
 
Pathogenesis of Amyloidosis and Degradation  
 
Although there is no doubt that substantial amyloid deposits disrupt organ 
function through their physical presence, it remains possible that pre-fibrillar 
amyloid aggregates may themselves have toxic effects. This hypothesis has so far 
mostly been explored in cardiac tissue.
12
 The factors which determine the pattern 
of organ involvement is not fully understood.  There can be major phenotypic 
Type Fibril Protein Precursor Clinical Syndrome 
AA Serum amyloid A protein Reactive systemic amyloidosis associated 
with chronic inflammatory diseases 
AL 
Monoclonal immunoglobulin light 
chains 
Systemic amyloidosis associated with 
monoclonal plasma cell dyscrasias 
AH 
Monoclonal immunoglobulin heavy 
chains 
Systemic amyloidosis associated with 
monoclonal plasma cell dyscrasias 
A2M 2-microglobulin 
Periarticular and, occasionally, systemic 
amyloidosis associated with long-term 
dialysis 
ATTRwt Normal plasma transthyretin Senile systemic amyloidosis with prominent 
cardiac involvement 
ATTRm Genetically variant transthyretin Familial amyloid polyneuropathy 
ACys Genetically variant cystatin C Hereditary cerebral haemorrhage with 
cerebral and systemic amyloidosis 
AGel Genetically variant gelsolin Predominant cranial nerve involvement with 
lattice corneal dystrophy 
ALys Genetically variant lysozyme Non-neuropathic with prominent visceral 
involvement 
AApoAI Genetically variant apolipoprotein AI Predominantly non-neuropathic with 
prominent viscera involvement 
AApoAII Genetically variant apolipoprotein AII Non-neuropathic with prominent renal 
involvement 
AFib 
Genetically variant fibrinogen A alpha 
chain 
Non-neuropathic with prominent renal 
involvement 
ALect 2 Leukocyte chemotactic factor 2 
Slowly progressive renal amyloid with 
nephrotic syndrome and liver involvement 
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differences between members of the same kindred with the same genetic mutation 
that encodes for a particular variant protein in hereditary forms of amyloidosis. 
One hypothesis is that once amyloid fibrils have begun to deposit a template is 
formed. The amyloid fibrils themselves act as the amyloid-enhancing factor 
(AEF). The continued supply of the precursor protein then deposits in an 
exponential manner onto the template. This theory is supported by the evidence 
that the development of AA Amyloidosis in mice is markedly accelerated when 
protein from other AA amyloid-laden mouse tissue is injected, in addition to an 
inflammatory stimulus.
13
 
Amyloid deposits are dynamic, with a continuous supply of the precursor 
protein the deposition of amyloid builds up leading to tissue damage, organ 
dysfunction and eventually death.
14
 However when the supply of precursor 
protein is suppressed deposits of amyloid can be seen to regress.
15, 16  
This has lead 
to the notion of a continuous process of amyloid ‘turnover’.17 The mechanisms by 
which amyloid is cleared from the body is not fully explained, but there is 
emerging evidence that clearance may be antibody mediated. Anti AA antibodies 
have been detected in mice that completely clear amyloid deposits.
18
 Anti-AA 
antibodies can be detected in humans with inflammatory diseases. Lower 
concentrations have been reported in patients with rheumatoid arthritis (RA) and 
AA amyloidosis compared to controls with RA alone.
19
 Peripheral administration 
of amyloid-specific antibodies has been a successful approach to reduce amyloid 
load in Alzheimer’s disease20 and AL amyloidosis.21 Degradation of amyloid is in 
part macrophage driven. Macrophage depletion with liposomal clodronate has 
been shown to slow amyloid regression.
22
 Murine macrophages have been shown 
to completely degrade Aβ-amyloid fibrils in vitro.23 Infiltration of amyloid 
Chapter 1   
 
24 
 
deposits by macrophages is followed by the formation of multinucleated giant 
cells, which surround and engulf the amyloid. Some patients are seen to have 
rapid clearance of amyloid on SAP scintigraphy when there is suppression of the 
precursor protein whereas other patients will have no regression despite complete 
suppression. It has been postulated that different phenotype and function of 
macrophages may have a role here. 
 
Epidemiology 
 
Amyloidosis is a rare condition; the incidence of the disease is not well described. 
Approximately 500 new cases are referred to the UK National Amyloidosis 
Centre (NAC) each year and it has been estimated that 0.5-1.0 deaths per 1000 in 
the UK are due to the most prevalent AL type.
24
 Very little population-based data 
are available to estimate the incidence of the disease. Kyle et al attempted to 
determine the incidence of AL amyloidosis from centralized records in Olmstead 
County. A total of 21 patients were found to have the disease during the period of 
1952-1992, the annual incidence rate was 8.9 per million person years.
25
 From 
this data the authors estimated that approximately 2225 new AL cases per year 
should occur in the USA. A group from Boston estimated the incidence of AL 
amyloidosis using mortality data. The diagnosis of the disease was made based on 
information recorded on the death certificate which might not have been specific 
to the underlying type of amyloid. The estimated incidence was as 4.5/100000.
26
  
Since 1994 there have not been any further estimates of incidence of the disease. 
Both previous reports described an increase in the incidence in the last few years 
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indicating a possible increase in the incidence of the disease or perhaps an 
improvement in detection. 
Systemic amyloidosis is likely to be under-diagnosed. One study found the 
presence of AL amyloid in 38% of screening biopsies performed in patients with 
multiple myeloma,
27
 However organ dysfunction from AL amyloidosis has only 
been estimated to complicate 3-7% of cases.
28
  
The prevalence of amyloid was estimated by the AMYPRO study 
published in 2008. This study looked at histological samples with amyloid 
staining from any tissue over a 2 year period in Eastern France. An estimated 14 
cases per million person years were found to have amyloid, 66 patients were 
identified, 40 cases (60.6%) were diagnosed with ATTRwt, 13 (19.7%) had AL 
and 9 (13.6%) showed AA staining.
29
 These histological findings contrast with the 
proportion of patients actually diagnosed with the clinical disease where by far the 
most common type is AL amyloidosis. 
Within the western world AA amyloidosis is reportedly under diagnosed. 
An autopsy study of 369 patients with RA found that the prevalence of cases 
nearly doubled from 18% of cases known to have amyloid in life to 30% at post 
mortem. Only 56% of cases where amyloid was found on renal tissue at autopsy 
had been reported to have proteinuria before death. Some deposits of amyloid 
may have therefore been incidental and subclinical or some patients may have 
been missed.
30
 
There have been several studies describing the incidence of AA 
amyloidosis secondary to specific underlying diseases. There is much variability 
between countries depending on the prevalence and treatment of inflammatory 
conditions. In developing countries where there is limited access to health care, 
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and chronic infectious diseases such as tuberculosis are common, it is likely that 
AA amyloidosis is very much under diagnosed. The incidence of AA amyloidosis 
is much lower in the United States than in Europe, although the reason for this 
remains unexplained.
31,32
 Even in cases with the same underlying disease there is 
reported variability between countries. A study of patients with Familial 
Mediterranean Fever (FMF) from 14 countries by Touitou et al in 2007, 
diagnosed 260 out of 2482 patients with AA amyloidosis. The country of 
recruitment was the main risk factor for developing amyloid.
33
 Whether this 
reflects ascertainment bias, management variation or genuine environmental or 
ethnic differences is unclear but the latter two factors seem much the most likely. 
There is a suggestion from previous work at the UK National Amyloidosis Centre 
(NAC) and from a histology series in the USA, that patients of African origin are 
relatively less likely to develop AA amyloidosis, whereas those of Mediterranean 
or Semitic origins seem over represented in the cohorts studied. Whether this 
reflects differences in predisposition to amyloidosis or to diseases which confer a 
risk of AA amyloidosis is unclear although there is data that RA is less common 
in patients of African origin. 
The incidence of hereditary amyloidosis has been little studied and varies widely 
between countries. Familial amyloid polyneuroapthy (FAP) is rare in the UK. The 
most common mutation worldwide is ATTRV30M which is well described in 
Portugal where the incidence is reported to be 3.1 x 10
-5 
with a gene carrier 
frequency of 1/1000.
34 
Disease frequency varies widely between countries and 
within kindreds.  The estimated number of carriers in Sweden was 7500 in a total 
population of 500000.
35
 The most common aetiology of FAP in the UK and 
Ireland is the T60A variant.
36 
Between 3-4% of  black individuals have the V122I 
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transthyretin variant, which is associated with a predominantly cardiac phenotype 
that is thought to be clinically indistinguishable from ATTRwt.
37
 
 
Diagnosis and Assessment of Organ Function 
 
Histology 
 
Diagnosis of amyloidosis is often made late in the course of the disease, and 
frequently as an unexpected histologic finding when a failing organ is biopsied.  
Congo red staining of tissue yielding the characteristic apple green birefringence 
under crossed polarized light remains the gold standard for confirming the 
presence of amyloid. The pathognomonic optical effect is produced by alignment 
of the dye molecules along the fibrils.  It is not a very sensitive test; sensitivity is 
dependent on several factors: the presence of an adequate amount of amyloid, use 
of sufficiently thick tissue sections, technically correct staining and visualization 
procedures, and adequate observer experience. Target organ biopsies are usually 
diagnostic; however random ‘screening’ biopsies of fat or gastro-intestinal (GI) 
tract may not be positive due to the patchy nature of the deposits. The sensitivity 
of rectal biopsies has been estimated to be between 75-94% in published series.
38
 
Fat pad biopsies are a safe and convenient screening tool but the yield can be 
low.
39
 It is therefore very important to consider the affected organs when 
performing a biopsy as this may greatly increase the rate of detection.  
After the Congo red stain confirms the presence of amyloid deposition, the 
protein composition of the amyloid fibril i.e. the type of amyloidosis, must then be 
ascertained, and this is most accessibly achieved by immunohistochemistry.  
Immunohistochemical staining of amyloid deposits can be confounded by many 
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factors including background staining and loss of antigenic determinants in the 
fibrillar conformation, this is especially true in the common AL type.   
Proteomic analyses comprising mass spectrometry on amyloid material cut 
out from tissue sections by laser capture microscopy has lately been shown to be 
effective in a large proportion of cases.
40-42
  Biopsy can be hazardous although this 
does appear to be organ specific. Significant bleeds have been reported in 5% of 
liver biopsies.  This is attributable to the increased fragility of affected blood 
vessels and reduced elasticity of severely amyloidotic organs. Renal biopsies do 
appear less hazardous with no increased incidence of bleeds reported in a large 
series of patients with amyloidosis, monoclonal gammopathy of undermined 
significance (MGUS), or myeloma.
43
  
 
Genetic Sequencing 
 
It is estimated that between 5-10% of systemic amyloidosis is hereditary. Genetic 
testing is frequently required, but the results must be interpreted in combination 
with histological and clinical findings.
44-47
 The clinical phenotype associated with 
particular mutations may vary and since penetrance is variable, patients with AL 
amyloidosis can occasionally have an incidental mutation.
48,49
 Conversely, some 
patients with hereditary amyloidosis have a potentially misleading but coincidental 
MGUS.
49, 50
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Imaging  
 
SAP Scintigraphy 
 
Various imaging techniques can make an important contribution to diagnosis and 
evaluation of organ involvement in amyloidosis.  Of these, only radio labelled 
SAP scintigraphy is specific.
51
 SAP is highly concentrated within deposits 
accounting for up to 15% of the total mass. SAP is a calcium dependent ligand 
binding protein which binds to DNA and chromatin.
52
 Following intravenous 
injection, 
123
I-SAP rapidly equilibrates between the relatively small pool of 
endogenous SAP within the circulation and much larger pool of SAP within the 
extra vascular amyloid deposits. The radio labelled SAP reversibly binds to all 
types of amyloid and localizes in proportion to the quantity of amyloid present, 
enabling deposits to be visualised in a semi quantitative manner.
53
 The dose of 
radioactivity is small; 80-90MBq for a six hour scan and 120-190MBq for a 24 
hour scan, meaning that serial scans can be safely used. SAP scintigraphy can be 
used to visualise the anatomical distribution of amyloid deposits and when used 
over time is able to detect evidence of progression or regression of deposits within 
organs.
51
 Radiolabelled SAP scintigraphy has routinely been used at the NAC 
since 1988.
51
 Scans reliably demonstrate deposits in the liver, spleen, kidneys, 
adrenal glands and bones. Unfortunately there is insufficient resolution to identify 
deposits in hollow, diffuse or very small structures such as the GI tract, skin and 
nerves. It is also unable to reliably evaluate deposits in the heart and lungs due to 
movement and blood pool content.
54
 Once patients have reached end stage renal 
failure (ESRF) uptake of the tracer into the kidneys lessens due to a reduction in 
the blood supply and deposits are often not visualized. 
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The extensive use of this technique has provided information on the 
distribution of deposits in different forms of amyloid. It is not always possible to 
obtain a suitable biopsy to prove the amyloid type histologically as some anatomic 
sites such as the spleen or adrenal glands are not readily accessible for biopsy. 
Scans have shown that the distribution of amyloid within an individual organ can 
be patchy which may explain cases of false negative biopsies. There is a 
surprisingly poor correlation between the quantity of amyloid present in a 
particular organ and the severity of organ dysfunction.
55
  
Sometimes the distribution of uptake seen on SAP scintigraphy is 
pathognomonic of a particular fibril type. For example substantial bone uptake is 
virtually always diagnostic of AL amyloidosis
51 
(Figure 1). This can be extremely 
helpful in patients who do not have biopsy proof of AL amyloidosis and may 
enable treatment to be initiated rapidly. Likewise in localized AL amyloidosis, the 
lack of visceral deposits is helpful in supporting the diagnosis which is important 
as systemic chemotherapy treatment would be inappropriate.
56
 
In a study by Hazenberg et al the distribution of deposits in AA amyloidosis 
showed deposition in the spleen in 87% of the 54 cases reviewed. Signal was seen 
in the spleen and kidneys in 35%, spleen only in 23%, spleen, kidneys and adrenal 
glands in 20%, spleen, kidneys and liver in 8% and kidneys only in 3%. In AL 
amyloidosis the distribution of deposits was much more diverse, the most 
common abnormality was also the spleen, seen in 75% of cases. Bone marrow 
uptake was seen in 21% of cases. The diagnostic sensitivity of SAP scintigraphy 
in both AA and AL types is 90%.
57
 SAP scintigraphy in hereditary systemic 
transthyretin amyloidosis (ATTRm) is often negative, however abnormal uptake 
has been seen in the spleen and kidneys, the frequency of which is dependent on 
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the underlying mutation. Renal deposits are seen on SAP scintigraphy in all 
patients with hereditary fibrinogen amyloidosis who have not yet reached ESRF, 
splenic uptake is seen in 89% and adrenal uptake in 21%
45,58
 (Figure 1.1). 
Extensive liver and spleen deposition can be seen in hereditary apolipoprotein AI 
amyloidosis; renal uptake is also commonly seen, however, this is dependent on 
the underlying disease causing mutation. Few patients with hereditary lysozyme 
amyloidosis have had SAP scintigraphy performed, the only kindred reported 
demonstrated extensive deposits in the kidneys, spleen and liver with extremely 
slow progression of deposits noted over many years.
59
 
SAP scintigraphy has demonstrated the dynamic nature of amyloid (Figure 
1.2). It has become a useful tool in monitoring the response to treatment in 
patients and in exploring the variation in the degree of suppression of the 
precursor protein needed to stabilize disease. Unfortunately SAP scintigraphy has 
not been developed commercially and is limited to a few clinical centers in 
Europe. This is due to availability issues for human SAP and I
123
 and cost of 
labeling.  
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Figure 1.1 (Left) Anterior whole body scintigraphic image following intravenous 
injection of 
123
I-human serum amyloid P in a patient with AL amyloidosis. Uptake 
is seen in the bones, a finding which is pathognomonic for AL amyloidosis, 
uptake is also seen in the liver and spleen. (Right) Posterior whole body SAP 
scintigraphic image in a patient with hereditary fibrinogen amyloidosis. Uptake is 
seen in the spleen and kidneys. 
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Figure 1.2 (Left) Anterior whole body SAP scintigraphic image in a patient with 
AA amyloidosis and end stage renal failure. Uptake is seen in the liver and spleen. 
(Right) The same patient with AA amyloidosis three years later demonstrating 
regression of amyloid deposits in the liver and spleen. 
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Cardiac Imaging 
 
The degree of cardiac amyloidosis has a massive impact on prognosis in all types 
of systemic amyloidosis. There is much interest in utilising novel ways in which 
to characterise the degree of cardiac disease using a variety of imaging modalities. 
Echocardiography has long been used to demonstrate thickening of the ventricular 
walls and valves, and to evaluate the predominant diastolic restrictive abnormality 
that occurs in cardiac amyloidosis. Cardiac involvement in AL amyloidosis is 
defined as a mean left ventricular wall thickness of >12mm in the absence of 
hypertension or other causes of left ventricular hypertrophy.
60
 Poor 
echocardiographic windows and inter-operator variability are significant 
limitations.  Cardiac magnetic resonance imaging (CMR) has lately become more 
readily available and is now utilised in widespread clinical practice. This 
technique demonstrates very characteristic late gadolinium enhancement in sub-
endocardium or in some cases more diffusely.
61,62
 Availability of CMR 
throughout the UK has led to more frequent identification of cardiac amyloidosis 
and subsequent referral to the NAC from cardiology clinic. The role of CMR for 
monitoring progression or regression of amyloid has yet to be defined, the use of 
equilibrium CMR may prove a useful tool in quantification of amyloid, a 
technique which has been validated in fibrosis,
63
 and recently in cardiac 
amyloidosis. This technique shows massive interstitial expansion in hearts with 
cardiac amyloid.
64
 
99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) 
scintigraphy has more recently proved to be a useful tool in visualising cardiac 
amyloidosis.
65 
DPD is a bone tracer used historically for bone scans. In patients 
with amyloidosis, tracer is seen to localise to the myocardium and muscles. The 
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degree of localisation and distribution appears to be different in patients with 
transthyretin amyloidosis compared to AL amyloidosis. This technique may be 
helpful in distinguishing between these two types of amyloid; the true sensitivity 
and specificity are yet to be ascertained in a large cohort of patients.
66
 The degree 
of uptake is graded according to the Perugini scoring system: Score 0 - absent 
cardiac uptake and normal bone uptake. Score 1 - mild cardiac uptake, inferior to 
bone uptake. Score 2 - moderate cardiac uptake and normal bone uptake. Score 3 - 
Strong cardiac uptake with attenuated bone uptake.
67
  
 
Cardiac Rhythm Analysis 
 
The characteristic low QRS (limb leads <5mm) with poor R wave progression in 
the chest leads (pseudo infarct pattern) is the classical description associated with 
cardiac amyloidosis, and is reported to occur in up to 50% of patients with cardiac 
AL amyloidosis.
68
 In practice a wide variety of electrocardiographic (ECG) 
changes and rhythm abnormalities are seen. In one series 21% had first degree 
atrioventricular (AV) block, 16% non specific intraventricular conduction delay 
and 3% second and third degree AV block. In the same series atrial fibrillation 
(AF) and atrial flutter was seen in 20% and 5% were reported to have non 
sustained ventricular tachycardia (NSVT).
69 
ECG patterns alone cannot 
distinguish between types of amyloid but some patterns such as left bundle branch 
block are more commonly seen in ATTRwt.
70
  
The characteristic ECG changes have historically been thought to be 
synonymous with cardiac involvement, such that the ECG has been incorporated 
into the diagnostic consensus criteria.
60
 ECG findings have been shown not to 
have prognostic implications, and yet cardiac involvement is a strong prognostic 
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feature. Current literature has found that pacemakers or implantable defibrillators 
have not prevented sudden cardiac death resulting in the hypothesis that death is 
often due to electromechanical dissociation.
71
 Defibrillator thresholds may be high 
due to the massive interstitial expansion of cardiac tissue.
72,73 
Biventricular pacing 
appears to have a limited role, theoretically this may be the ideal pacing option to 
avoid decompensation of the stiffened ventricle as a result of induced 
dyssynchrony from right ventricular pacing.
74
 There is limited literature 
describing the frequency and prognosis of rhythm disturbances in cardiac 
amyloidosis. Holter abnormalities have been shown to adversely affect survival. 
Complex ventricular arrhythmias are reportedly common but only couplets have 
been shown to be an independent predictor of survival and correlate with sudden 
death.
75
  
 
Biochemical Analysis 
 
Investigations for Clonal Disease 
 
The source of the precursor protein in systemic AL amyloidosis is excess 
monoclonal light chains, produced by an underlying clonal disorder. All patients 
with amyloidosis should therefore have investigations performed to identify if 
there is an underlying clonal disorder. A plasma cell dyscrasia is identified in 
approximately 94% of patients with AL amyloidosis.
76
 In patients seen as part of 
the ALchemy study at the NAC only one of 494 new patients with AL 
amyloidosis had no evidence of a plasma cell dyscrasia in either serum or urine 
tests.
77 
Monoclonal proteins can be detected by serum and urine electrophoresis 
and immunofixation. The fully quantitative high sensitivity serum free light chain 
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immunoassay (Freelite) has improved the sensitivity of detection of an underlying 
clone.
78
 Bone marrow examination and skeletal X-rays are required to exclude 
frank multiple myeloma.  It is important to note that the incidence of MGUS 
occurs in at least 3% of people over 50 years old, and demonstration of a plasma 
cell dyscrasia therefore does not by itself confirm amyloidosis is of AL type. In 
fact, at the NAC 9.7% of patients with hereditary amyloidosis were initially 
wrongly diagnosed with AL amyloidosis based on the detection of an underlying 
clone.
44
  
 
Serum Amyloid A Protein 
 
Amyloid fibrils in AA amyloidosis are derived from the acute phase reactant 
SAA.
79
 SAA is an apolipoprotein, which, like C-reactive protein (CRP) is 
synthesized by hepatocytes under the transcriptional regulation of 
pro-inflammatory cytokines, particularly tumor necrosis factor (TNF) alpha, 
interleukin-1 (IL-1) and interleukin-6 (IL-6).
80
 The median plasma concentration 
of SAA in health is 3 mg/l,
81
 but this can increase to over 2000 mg/l during an 
acute phase response. SAA has an inherent propensity to aggregate as amyloid 
fibrils and homozygosity for the SAA1.3 allele has been proven to be a risk factor 
for AA amyloidosis.
82
 The exact function of SAA remains unknown; there is 
speculation that its role may include modulating effects on reverse cholesterol 
transport and on lipid functions in the microenvironment of inflammatory foci. 
Under normal circumstances SAA is rapidly taken up by macrophages and 
transported to the lysosomal compartment and completely degraded. In patients 
with amyloidosis, intermediate SAA products appear to aggregate into fibrils. It is 
not known whether cleavage of SAA occurs before and/or after aggregation of 
Chapter 1   
 
38 
 
monomers during fibrillogenesis.  After deposition of accumulated intermediates 
in the extracellular space, glycosaminoglycans, SAP and lipid components bind to 
the fibril and are thought to confer resistance to proteolysis.
10, 83, 84
 The major 
determinant of whether amyloid deposits accumulate or regress is the SAA levels 
in an individual patient.
85
 Remarkably minor changes in median SAA levels are 
associated with dramatic increases in the relative risk of death. In a time updated 
analysis patients who had an annualised median SAA of between 4-9mg/L were 
found to have a fourfold increase risk of death when compared to those with an 
SAA of less than 4mg/L (i.e. almost the same as healthy blood donors); the 
greater the median SAA level the higher the relative risk of death. Higher levels 
of SAA are also associated with a risk of progression to ESRF.
86
 SAA levels are 
measured serially in order to identify the ongoing degree of inflammation in 
patients with AA amyloidosis, they act as a guide to whether the current treatment 
of the underlying disease is adequate. 
 
Cardiac Biomarkers  
 
The biomarkers N terminal pro brain natruiretic peptide (NT-Pro BNP) and 
cardiac troponins are also now widely used to provide information on cardiac 
involvement at diagnosis.
87 
The MAYO staging system has prognostic 
implications for patients with AL amyloidosis. MAYO stage I is defined as NT-
proBNP <332ng/L and Troponin T <0.035microg/L, MAYO stage II NT-proBNP 
>332ng/L and Troponin T <0.035microg/L, and MAYO stage III is defined by 
both NT-proBNP >332ng/L and Troponin T >0.035microg/L and confers the 
poorest prognosis.
88
 It is not yet determined whether this staging system is 
applicable for use in patients with transthyretin amyloidosis. 
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Renal Biomarkers 
 
Quantification of proteinuria is assessed at diagnosis and follow-up. Non Bence 
Jones proteinuria is commonly seen when there is renal involvement in systemic 
amyloidosis and, changes in proteinuria can indicate organ progression or 
response. The amount of proteinuria is extremely variable and can depend on the 
underlying fibril type. In AA amyloidosis the degree of renal impairment at 
presentation and serum albumin level have prognostic implications for both 
patient outcome and progression to ESRF.
86
  
 
Liver Function Tests 
 
The liver appears to tolerate amyloid deposition reasonably well. Organ 
dysfunction is frequently not seen despite large amounts of amyloid visualised on 
SAP scintigraphy. An elevated bilirubin is associated with a relative risk of death 
of 2.33 (95% CI 1.14 to 4.77, P = 0.02) in AL amyloidosis
89
 and is felt to be a 
terminal sign when attributed solely to amyloid infiltration.
90
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General Management Principles  
 
Excellent supportive care is vital for patients with all types of amyloidosis, in 
order to reduce the risk of complications and support organ function. This must be 
continued whilst awaiting amyloid regression in response to therapy directed at 
the underlying disease. Kidneys extensively infiltrated by amyloid are exquisitely 
vulnerable to inter-current insults such as hypo-perfusion, hypertension, 
nephrotoxic drugs and surgery, all of which should be avoided if possible. 
Nephrotic syndrome is common in renal amyloidosis. General supportive 
management is therefore primarily directed at managing the, often, extensive 
oedema. In order to create a negative sodium balance patients are advised to limit 
their sodium intake to 3g per day and to restrict their fluid intake to less than 1.5L 
per day. Diuretics are often the mainstay of medical management, loop diuretics 
may be needed in high doses. A combination of loop diuretics with either thiazide, 
or potassium sparing diuretics can also be useful.
91
 Angiotensin-converting 
enzyme (ACE) inhibitors have been shown to reduce proteinuria and reduce the 
risk of progression to ESRF in people with nephrotic syndrome.
92, 93
 There is 
limited data on whether this extends to patients with amyloidosis. One study of 44 
patients with AA amyloidosis did show a reduction of proteinuria in patients 
treated with Losartan (an angiotensin II receptor antagonist); whether this 
reduction in proteinuria confers any long term benefit in slowing renal 
progression in amyloidosis remains unknown.
94
 
Patients with nephrotic syndrome are susceptible to infection; the last 
Cochrane review updated in 2009 concluded that there was no strong evidence for 
recommending any interventions to prevent infection in patients with nephrotic 
syndrome.
95
 In AA amyloidosis due to chronic infection targeted management of 
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the disease is to prevent and treat infection in order to suppress SAA levels. 
Prophylactic antibiotics in other patients are not recommended but care must be 
taken to avoid infectious episodes if possible and patients are recommended to 
have vaccinations such as seasonal influenza, haemophilus influenza and 
pneumococcus.  
Anticoagulation remains a controversial issue in nephrotic syndrome with 
no current consensus. Patients with amyloidosis have an increased risk of 
bleeding, due to fragile vessels and there are case reports of spontaneous splenic 
rupture.
96
 Patients with very heavy proteinuria are at increased risk of thrombosis 
and the decision to anticoagulate must be made on an individual patient basis. 
General management principles apply to patients with amyloidosis for lipid 
lowering and diet as in other causes of nephrotic syndrome.  
In AA amyloidosis adrenal involvement is common, but clinical adrenal 
insufficiency is rare. Often patients are on treatment with steroids for their 
underlying disease. Addisonian symptoms may be difficult to determine as 
hypotension can be due to reduced orthostatic pressure secondary to nephrotic 
syndrome, and diuretic use can lead to hyponatraemia. It is prudent to investigate 
patients for adrenal insufficiency if there are unexplained symptoms.
97
 
Direct gastrointestinal tract infiltration can be seen in both AA and AL 
amyloidosis and chronic diarrhea can be a disabling symptom, often resistant to 
conventional therapies. Somatostatin analogs have provided relief in some case 
studies.
98, 99
 Pseudo-obstruction can occur due to amyloid deposits in the 
myenteric plexus; in general promotility agents are not often successful. There has 
been some reported success with Cisapride, a prokinetic agent that acts by 
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releasing acetylcholine from the myenteric plexus,
100  
but total parenteral nutrition 
may be needed to support the patient until bowel function improves. 
Autonomic failure can be seen in AL amyloidosis and is particularly 
difficult to manage, especially in combination with cardiac involvement or 
nephrotic syndrome.  
Management of heart failure secondary to cardiac amyloidosis is lacking 
in evidence. Patients with AL amyloidosis do not tolerate hypotension well and 
anti-hypertensive medications often need to be discontinued. There is currently no 
evidence to support or refute the use of anti-arrhythmic agents such as B-blockers 
or amiodarone in cardiac amyloidosis. Patients found to have rhythm disturbances 
secondary to amyloid are currently treated in line with general guidelines. It is 
recommended that patients found to have cardiac arrhythmias are anticoagulated, 
this is especially important in patients with AL amyloidosis who are at additional 
risk of thrombosis with some forms of chemotherapy, such as thalidomide and 
lenalidomide. When there is a history of excessive bruising or haemorrhage the 
risk of anticoagulation may however outweigh the potential benefits.  
Amyloid infiltration can be painful depending on the site. Peripheral 
neuropathy can be a direct consequence of infiltration of amyloid in the peripheral 
nerves, which can occur in AL and some forms of hereditary amyloid. Amyloid 
causes an ascending motor sensory axonal peripheral neuropathy. This is length 
dependent and invariably symptoms start in the toes and progress upwards.
101
 
Some forms of chemotherapy used to treat AL amyloidosis can also cause a 
peripheral neuropathy, this is also length dependent hence tall patients have an 
increased risk of neuropathy. Analgesics such as gabapentin, pre-gabalin and 
amitriptyline may be helpful.
102
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Dialysis 
 
Outcome on dialysis is reportedly improving. Survival on dialysis is superior in 
AA patients compared to AL.
103
 Cardiac involvement in both AL and AA 
amyloidosis is associated with worse survival.
103, 104
 Treatment with 
chemotherapy is associated with better outcomes, whilst older age and baseline 
creatinine are both associated with worse survival on dialysis in AL patients. The 
most common cause of death on dialysis is sepsis or sudden cardiac death.
104
  
 
Organ Transplantation 
 
Organ transplantation is controversial in amyloidosis for several reasons. In AL 
amyloidosis survival has historically been thought to be too poor for patients to 
benefit from an organ transplant such as a kidney. The other major concern is 
recurrent disease in the graft and subsequent graft loss. In AA amyloidosis 
infectious complications were reported in a recent French series.
105
 Deaths 
following transplantation are reported as predominantly due to infection or 
cardiovascular disease. In multivariate analysis older age and recurrent amyloid 
are both associated with an increased risk of death.  
In some hereditary forms of amyloidosis where the precursor protein is 
produced in the liver (e.g. hereditary transthyretin and fibrinogen amyloidosis), 
liver transplantation can be used as a form of gene therapy. The donor organ 
produces a wild type form of the amyloidotic precursor protein and theoretically 
no further deposition of amyloid should occur. Domino transplantation can be an 
option in ATTRm as the liver in patients with variant transthyretin does not have 
deposits of amyloid within it. It is likely to take decades for amyloid to build up in 
a recipient.  
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Types of Amyloid 
 
Localised Amyloid 
 
Localised amyloid deposition results from the local production of fibril precursor 
proteins.
106
  Most deposits are found to be  AL type, associated with foci of low 
grade monoclonal B cells which secrete monoclonal immunoglobulin light chains 
in the immediate vicinity.
107, 108
 The respiratory tract, urogenital tract, skin and 
orbits,  are the most frequent sites of deposition but all are rare.
109
 There are case 
reports of amyloid affecting almost any site ranging from intracranial 
amyloidomas,
110
  laryngeal and oropharynx amyloidomas,
111
 to localised amyloid 
of the vagina.
112
 Local resection of the ‘amyloidoma’ can sometimes be 
curative,
113
 but amyloid deposits can recur within the same site or elsewhere 
within the same tissue. Amyloid deposits that appear initially to be localised can 
sometimes be a manifestation of systemic disease, it is therefore important to fully 
investigate patients in order to exclude systemic amyloidosis.
114
 Once established 
that the amyloid deposit is a localised area, the management is dictated by the area 
involved and the degree of symptoms. Due to the extremely rare nature of the 
disease, management strategies have been somewhat experimental ranging from 
radiotherapy
115
 to carbon dioxide laser ablation.
116 
If the lesions are not causing 
symptoms then clinical surveillance may be all that is required. 
Localised masses of amyloid can be found at insulin injection sites when 
repeated administration to the same area has occurred over many years.
117
 This 
form of amyloid stains with antibodies to insulin and has been termed iatrogenic 
A-Ins type amyloid.  
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Systemic Amyloidosis 
 
Four major acquired forms of systemic amyloidosis have so far been identified 
these comprise; systemic light chain amyloidosis (AL), systemic amyloid A 
amyloidosis (AA), dialysis related amyloidosis (DRA) and senile systemic 
amyloidosis (ATTRwt). 
 
Systemic AL Amyloidosis  
 
Fibrils in AL amyloidosis are formed from fragments of monoclonal 
immunoglobulin light chains consisting of all or part of the variable domain 
(VL).
118
 AL amyloidosis is a rare complication of monoclonal gammopathies and 
can occur in association with any form of monoclonal B cell dyscrasia.
76
 The 
plasma cell proliferation fraction is usually similar to that of MGUS.
119
 
Symptomatic myeloma is unusual, approximately 15% of patients have multiple 
myeloma based on bone marrow biopsy findings.
76
 Median age at presentation is 
50-60 years and both sexes are equally affected.
76
 Presentation is extremely 
variable as almost any organ can be affected except the brain.  
Clinical suspicion of amyloidosis should be raised in any patient with 
unexplained nephropathy, cardiac failure, peripheral or autonomic failure, 
hepatomegaly or splenomegaly, or any unexplained multisystem disease. 
Approximately 50% of cases involve the kidneys presenting with proteinuria and 
frequently nephrotic syndrome. Renal histology remains the commonest tissue in 
which the disease is identified. Patients with AL amyloidosis can develop 
acquired factor X deficiency, underlying some reluctance to perform biopsies in 
patients with AL amyloidosis. Factor X assays are important in patients with 
abnormal clotting, and replacement with fresh frozen plasma prior to biopsy in 
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those who are deficient is recommended.
120
 Cardiac involvement causing heart 
failure at presentation occurs in 15-30% of cases. Symptoms of cardiac 
involvement are those of congestive cardiac failure, most commonly with 
progressive breathlessness.
76,121
 Postural hypotension is common in patients with 
cardiac involvement however this can also be a feature of autonomic nerve 
involvement or intravascular depletion due to nephrotic syndrome. Liver 
involvement is the predominant presenting feature in relatively few cases but is a 
common finding on post mortem studies with between 62-90% reported.
122
 
Hepatomegaly and elevated alkaline phosphatase (ALP) are the most frequent 
findings,
123
 which does not always correlate with the amount of amyloid 
deposited. Soft tissue involvement such as macroglossia is pathognomonic for AL 
amyloidosis and not a feature in other forms of amyloid. 
The current management of AL amyloidosis is to aim to suppress the 
production of the underlying B cell clone with chemotherapy and in turn halt the 
production of amyloidotic light chains. Evidence suggests that remission of the 
underlying clonal disease is associated with preservation of organ function and in 
some cases remission of amyloid deposits. Early identification and treatment is 
associated with improved survival.
78
 All current therapies in AL amyloidosis have 
been derived from experience in multiple myeloma, but adverse effects are far 
more frequent and severe in AL due to the multisystem nature of the disease. It is 
vitally important that an individual assessment is made for each patient and 
treatment regimens are tailored accordingly. A variety of therapies have been 
employed ranging from high dose autologous stem cell transplantation (ASCT) to 
oral based regimens. The mortality associated with ASCT is significant. In the UK 
over 10 years treatment related mortality was 23%, this fell to 13% in the second 
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half of the decade.
124
  Higher mortality is associated with the number of organs 
involved, cardiac involvement, age, performance status and serum albumin 
level.
125, 126
 
 It is also important to note that ASCT itself poses a risk of ESRF and in 
patients where preventing further renal decline is the goal of therapy this should 
be carefully considered. Conventional non transplant chemotherapy has been used 
for over 25 years in this disease and novel agents are constantly being trialled. 
Supportive management is imperative in this disease. Management of heart failure 
and nephrotic syndrome with diuretics is vital especially during treatment when 
side effects of agents such as dexamethasone and thalidomide can cause massive 
salt and water retention.  
Outcome on dialysis was previously reported to be in the order of 12 
months.
127
 Historically there has been some reluctance to dialyse patients with AL 
amyloidosis due to the perceived poor outcome and difficulty with those who 
have cardiac or autonomic involvement. Transplantation in amyloidosis has also 
been contentious due to concerns that patients may not survive long enough to 
benefit from an organ transplant and that amyloid may recur within the graft. The 
UK experience following solid organ transplantation has in fact has shown that 
very few patients develop clinically significant graft amyloidosis. In a recent 
report twenty-two patients had received renal transplants with a 67% 5 year 
survival and no graft failures due to recurrent amyloid. Fourteen patients received 
cardiac transplants with a 45% 5 year survival. In 8 patients cardiac 
transplantation was performed to enable a subsequent stem cell transplant and the 
median survival in this group was 9.7 years.
128
 It is important to appreciate that 
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these transplant recipients represent only 2% of all patients presenting with AL 
amyloidosis, i.e. a highly selected group. 
The prognosis of untreated AL amyloidosis is very poor with a median 
survival of only 6-15 months and a 10 year survival rate of <5%.
76 
The prognosis 
however is somewhat dependent on the organs involved with cardiac and 
autonomic nerve involvement conferring a particularly poor prognosis.
76,121
 In 232 
patients with cardiac involvement, patients with symptoms of congestive cardiac 
failure had shorter overall survival.
121
 Echocardiographic features in patients with 
cardiac involvement, such as shortened deceleration time and increased early 
diastolic filling velocity to atrial filling ratio, have been shown to be predictors of 
death.
129
 
Survival has significantly improved with the development of more 
therapeutic options. A recent report from the Mayo clinic showed improved 
survival rates over time with a most recent cohort from 2003-2006 having a 42% 
overall survival after 4 years.
130
 
Response to treatment is best monitored using serial serum free light 
chains in the majority of patients.  The degree of haematological response needed 
to result in the gradual net regression of amyloid varies from patient to patient, 
reflecting the differing capacity among individuals to clear their amyloid deposits. 
Studies have shown that achieving a complete clonal response (CR) in patients 
who have received ASCT have better survival outcomes,
131
 and patients who 
achieve a greater than 50% response to treatment were shown to have superior 
survival outcomes regardless of the treatment they received.
78
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Systemic AA Amyloidosis  
 
AA amyloidosis is a rare complication of chronic inflammatory conditions.  The 
fibrils in AA amyloidosis are derived from SAA. Longstanding elevation of SAA 
is a prerequisite to development of AA amyloidosis but it is rare and its incidence 
varies throughout the world. The commonest predisposing conditions in the 
Western world are the chronic inflammatory arthopathies, which account for over 
50% of cases. In the developing world reported cases are mainly associated with 
underlying infection. Patients with hereditary periodic fever syndromes are 
especially susceptible, perhaps due to the life-long nature of these inflammatory 
diseases, and this risk is substantially increased when there is a family history of 
AA amyloidosis. Other rare causes include Castleman’s disease, vasculitis and 
neoplasias such as lymphoma and mesothelioma (Table 1.2).
86
 Biopsy and post-
mortem studies have suggested a prevalence of up to 3-6% in RA,
132,133
 and 11-
13% in FMF despite availability of colchicine treatment for the latter.
134
 The 
factors that govern susceptibility to AA amyloidosis in the face of a high SAA 
concentration are yet to be determined.  Polymorphisms in the gene encoding for 
SAA1 isotype may contribute in part.
135
  
AA amyloidosis predominantly affects the kidneys, with more than 95% 
of patients presenting with proteinuria, and around 10% of patients having already 
reached ESRF at diagnosis. Splenic involvement is evident on SAP scintigraphy 
almost without exception, and deposits commonly occur in the adrenal gland, 
liver and GI tract, although usually without associated organ dysfunction.  Cardiac 
and neuropathic involvement is extremely rare.
86
 Patients with persistent 
inflammation frequently develop progressive renal dysfunction and ESRF within 
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5-10 years. Almost 60% have nephrotic syndrome at presentation, which confers a 
high risk of infection.  
Treatment will differ according to the nature of the underlying chronic 
inflammatory disorder, and there has lately been much progress with biologic 
therapies for RA etc, but progressive renal dysfunction remains common and 
ESRF occurs in up to a third of patients.  Median survival on dialysis is in the 
order of 4-5 years, which is similar to that among age-matched non-diabetic 
patients. Renal transplantation has been performed in selected cases with 
reportedly excellent outcomes. 
Patient outcome has gradually improved, with a reported median survival 
of 133 months.
86
 Outcome is poorer in association with older age, lower serum 
albumin and ESRF at presentation. Serum SAA concentration has a powerful and 
modifiable influence on outcome. Complete suppression of inflammation (SAA 
concentration persistently <5mg/L) is frequently associated with regression of 
amyloid and preservation of renal function.  
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Table 1.2 Conditions Associated with AA Amyloidosis 
 
Inflammatory Arthritis 
Adult Still’s Disease 
Ankylosing Spondilitis 
Juvenile Idiopathic Arthritis 
Psoriatic Arthropathy 
Reiter’s Syndrome 
Rheumatoid Arthritis 
Gout 
 
Chronic Infections 
Bronchiectasis 
Chronic Cutaneous Ulcers 
Chronic Pyelonephritis 
Leprosy 
Osteomyelitis 
Q Fever 
Subacute Bacterial Endocarditis  
Tuberculosis 
Whipples Disease 
 
Immunodeficiency States 
Common Variable Immunodeficiency 
Cyclic Neutropenia 
Hyperimmunoglobulin M Syndrome 
Hypogammaglobulinaemia 
Sex Linked Agammaglobulinaemia 
HIV/Aids 
 
Other Conditions Predisposing To 
Chronic Infections 
Cystic Fibrosis 
Epidermolysis Bullosa 
Injected Drug Abuse 
Jejuno-Ileal Bypass 
Kartagener’s Syndrome 
Paraplegia 
Sickle Cell Anaemia 
 
 
Hereditary Periodic Fevers 
Cryopyrin associated periodic fever 
syndrome (CAPS) 
Familial Mediterranean fever (FMF) 
Mevalonate Kinase Deficiency (MKD or 
HIDS) 
TNF receptor associated periodic 
syndrome (TRAPS) 
 
Inflammatory Bowel Disease 
Crohn’s disease 
Ulcerative colitis 
 
Neoplasia 
Adenocarcinoma of the lung, gut, 
urogenital tract 
Basal cell carcinoma 
Carcinoid tumour 
Castleman’s disease 
Gastrointestinal stromal tumour 
Hairy cell leukaemia 
Hepatic adenoma 
Hodgkin’s disease 
Mesothelioma 
Renal cell carcinoma 
Sarcoma 
 
Systemic Vasculitis 
Behcet’s disease 
Giant cell arteritis 
Polyarteritis nodosa 
Polymyalgia rheumatic 
Systemic lupus erythematosis 
Takayasu's arteritis 
 
Other 
Atrial myxoma 
Inflammatory abdominal aortic aneurism 
Retroperitoneal fibrosis 
SAPHO syndrome 
Sarciodosis 
Sinus histiocytosis with massive 
lymphadenopathy 
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Dialysis Related Amyloidosis  
 
Dialysis related amyloidosis (DRA) is a complication of long-term dialysis 
following ESRF. The underlying fibril is due to β2-microglobulin (β2M) which is 
the light chain component of the major histocompatibility complex (MHC) class 1 
molecule. It is synthesized in all cells that express MHC class 1 molecules.
136
 
β2M is cleared from the body by the kidney. It is freely filtered by the glomerulus 
and reabsorbed by the proximal tubular cells.
137
 When patients develop ESRF, 
β2M accumulates and the circulating concentration rises from normal levels (1-
2mg/L) to ~50-70 mg/L. Most cases present clinically after 10 years on dialysis 
and this form of amyloid has a tropism for osseo-articular surfaces. Symptoms of 
DRA manifest as carpal tunnel syndrome, arthralgia, spondyloarthopathy, 
subchondral bone cysts and fractures. Whilst modern high flux dialysis techniques 
may have reduced the incidence of β2M amyloidosis, renal transplantation 
remains the only effective treatment in reducing the symptoms of established 
disease.
138
 
 
Senile Systemic Amyloidosis, Wild Type Transthyretin 
Amyloidosis  
 
Wild type transthyretin amyloidosis (ATTRwt) also known as senile systemic or 
senile cardiac amyloidosis is a disease of the elderly which usually affects men. 
The fibril is composed of normal wild-type transthyretin.
139
 Amyloid deposits of 
this type are found at autopsy in about 25% of patients over age 80, with 
predominant involvement of the heart.
140
 Non-clinically significant deposits are 
frequently present in other sites including the lungs, gut, bladder and small 
arteries in many other tissues.
141
 A relatively small proportion of patients with 
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wild-type transthyretin amyloid deposits present with clinical disease, and among 
those who do, most present with restrictive cardiomyopathy and congestive 
cardiac failure. Wild type transthyretin derived amyloid has been found in 
specimens following carpal tunnel release surgery,
142
 which often precedes 
cardiac manifestations.
143
 Echocardiography demonstrates a markedly thickened 
myocardium, which is typically greater than in AL amyloidosis. In a study of 18 
patients with ATTRwt the mean interventricular septum thickness was 17.8mm in 
the ATTRwt group as compared to 14.3mm in the AL group (P=0.002).
144
 
Identification of ATTRwt has lately increased due to the advent of CMR imaging, 
but definitive diagnosis continues to rest on endomyocardial biopsy confirming 
amyloid of transthyretin type in conjunction with wild-type TTR gene 
sequence.
145 
There is limited data regarding the natural history and outcome of the 
disease, with current series limited by small numbers of patients. Progression of 
heart failure appears to be slow with much better median survival than AL 
amyloidosis.
144 
The mainstay of management is supportive care and symptomatic 
management of heart failure with fluid restriction, low salt diet and diuretics.  
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The Hereditary Systemic Amyloidoses 
 
Hereditary amyloidosis is a group of diseases due to mutations in different 
specific proteins. All are autosomal dominant but penetrance is variable and there 
is often no family history. Age of onset, disease penetrance and phenotype vary 
widely between different mutations and even within kindreds, presenting a 
challenge for genetic counselling. Hereditary systemic amyloidosis can be divided 
into neuropathic and non-neuropathic forms. The former comprise FAP, usually 
caused by mutations in the transthyretin gene (ATTR) and gelsolin amyloidosis 
(AGel). Non-neuropathic forms include fibrinogen A-chain amyloidosis (AFib), 
apolipoprotein AI amyloidosis (AApoAI), apolipoprotein AII amyloidosis 
(AApoA11), and lysozyme amyloidosis (ALys). 
 
Hereditary Transthyretin Amyloidosis (ATTRm, Familial 
Amyloid Polyneuropathy) 
 
The most common type of hereditary amyloidosis worldwide is associated with 
mutations in the gene for transthyretin. There are some 100 point mutations 
associated with the clinical syndrome, which is typically characterized by 
progressive peripheral and autonomic neuropathy.  Cardiac amyloidosis is 
frequent, as are varying degrees of amyloid deposition in the viscera, vitreous, 
gut, and occasionally the central nervous system.
146,147
 Clinical presentation is 
typically from the third decade, though this varies dependent upon the specific 
mutation.
148,149
   
Transthyretin is a transport protein that circulates in a tetrameric form. 
More than 95% of transthyretin is produced in the liver, with the remainder 
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produced in the choroid plexus and retina.
101,150
 The most common transthyretin 
mutation involves the substitution of methionine for valine at position 30 
(ATTRV30M). This usually presents with an ascending sensorimotor peripheral 
neuropathy, and unlike most other mutations, cardiac involvement is rare. The 
disease typically develops by age 30-40 years in the Portuguese focus, but about 
20 years later in the Swedish one. The most common aetiology of FAP in the UK 
and Ireland is the T60A variant.
36
 This usually presents after the age of 50 and 
often with autonomic symptoms, but cardiac amyloid is virtually always present at 
diagnosis.
151
 3-4% of black individuals have the V122I transthyretin variant, 
which is associated with a predominantly cardiac phenotype that is clinically 
indistinguishable from ATTRwt; it usually presents after age 60 and is not 
associated with neuropathy.
37
  
TTR amyloidosis has become a particular focus for development of novel 
anti-amyloid therapies, both with a view to stabilizing soluble TTR in the blood 
and inhibiting its production through silencing RNA and anti-sense 
oligonucleotide approaches.  Several strategies have already progressed to clinical 
trial.  However, the only therapy that has been adopted into widespread clinical 
practice is orthotopic liver transplantation (OLT). This technique was introduced 
in 1990 on the basis that almost all mutant TTR is produced in the liver.
152, 153
 
Since this date over 700 transplants have been performed. The Familial Amyloid 
Polyneuropathy World Transplant Registry reported seven years of registry data 
in 2003, the most common mutation was ATTRV30M representing 83% of cases 
and 5 year survival was significantly better in this group when compared to 
patients with non-ATTRV30M mutations (79% vs. 56% respectively, P<0.001). 
Symptoms of peripheral neuropathy were reported to gradually improve in up to 
Chapter 1   
 
56 
 
50% of cases,
154
 with better outcomes associated when transplantation is 
performed earlier on in the course of the clinical disease.
151
 OLT remains 
controversial; cardiovascular death is higher in patients with FAP as compared to 
other indications for liver transplantation, and progression of cardiac amyloidosis 
can occur afterwards due to on-going deposition of wild-type TTR in this 
particular anatomical site.
155, 156
 The indications, timing and outcome of OLT for 
FAP remains unclear. This is especially true in patients with non-ATTRV30M 
mutations who already have cardiac amyloid deposits.   
 
Hereditary Gelsolin Amyloidosis (AGel) 
 
Hereditary amyloidosis of the Finnish type, in which the amyloid fibrils are 
derived from cleavage fragments of variant gelsolin, was first described by the 
Finnish ophthalmologist Jouko Meretoja in 1969.
157
 This disease has since been 
reported in various other countries but the largest population remains in Finland.  
Two variants have been found, G654A and G654T. The G654A type has been 
reported in Portugal, Japan and Iran, whereas patients with the G654T variant 
have been reported in Denmark, the Czech Republic and France.
158
 Gelsolin is an 
actin-modulating protein that enhances migration of cells. Mutated gelsolin is 
unable to bind calcium ions and it is thought that this may render it more prone to 
proteolysis and subsequent fibril formation.
159-161
  
Typical presentation is with corneal lattice dystrophy during early middle-
age with subsequent development of a slowly progressive but very disabling and 
deforming cranial neuropathy.
162
 Life expectancy is near normal. Substantial renal 
amyloid deposits are present at an early stage; interestingly there is usually no 
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associated clinical evidence of visceral involvement. Rare cases of homozygous 
mutations have been reported with a rapid decline and renal failure.
163
 
 
Fibrinogen A-Chain Amyloidosis (AFib) 
 
Hereditary fibrinogen amyloidosis (AFib) is the most common cause of hereditary 
renal amyloidosis in the UK, it was first characterized in a Peruvian kindred in 
1993.
164
 Disease penetrance is variable and a family history is very often absent.  
To date, nine amyloidogenic mutations in fibrinogen have been identified with the 
E526V variant being the most common.  Presentation is universally with 
proteinuria and renal impairment and the diagnosis is therefore almost always 
made on renal biopsy. Histological findings show a characteristic picture of 
massive glomerular amyloid infiltration with almost complete obliteration of the 
normal architecture but little or no vascular or interstitial deposits. Hypertension is 
common.  Extra-renal amyloid deposits are usually evident in the spleen and 
sometimes adrenal glands on radiolabelled 
123
I-labelled SAP scintigraphy. Liver 
involvement is rare, but can in some cases, be clinically significant.
45
 Cardiac 
involvement has been reported in a few non-E526V associated cases. Presentation 
typically occurs around age 60 years, with progression to ESRF within about 5 
years from diagnosis.  The absence of clinically significant extra-renal disease is 
consistent with median survival from presentation of 15 years.
45
 
Median graft survival following isolated renal transplantation is 
approximately seven years, recurrent amyloid disease is the main cause of graft 
loss beyond this stage. On the basis that the amyloidogenic protein is produced 
exclusively by the liver, combined liver and renal transplantation has been offered 
to some younger patients who have developed ESRF. Whilst further amyloid 
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deposition is prevented by these means, and long term outcome can be excellent, 
there has been substantial early mortality. Three out of nine reported cases died 
due to complications of surgery.
165
   
 
Hereditary Apolipoprotein AI Amyloidosis (AApoAI) 
 
Apolipoprotein AI is produced in the liver and intestines, and is catabolised in the 
liver and kidneys. It is the predominant protein in high density lipoprotein
166
 and 
plays a key role in reverse cholesterol transport.
167
 Whilst tiny wild-type 
apolipoprotein AI-derived (AApoAI) amyloid deposits have been identified in
 
atherosclerotic plaques, some 13 variants have been associated with major 
visceral amyloidosis, i.e. hereditary systemic amyloidosis. The pathogenesis 
involves proteolytic cleavage, with the amino terminal 83-93 residues typically 
being incorporated into the amyloid fibrils.
168 
 Currently, of the more than 50 
ApoAI variants
 
known, 13 are associated with amyloidosis.
169
 Different mutations 
are associated with a variety of phenotypes and again there is marked variability 
even within families which makes genetic counselling extremely challenging. The 
most common manifestation is renal involvement with subsequent chronic renal 
failure but there may also be significant neurological, cardiac, and hepatic 
dysfunction. The phenotype of the following six variants: Gly26Arg, Trp50Arg, 
Leu60Arg, Del70-72, Leu75Pro and Leu64Pro is characterized by renal 
manifestations in association with extensive visceral amyloid deposits and 
hepatosplenomegaly. Clinical presentation is usually with hypertension and 
proteinuria between 18 and 55 years of age. Patients with the Leu75Pro variant 
have reportedly presented as late as their seventh decade and survived into their 
90s.
50, 170
 Progression of renal impairment is slow with a median time to ESRF 
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from presentation of eight years in one series. A large load in the liver frequently 
occurs in association with elevated serum ALP and gamma-glutamyl 
transpeptidase (GGT), but synthetic function is rarely affected and usually is a late 
feature after many years of progressive amyloid deposition, and fulminant hepatic 
failure is extremely rare.
171
 Several ApoAI variants (Leu90Pro, Arg173Pro, 
Leu174Ser and Leu178His) are associated with skin and cardiac amyloid deposits 
with death usually occurring due to progressive cardiomyopathy within 10 years 
of diagnosis.
172-175
 
It is thought that at least 50% of ApoAI is produced in the liver.
176
 Liver 
transplantation has been associated with regression of extra-hepatic amyloid in a 
number of cases,
177
 the reduction in supply of variant ApoAI by around 50% can 
be sufficient to alter the balance of amyloid deposition and its natural turnover in 
favour of regression.  ApoAI amyloidosis is a slowly progressive disorder and 
reports following renal transplantation have shown remarkable graft survival, 
frequently exceeding 10-15 years despite histological evidence of recurrent 
amyloid in the transplanted organ.
176
 Liver transplantation has been performed 
very rarely, but would appear to have the potential to benefit patients with extra-
renal amyloidosis, notably peripheral nerve and cardiac involvement, or those 
with progressive liver dysfunction. 
 
Apolipoprotein AII Amyloidosis (AApoAII) 
 
Apo AII amyloidosis was first described by Weiss and Page in 1973.
178
 It is the 
second most abundant HDL apolipoprotein. Four amyloidogenic mutations have 
been reported to date. Presentation is with proteinuria and progressive renal 
impairment. Age of onset tends to be earlier than Apo AI amyloidosis with cases 
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requiring renal replacement therapy by age 30-40 years. Russian and Spanish 
kindreds have reported later onset with presentation age 30 years and onset of 
renal replacement therapy at age 50 with the Stop78Arg mutation.
179,180 
Outcome 
following transplantation has been reported to be excellent but the number of 
reported patients is very small. To date no patients with this form of amyloidosis 
have been reported in the UK. 
 
Lysozyme Amyloidosis (ALys) 
 
Lysozyme amyloidosis was first described by Pepys et al in 1993. Lysozyme is a 
bacteriolytic enzyme found in high concentrations in the liver, articular surfaces, 
saliva and tears. It is highly expressed in granulocytes, monocytes and bone 
marrow precursor cells. To date seven amyloidogenic mutations have been found: 
Ile56Thr, Phe57Ile, Trp64Arg, Asp67His, Trp112Arg, Tyr54Asn and D67G. 
Clinical presentation is with very slowly progressive renal failure, which usually 
presents in the third and fourth decades of life. Involvement of the liver, lymph 
nodes, GI tract, and spleen also occurs. Sicca syndrome due to salivary amyloid 
deposition is frequently reported  in patients with Try64Arg and Asp67His 
variants, and lung and thyroid deposits have been reported in patients with 
Ile56Thr.
180
 Renal decline can take decades, and the few reports of renal 
transplantation have been excellent, with reported graft function of over 15 years 
in some patients. 
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Therapeutic Targets 
 
To date the objectives of therapy in amyloidosis have comprised supportive 
measures coupled with efforts to suppress production of the respective 
amyloidogenic precursor protein as previously discussed.  The latter is frequently 
associated with gradual regression of existing amyloid deposits and preservation 
of vital organ function, and associated improvement in survival.
78, 181
 Although 
great strides have been made in the management of AL and AA amyloidosis, this 
strategy still often fails and it has not been applicable in many other types of 
amyloid.  This has led to the search for new drug therapies which apply a different 
approach to either inhibit amyloid deposition or enhance removal of established 
amyloid deposits.  
 
Inhibiting Amyloid Fibrillogenesis 
 
Highly sulphated glycosaminoglycans, particularly heparan and dermatan sulfate 
proteoglycans, are universal constituents of amyloid deposits and are thought to 
promote fibril assembly and aid in maintenance of the conformational changes 
associated with amyloidogenesis.
182, 183
 Eprodisate (1, 3-propanedisulfonate) is a 
negatively charged, sulfonated molecule of low molecular weight that has 
structural similarities to heparan sulphate. It binds to the binding site on SAA to 
prevent its interaction with GAGs thus inhibiting the conformational change 
needed to render SAA amyloidogenic. In vivo studies have shown that Eprodisate 
inhibits the development of amyloid deposits in mouse models.
184,185
 
Eprodisate remains the only drug to have been tested as a phase II/III 
multicentre, placebo controlled, double blinded study in amyloidosis.
186
 Patients 
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with AA amyloidosis were stratified by the presence of nephrotic syndrome and 
treatment centre and then randomized either to Eprodisate or placebo twice daily 
for up to two years. Outcome measures were a composite end point of serum 
creatinine, creatinine clearance, and progression to ESRF or the patient’s death. 
Secondary outcomes were the slope of creatinine clearance, change in proteinuria, 
improvement in diarrhoea and change in the amyloid content of abdominal fat. 
Unfortunately the study enrolled only 183 patients, this may have contributed to 
the failure to achieve the pre-specified primary endpoints although renal benefits 
were seen in the drug treated group.  The hazard ratio for worsening disease with 
Eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). 
The mean rate of decline in creatinine clearance was also significantly slower in 
the Eprodisate group than placebo; 10.9 compared to 15.6 ml per minute per 1.73 
m
2
 of body-surface area per year (P=0.02). Unfortunately the study failed to 
demonstrate a significant benefit from active therapy on progression to ESRF or 
risk of death, although there was a trend to benefit. A second clinical study is 
currently underway.  
TTR amyloidosis has emerged as a particular focus for novel drug 
development, and several novel approaches are being pursued.  The native soluble 
TTR molecule is a tetramer comprising two dimers that create and span a thyroid 
hormone-binding pocket.  It is thought that a requisite step in the transformation 
of soluble TTR to its amyloid form is disruption of the normal TTR homotetramer 
into its monomeric components, which can auto-aggregate in the misfolded but 
highly ordered fibrillar conformation.
187
 The approach pursued by Kelly and his 
colleagues has been to identify ligands that occupy the thyroid hormone-binding 
pocket and stabilize the structure in its native tetrameric form.
188
 This has led to 
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the development of a novel drug compound tafamidis, which has shown promise 
in a randomized trial in hereditary TTR amyloidosis associated with the Met30 
variant.
189
  Our group at University College London (UCL) has identified other 
very potent stabilising compounds that simultaneously occupy both T4 binding 
sites in each tetrameric TTR molecule, confirmed by X-ray crystallographic 
analysis, which is irreversible under physiological conditions, and inhibited 
amyloidogenic aggregation more potently than other known ligands.
187
 The 
hepatic origin of circulating TTR has encouraged development of RNA inhibiting 
approaches to treatment, given the preferential potential of targeting the liver with 
these new technologies. Both silencing RNA and anti-sense oligonucleotide 
approaches, which aim to reduce production of TTR, are being developed for 
clinical trials.  
 
Targeting SAP  
 
An alternative approach has been to target other components of amyloid deposits 
in order to destabilise fibrils. The normal plasma protein SAP is a universal 
constituent of amyloid deposits, its presence may mask the presence of amyloid 
deposits and inhibit effective clearance.
190
 Further amyloid formation is inhibited 
in SAP knockout mice.
191
 In 1984 Pepys identified its role as a therapeutic 
target,
192
 which subsequently led to the development of R-1-[6-[R-2-carboxy-
pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid (CPHPC), this 
drug acts by inhibiting the binding of SAP to amyloid. The activity of this 
palindromic agent relates to its ability to crosslink pairs of SAP molecules face to 
face which both results in rapid hepatic clearance, and completely occludes the 
binding face of the SAP molecule.
193
 A preliminary clinical study of CPHPC in 
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several forms of amyloidosis confirmed that regular administration produced 
profound and sustained depletion of SAP.  The drug was given to a number of 
patients for several years with no apparent adverse effects, though the magnitude 
of potential clinical benefit was not sufficiently large to be ascertained in this 
open, non-controlled study.
194
 This drug is now available for use on 
compassionate grounds to a limited number of patients. 
 
Immunotherapy 
 
Antibodies that recognise a common fibril epitope have been raised and 
administered to mice,
195
 with both experimentally created AL amyloidomas,
21
 and 
systemic AA amyloidosis resulting in a reduced amyloid burden.  Most recently 
the observation that CPHPC efficiently depletes SAP from the blood, but only 
very slowly from the amyloid deposits has enabled the development of an 
antibody directed at SAP. By using CPHPC to deplete the plasma of SAP 
followed by an anti-SAP antibody rapid clearance of experimentally induced 
amyloid deposits by macrophages can be seen, this approach is currently in 
translation for patients.
196
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Aims and Scope of the Thesis 
 
 
The studies within this thesis are centred on the two organs which are most 
commonly involved; the heart and kidneys. Deposition of amyloid within these 
organs has a significant impact on patient morbidity and mortality. This thesis 
describes the disease phenotype within the heart and kidneys defined according to 
the underlying precursor protein.  Different variants of amyloidosis have a 
predilection for different organ systems because of the underlying precursor 
protein which forms the fibril. Much of the work within this thesis describes the 
relationship between the fibril precursor protein and its effect on the disease 
phenotype. 
Referral patterns to the NAC have changed in recent years and increasing 
numbers of patients with wild type transthyretin amyloidosis are being identified. 
The epidemiology of systemic amyloidosis has been little studied. In the first 
results chapter the burden of systemic amyloidosis in the English population is 
identified. Using death certificate data the proportion of deaths attributable to 
amyloidosis is described and the sensitivity of such data evaluated. By combining 
data from the office of national statistics (ONS) and data from the NAC database 
it is possible to estimate the proportion of patients seen at the NAC and 
extrapolate an estimated disease incidence. 
The epidemiology of amyloidosis is changing, in recent years there has 
been a marked increase in patients who are diagnosed with ATTRwt and elderly 
patients with this disease are being increasingly referred for diagnosis and review 
at the NAC. The published literature provides limited information on small 
cohorts of patients with ATTRwt. There is little data on prognostic features and 
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natural history. Patients with ATTRwt frequently pose a diagnostic challenge. The 
diagnosis of amyloidosis rests on histological proof of amyloid and identification 
of the underlying fibril type, predominantly using immunohistochemical 
techniques. Because of the increasingly well characterised nature of cardiac 
amyloidosis on a variety of imaging modalities, there has been a shift away from 
confirming amyloid histologically prior to referral to the national centre. This 
poses the frequent question of how confident we can be in correctly identifying 
the type of amyloid using imaging and clinical features alone. The aims of this 
section of the thesis were therefore twofold; firstly to characterise the disease 
phenotype of ATTRwt; and secondly, to determine differences between ATTRwt 
and cardiac AL amyloidosis. Using a statistical model, the probability of the 
underlying diagnosis of ATTRwt is calculated in patients with isolated cardiac 
amyloid and an underlying clonal disorder, the most challenging group of patients 
to diagnose. 
In chapter four the marked difference in disease phenotype between 
patients with cardiac AL amyloidosis and ATTRwt is highlighted. Abnormalities 
on the ECG appear common in both disease type, patients with ATTRwt appear to 
have a higher prevalence of atrial fibrillation. This theme is explored further in 
chapter five where Holter monitors are used with the aim to assess the frequency 
of dysrhythmias in patients with systemic amyloidosis and to identify whether 
arrhythmic activity is associated with disease severity or amyloid fibril type. 
The final two results chapters concentrate on the disease phenotype of 
renal amyloidosis and the close relationship between the fibril precursor protein 
and patient outcome. Renal involvement is the most common presentation of AL 
amyloidosis and progression to ESRF is a frequent complication of the disease. 
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By utilising data from over 900 patients over a 21 year period, features at baseline 
which affect survival are identified and outcome following renal replacement 
therapy is assessed. Suppression of the precursor protein has been previously 
described in several studies to affect patient outcome but little data exists 
identifying the effect on organ function. The primary aim of chapter six is to 
identify factors associated with renal outcome. Suppression of the monoclonal 
light chain protein is shown to affect renal outcome and the dFLC (difference 
between he involved and uninvolved light chain) is validated in amyloidosis for 
the first time. Baseline factors which affect patient outcome and survival on 
dialysis are also described. 
In the final chapter, renal transplant outcome in amyloidosis is assessed. 
There is currently no consensus on who is potentially eligible for listing on the 
deceased donor waiting list. Whilst patients who have received transplants with 
systemic amyloidosis are a highly selected group it is important to identify those 
who have achieved successful transplant outcomes and those who have developed 
recurrent disease and lost their grafts. Following on from the previous results in 
which a reduction in the precursor protein conferred a greater chance of a better 
renal outcome; the hypothesis was that suppression of the precursor protein would 
also confer a benefit to graft outcome, prior to and following renal transplantation. 
The importance of disease natural history is also highlighted with regard to graft 
outcome. 
 .
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Chapter Two: Materials and Methods 
 
Declaration 
 
I have designed the studies, carried out the data collection and the analysis of the 
data. I recruited the patients to the Holter monitor study, collected the data and 
performed the statistical analysis in my role as a clinical research fellow at the 
National Amyloidosis Centre, University College Medical School (Royal Free 
Campus). Several diagnostic methods were carried out by other individuals in the 
department they were as follows: 
Histological and immunohistochemical analyses were performed by Janet 
Gilbertson and Toby Hunt. 
Gene sequencing was performed by Dorota Rowczenio, Tonia Russell and Hadija 
Trojer. 
Echocardiography was performed by Babita Pawarova, Carolyn McCarthy and 
Oliver Manalo. 
123
I-SAP scintigraphy was performed by David Hutt and Dorothea Gopaul. 
Holter monitoring was read by Elizabeth Collins and reports were reviewed by Dr 
Carol Whelan and Dr Dominic Rogers. 
Measurement for biochemical and haematological data were performed by the 
Royal Free Hospital laboratory services. 
Statistics advice was given by Loveleen Bansi for chapter 6 and Aviva Petrie from 
the Biostatistics Unit at the UCL Eastman Dental Institute for chapters 2 and 3. 
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Patients  
 
All of the patients whose individual details are used within this thesis have been 
seen at the UK National Amyloidosis Centre. An access database has been 
maintained with details of all patients found to have amyloidosis. All patients 
included from the database provided explicit informed consent. Death certificate 
data entailing the number of deaths from amyloidosis in England was provided by 
the Office of National Statistics. Individual level data from this source was only 
provided in patients who had been seen at the NAC and therefore previously 
consented for their information to be used. 
 
SAP Scintigraphy  
 
SAP scintigraphy was performed in all patients at the initial assessment and at 
follow up assessment if clinically indicated for the monitoring of amyloid 
deposits. Female patients of child bearing age were asked to confirm that they 
were not pregnant. Each subject undergoing SAP scintigraphy received 
approximately 200µg of SAP with 190MBq of 
123
I, the equivalent of 3.8 mSV of 
radiation. Thyroid uptake was blocked by the administration of 60mg of 
potassium iodide immediately prior to the study and 5 further doses were given 
over the following three days. Anterior and posterior imaging was performed at 
either 6 or 24 hours after injection using an IGE-Starcam gamma-camera (IGE 
Medical Systems, Slough, UK). 
The classification of amyloid load was defined as ‘normal’ if there was no 
abnormal localisation of the tracer; ‘small’ when uptake in one or more organs 
was visible with normal intensity in the blood pool; ‘moderate’ when abnormal 
Chapter 2 
 
70 
 
uptake was seen within organs and the blood pool was diminished and ‘large’ 
when the blood pool signal was lost with adjustment of the grey scale to 
encompass the target organ. 
Regression of amyloid was defined as reduction of the tracer within an 
affected organ and/or an increase in the background blood pool. Amyloid 
progression was defined as an increase in the tracer uptake within an affected 
organ or a reduction in the background blood-pool signal in combination with a 
stable amyloid burden. 
 
Cardiac Assessment 
 
SAP scintigraphy is not used as part of the cardiac assessment. The large blood-
pool within the chambers of the heart and cardiac motility mean that amyloid is 
poorly visualised using this technique. A combination of electrocardiogram, 
echocardiogram and cardiac biomarkers are used routinely at the NAC to evaluate 
whether there is cardiac amyloid. CMR is not available at the centre. Where 
patients have previously had a CMR the images were viewed on CDs by Dr Jason 
Dungu who evaluated whether the changes were consistent with amyloid. In 
patients where the diagnosis of cardiac amyloid was in doubt CMR was arranged 
either through the referring physician or patients were scanned at the heart 
hospital. 
 
Functional Evaluation 
 
Functional evaluation of patients performance status was evaluated in the clinic 
by the Eastern Co-operative Group (ECOG) performance status
197
 (Table 2.1) 
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This has been used historically as a guide for cancer patients to determine whether 
patients will tolerate treatment, whether dose adjustment may be necessary or 
whether palliation may be a suitable option. The New York Heart Association 
Classification (NYHA) was also used in patients attending the clinic, this 
classification provides a useful standardised way of classifying the extent of heart 
failure symptoms in patients (Table 2.2).
198
 
 
Table 2.1 Definition of Eastern Co-operative Group Performance Status 
 
 
Grade 
 
Summary Description 
0 
 
Normal No restriction to carrying out normal activities 
1 With effort 
Ambulatory, able to do light work. Restricted only in 
strenuous activity 
2 
 
Restricted Self caring and ambulatory but unable to carry out work 
3 Dependent 
Capable of limited self-care, confined to bed or chair for 
over 50% of waking hours 
4 Immobile 
Unable to carry out self-care, completely confined to bed 
or chair 
 
 
 
Table 2.2 Definition of New York Heart Association Classification 
 
 
NYHA 
Class 
Summary Description 
I Normal 
No limitation of physical activity. Ordinary physical 
activity does not cause shortness of breath or undue 
fatigue 
II Mild 
Slight limitation of physical activity. Comfortable at rest, 
but ordinary physical activity results in fatigue, 
palpitation or dyspnoea 
III Moderate 
Marked limitation of physical activity. Comfortable at 
rest but less than ordinary activity causes fatigue, 
palpitation or dyspnoea 
IV Severe 
Unable to carry out any physical activity without 
discomfort. Symptoms of cardiac insufficiency at rest. If 
any physical activity is undertaken, discomfort is 
increased 
Chapter 2 
 
72 
 
Echocardiography  
 
Echocardiography was performed in all patients with two-dimensional and M-
mode settings using a GE Vivid 7 system. Parasternal long axis and apical long 
axis views were most commonly used. Evaluation of left ventricular wall 
thickness, left ventricular diastolic function, left ventricular systolic function and 
atrial diameter were measured using defined criteria from the British Society of 
Echocardiography (http://www.bsecho.org). Left atrial area was measured using 
criteria defined by the American Society of Echocardiography 
(http://www.asecho.org). 
 
Electrocardiogram 
 
All patients had a standard 12 lead ECG at each visit. Standard sensitivity of 1cm 
per mV was used. Historical data has shown an association between a low voltage 
ECG and increased cardiac mass on echocardiography with cardiac 
amyloidosis.
199
 The current amyloidosis consensus criteria define low voltage 
ECG as QRS complexes of <5mm in all limb leads.
60
 These criteria have been 
used to define low QRS complexes on the ECG. Total QRS score and mean QRS 
in leads II/III/AVF and V4/V5/V6 have also been reported. 
 
Holter Monitoring  
 
Twenty-four hour electrocardiographic monitoring (Holter monitoring) was 
performed using a portable cassette recorder with three lead placements 
(Spacelabs Healthcare Lifecard CF). Analysis of the 24 hour records was 
performed by an experienced electro physiologist using Pathfinder Digital 
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software V8.701 (Spacelabs). Two consultant cardiologists reviewed the reports. 
Referring physicians were contacted with the results of significant results and 
changes to management were recommended based on current clinical practice for 
cardiac rhythm disturbances. 
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Criteria for Diagnosis of Amyloid and Definition of Organ 
Response 
The definition of organ involvement and organ response was defined according to 
consensus criteria in combination with SAP scintigraphy (Table 2.3).
60
 
 
Table 2.3 Definition of Organ Involvement and Organ Response  
 
Organ 
Definition of Organ 
Involvement 
Definition of Organ Response 
Heart 
Echocardiogram: Mean wall 
thickness >12mm and no other 
cardiac cause or 
CMR showing late gadolinium 
enhancement 
Mean IVSd decreased by 2mm, 
20% improvement in EF, 
improvement by 2 NYHA 
classes without an increase in 
diuretic use and no increase in 
wall thickness 
Kidneys 
24 hour non Bence Jones 
Proteinuria >0.5g, or uptake on 
SAP scintigraphy 
50% reduction in proteinuria (at 
least 0.5g/day) creatinine and 
creatinine clearance must not 
worsen by 25% over baseline  
Liver SAP scintigraphy 
50% decrease in abnormal ALP 
or reduced organ uptake on SAP 
scintigraphy 
Spleen SAP scintigraphy 
Reduced organ uptake on SAP 
scintigraphy 
Adrenal SAP scintigraphy 
Reduced organ uptake on SAP 
scintigraphy 
Soft Tissue 
Tongue hypertrophy, periorbital 
bruising, spontaneous bruising, 
pseudo hypertrophy, 
lymphadenopathy, carpal tunnel 
syndrome 
Clinical assessment of 
improvement  
Gastrointestinal 
Tract 
Direct biopsy verification with 
symptoms 
 
Lung 
Direct biopsy verification with 
symptoms, interstitial 
radiographic pattern 
Radiographic evidence of 
improvement in pulmonary 
interstitial amyloid (rare) 
Peripheral 
Neuropathy 
Symmetrical sensorimotor 
peripheral neuropathy in the 
lower limbs 
Clinical assessment 
Autonomic 
Neuropathy 
Impotence, diarrhoea or 
constipation, early satiety and/or 
impaired bladder emptying 
without other overt cause. 
Orthostatic hypotension 
(>20mmHb fall in systolic BP) 
Clinical Assessment 
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Histology  
Congo Red Staining  
 
Formalin fixed de-paraffinised tissue sections 6-8µg thick were rehydrated, and 
counterstained with haematoxylin under running tap water. Sections were then 
stained using the alkaline-alcoholic Congo-red method as previously described by 
Puchtler et al.
200
 A series of ascending ethanol concentrations to xylene were used 
to dehydrate the sections which were then mounted in DPX mounting medium. 
Stained slides were then viewed in bright field and under cross polarised light. 
Positive controls were obtained from a known Congo-red positive block validated 
by laser micro dissection and mass-spectrometry based proteomic analysis which 
was always processed in parallel. 
 
Immunohistochemistry  
 
The amyloid type was then characterised by immunohistochemical staining. 
Formalin fixed de-paraffinised 2µm sections of amyloidotic tissue were used.  
Sections were washed with water and endogenous peroxidise activity was 
quenched by incubation in aqueous (0.3%) hydrogen peroxide (H2O2) for 30 
minutes. They were then rinsed again in phosphate-buffered saline (PBS) 
containing 0.05% Tween (Calbiochem). Prior to the application of antisera, non 
specific tissue binding was abolished by incubation for a further 30 minutes in 
normal non-immune serum from the species providing the secondary antibody 
(Vector Part of the ImmPRESS Kit). Sections were then incubated overnight with 
primary antisera at 4
o
C. They were rinsed with PBS containing 0.05% Tween 
(Calbiochem) and labelled with secondary antibodies. Sections were washed in 
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PBS and bound enzyme-antibody bound complexes were then visualised using a 
metal-enhanced DAB (Fisher Scientific solution). 
A panel of anti-human monospecific antibodies reactive with: SAA 
(Eurodiagnostica, Huntington UK) AL kappa, lambda, transthyretin and lysozyme 
(Dako Ltd, Denmark House Ely UK), Apolipoprotein AI (Genzyme Diagnostics) 
and fibrinogen Aα chain (Calbiochem) were used where appropriate. Congo red 
overlay was used in duplicate sections. Immunohistochemically stained sections 
were counterstained in haematoxylin, ‘blued’ under running tap water and stained 
with Congo-red.
201
  
For TTR staining, pre-treatment was performed for enhanced antigen 
retrieval using 10 minute incubation with 1% sodium periodate, slides were then 
washed and further incubated for 10 minutes with 0.1% sodium metabisulphate, 
washed again and incubated for 5 hours at room temperature with 6M Guanadine 
in 0.9% sodium chloride. 
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Immunoassays  
Serum Amyloid A Protein  
 
SAA levels were measured using latex nephelometry (BNII autoanalyser Dade, 
Behring Marbury, Germany).
81 
The lower limit of detection is 0.7mg/L. 
Standardisation was based on WHO international reference standards 1987.
202 
 
Serum Free Immunoglobulin Light Chain Assay  
 
Both kappa and lambda serum free immunoglobulin light chains (FLC) were 
measured using a latex-enhanced immunoassay (The Binding Site, Birmingham, 
UK) on a ehring BNII autoanalyser (Dade Behring, Marburg, Germany).
203-205
 
Antibodies are directed against FLC epitopes hidden within whole 
immunoglobulin molecules. The sensitivity of the assay is <5mg/L. Sera from 100 
healthy blood donors were tested in order to determine the reference range. The 
mean concentrations of polyclonal free kappa and free lambda light chains were 
11.38mg/L (95% CI, 7.41-16.77mg/L) and 17.36mh/L ((%% CI, 8.91-29.87mg/l) 
respectively. The mean kappa/lambda ratio was 0.7 (95% CI, 0.37-0.95).  An 
abnormally high kappa or lambda light chain value or abnormal ratio in the 
context of preserved renal function was used as part of the assessment of an 
underlying clonal disorder in chapter four. In patients with renal impairment the 
ratio alone was used. The definitions of haematologic response are outlined in 
Table 2.4. 
Light chains are metabolised in the kidneys. Polyclonal free light chain 
levels rise in renal failure
206
 which makes interpretation of absolute levels of 
serum free light chains difficult to interpret. If the ‘normal’ ratio of kappa/lambda 
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is estimated to be 1:1, the amount of monoclonal light chain can be estimated by 
subtracting the uninvolved light chain from the involved light chain, a method 
previously validated in myeloma.
207
 This method has been used when calculating 
the light chain response in chapters six and seven. 
 
Table 2.4 Haematologic Response Criteria
60 
 
 
Gene Sequencing  
 
Genotyping was performed in patients with suspected hereditary amyloidosis 
where appropriate. Whole blood taken in an EDTA tube was frozen and stored for 
gene sequencing as required. Genomic DNA was isolated by a rapid method.
208 
The blood was added to NH4CL and spun, the sample was then re-suspended in 
0.9% NaCl and re-spun. It was then suspended again in 0.05M NaOH, incubated, 
cooled and neutralised with 1M Tris pH8. Polymerase chain reaction (PCR) using 
‘Ready-To-Go’ tubes (GE Healthcare) were used to amplify the coding regions 
for the following genes: transthyretin (exons 2,3 and 4), apolipoprotein AI (exons 
3 and 4) and fibrinogen A α-chain (exon 5). HotStar Taq DNA Polymerase kit 
Clonal Response Criteria 
Complete 
Response 
Serum and urine negative for a monoclonal protein by 
immunofixation, normal free light chain ratio 
Partial Response 
If serum paraprotein >0.5g/dL, a 50% reduction 
If light chain in the urine with a visible peak and 
>100mg/day and 50% reduction 
If free light chain >10mg/dL (100mg/L) and 50% reduction 
Progression 
From CR, any detectable monoclonal protein or abnormal 
free light chain ratio (doubling of light chain) 
From PR or stable response, 50% increase in serum 
paraprotein to >0.5g/dL or 50% increase in urine 
paraprotein to >200mg/day 
Free light chain increase of 50% to >10mg/dL (100mg/L) 
Stable No CR, no PR, no progression 
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(Qiagen) was used for the lysozyme gene (exon 2). The primers used as part of the 
PCR process are outlined in Table 2.5. 
 
Table 2.5 Primers Used in the PCR Process for Genotyping Hereditary 
Amyloidosis 
 
Gene 
 (exon) 
Forward primer sequence Reverse primer sequence 
Transthyretin (2) 5’-TTTCGCTCCAGATTTCTAATAC-3’ 5’-CAGATGATGTGAGCCTCTCTC-3’ 
Transthyretin (3) 5’-GGTGGGGGTGTATTACTTTGC-3’ 5’-TAGGACATTTCTGTGGTACAC-3’ 
Transthyretin (4) 5’-GGTGGTCAGTCATGTGTGTC-3’ 5’-TGGAAGGGACAATAAGGGAAT-3’ 
Apolipoprotein (3) 5’-GGCAGAGGCAGCAGGTTTCTCAC-3’ 5’-CCAGACTGGCCGAGTCCTCACCTA-3’ 
Apolipoprotein (4) 5’-CACTGCACCTCCGCGGACA-3’ 5’- CTTCCCGGTGCTCAGAATAAACGTT-3’ 
Fibrinogen (5) 5’-AGCTCTGTATCTGGTAGTACT-3’ 5’- ATCGGCTTCACTTCCGGC-3’ 
Lysozyme (2) 5’-GTTATATTGTTCGTTGGTGT-3’ 5’- CATTTGTATTGAGTCTCAATTC-3’ 
 
 
Statistical Analysis  
 
Statistical analyses were performed using Graph Pad Prism (Version 4 and 5), 
SPSS 15 (SPSS Inc, Chicago III) and Stata version 11 (Statacorp).  
Individual statistical methods are discussed separately in each results chapter.
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Results Section One: Epidemiology 
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Chapter Three: Systemic Amyloidosis in England: 
An Epidemiological Study 
Introduction 
 
Amyloidosis has been loosely estimated to cause about 0.5-1.0 deaths per 
thousand in the UK.
209
 There are almost no published epidemiological studies of 
amyloidosis in the medical literature; the most comprehensive being a study 
conducted by Kyle and colleagues at the Mayo Clinic of the general population 
residing in the surrounding area of Olmstead County, USA.
25
  They reported an 
incidence of AL amyloidosis of 5.1-12.8 per million person-years, using data from 
a centralized system recording virtually all medical, surgical and pathological 
diagnoses of the county residents.  Twenty one individuals from Olmstead County 
were diagnosed with AL amyloidosis between 1952 and1992.  The overall age 
and sex adjusted annual incidence rate was reported to be 8.9 per million person-
years.  The authors extrapolated that approximately 2225 new cases may occur 
annually across the USA, but this has not been verified.  
The NAC database effectively serves as a national registry of the disease.  
This database has enabled the natural history and response to therapeutic 
interventions of the various amyloidosis syndromes to be studied in large cohorts 
of patients.   
Studies using data from death certificates have been conducted in several 
rare diseases to estimate the burden of mortality
210-212
 and indirectly estimate 
incidence of disease.  Systemic amyloidosis lends itself to this approach since it is 
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an incurable and usually rapidly fatal disorder;
45,86,177,213
 it has specific 
pathological features enabling definitive diagnosis through biopsy, and which are 
overt in hitherto undiagnosed cases at autopsy.  Further, given the requirement for 
histological diagnosis, it is probable that false positive recording of amyloidosis 
on death certificates is exceptionally rare.   
The aim of this study was to estimate the incidence of amyloidosis in 
England based on analysis of two data sets: reported death certification from the 
Office of National Statistics (ONS) and information on referrals and deaths held 
on the NAC database. 
 
Chapter 3 
83 
 
Methods 
 
Office of National Statistics Death Certificate Data 
 
The number of deaths registered in each calendar year for people living in 
England and the proportion of those deaths in which the word ‘amyloidosis’ 
appeared anywhere on the death certificate, as defined by the International 
Classification of Diseases ninth revision (ICD-9) code for the year 2000 and tenth 
revision (ICD-10) code from 2001 onwards (Table 3.1), were obtained from the 
ONS.  All data was fully anonymised.   
 
Table 3.1 Amyloidosis deaths – International Classification of Diseases Ninth 
(ICD-9) and Tenth Revision (ICD-10) 
 
Cause of Death ICD-9 Code 
Amyloidosis 277.3 
Cause of Death ICD-10 Code 
Non-neuropathic heredofamilial amyloidosis E85.0 
Neuropathic heredofamilial amyloidosis E85.1 
Heredofamilial amyloidosis, unspecified E85.2 
Secondary systemic amyloidosis E85.3 
Organ-limited amyloidosis E85.4 
Other amyloidosis E85.8 
Amyloidosis, unspecified E85.9 
 
Data from the National Amyloidosis Centre Database 
 
All English residents diagnosed to have systemic amyloidosis between 2000 and 
2008 whose details were held on the NAC databases were identified and their 
details were provided to ONS.  Death data was returned from ONS for all 
matched individuals, including date and cause of death as listed in parts IA, IB, 
IC, and II of the respective death certificates.  Matching of individuals between 
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the ONS and NAC databases required agreement of name, date of birth and 
unique NHS number.  The type of amyloid and date of diagnosis was obtained for 
each case from the NAC database and survival from the first assessment at NAC 
was calculated.  Survival data were censored on January 1
st
 2012. 
 
Office of National Statistics Estimate of Population 
 
Estimates of the population in England were taken from the ONS website ‘Mid-
1971 to Mid-2010 Population Estimates: Quinary age groups for Constituent 
Countries in the United Kingdom; estimated resident population’ released on 21st 
December 2011.  Estimates are of the usually resident population on 30
th
 June of 
the reference year and reflect administrative boundaries that were in place on that 
day.  
 
Statistics 
 
The study was approved by the Royal Free Hospital ethics committee.  Graph Pad 
Prism version 5 was used for statistical analyses.  Patient survival was estimated 
by Kaplan-Meier Analysis using SPSS version 20.  The log-rank test was used to 
compare differences between stratified Kaplan-Meier survival curves.  Statistical 
significance was achieved if P <0.05.  
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Results 
Accuracy of Death Certificate Data 
 
Summary statistics on the total number of deaths attributable to systemic 
amyloidosis between 2000 and 2008 are shown in Table 3.2.  Amyloidosis 
appeared on the death certificates of 2543 English individuals during this period.  
There were 1143 deaths over the same period among patients with systemic 
amyloidosis who were registered on the NAC database, 903 (79%) of whom had 
amyloidosis reported on their death certificate.  Amyloidosis was recorded in 
Part 1A, 1B, and 1C of the death certificate in 261 (28.9%), 372 (41.2%) and 96 
(9.6%) respectively, and in Part 2, which identifies conditions contributing to the 
cause of death, in 174 (19.2%) individuals (Figure 3.1).  The proportion of 
patients registered on the NAC database in which amyloidosis was stated on the 
death certificate did not vary significantly over the study period.  However, there 
was an association between amyloid type and the frequency with which 
amyloidosis appeared on the death certificate (Table 3.3, P=<0.001); 83% percent 
of patients with AL amyloidosis had amyloidosis on their death certificate, 
compared to 74% of those with hereditary amyloidosis and ~62% of those with 
AA and transthyretin amyloidosis.   
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Figure 3.1 Position of amyloidosis on death certificates among patients who 
attend the National Amyloidosis Centre. 
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Table 3.2 Total number of deaths in England with amyloidosis recorded anywhere on the death certificate and total number of patients from 
England reviewed at the National Amyloidosis Centre between 2000 and 2008 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 Total 
Data from Death Certificates (ONS)           
Amyloidosis reported as the 
underlying cause of death (% of total 
certificates with amyloidosis stated) 
128 
(58) 
154 
(63.4) 
171 
(60.8) 
153 
(58.6) 
165 
(62.9) 
197 
(62.5) 
174 
(61.7) 
208 
(63.8) 
217 
(61.5) 
1567 
(61.6) 
Amyloidosis anywhere on the death 
certificate 
220 243 281 261 262 315 282 326 353 2543 
Total deaths in England 503024 497878 500795 504127 480716 479678 470326 470721 475763 4383028 
Proportion of deaths with amyloid 
mentioned on death certificate (per 
thousand deaths) 
0.44 0.49 0.56 0.5 0.54 0.66 0.60 0.69 0.74 0.58 
Data from NAC Database           
Number of deaths in patients  seen at 
NAC 
66 84 98 110 116 144 151 157 217 1143 
NAC deaths with amyloid on 
certificate N (%) 
55  
(83.3) 
69  
(82.1) 
82  
(83.7) 
87 
 (79.1) 
87  
(75) 
119 
(82.6) 
118 
(78.1) 
116 
(73.9) 
170 
(78.3) 
903 
 (79.0) 
Total deaths with amyloid on death 
certificate and confirmed NAC deaths 
with no mention of amyloid 
231 258 297 284 291 340 315 367 400 2783 
National proportion of deaths with 
amyloid from death certificate and 
NAC confirmed cases (per thousand 
deaths) 
0.46 0.52 0.59 0.56 0.61 0.71 0.67 0.78 0.84 0.63 
Number of patients with amyloid on 
death certificate not seen at NAC N 
(%) 
165  
(75) 
174 
(71.6) 
199 
(70.8) 
174 
(66.6) 
175 
(66.8) 
196 
(62.2) 
164 
(58.2) 
210 
(64.4) 
183 
(51.8) 
1640 
(64.5) 
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Table 3.3 Number of patients seen at the National Amyloidosis Centre with amyloid on their death certificate, stratified by amyloid fibril type 
 
 
 
 
 
 
 
Amyloid mentioned on  
death certificate 
AL Amyloidosis AA Amyloidosis Hereditary 
Amyloidosis 
Senile Systemic 
Amyloidosis 
 No Yes No Yes No Yes No Yes 
2000 4 (8) 46 (92) 6 (60) 4 (40) 1 (16.7) 5 (83.3) 0 0 
2001 7 (10.3) 61 (89.7) 5 (38.5) 8 (61.5) 3 (100) 0 0 0 
2002 12 (15.3) 72 (84.7) 3 (42.9) 4 (57.1) 1(14.3) 6 (85.7) 0 0 
2003 16 (18.4) 71 (81.6) 5 (29.4) 12 (70.6) 0 4 (100) 2 (100) 0 
2004 16 (18.2) 72 (81.8) 6 (54.6) 5 (45.4) 2 (22.3) 7 (77.7) 5 (62.5) 3 (38.5) 
2005 22 (18.1) 100 (81.9) 2 (14.3) 12 (85.7) 1 (12.5) 7 (87.5) 0 0 
2006 23 (19.3) 96 (80.7) 6 (31.6) 13 (68.4) 4 (40) 6 (60) 0 3 (100) 
2007 27 (22.3) 94 (77.7) 11 (47.8) 12 (52.2) 1 (16.7) 5 (83.3) 2 (28.6) 5 (71.4) 
2008 33 (9) 139 (81) 6 (37.5) 10 (62.5) 6 (30) 14 (70) 2 (22.3) 7 (77.7) 
Total (%) 160(17.5) 751(82.4) 50 (38.5) 80 (61.5) 19 (26) 54 (74) 11 (37.9) 18 (62.1) 
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Cause of Death Among Patients with Systemic Amyloidosis 
 
The primary cause of death was likely directly related to amyloidosis among 
127/174 (73%) patients, and was listed as follows: 12 end stage renal failure 
(ESRF), 22 heart failure, 56 sepsis, 14 multi-organ failure, 17 
myeloma/lymphoma, 5 pulmonary embolism and 1 nephrotic syndrome.  A 
further 32 (18%) deaths among these 174 individuals were possibly related to the 
amyloidosis and the primary causes were listed as follows: 17 cerebrovascular 
accidents (CVA), 9 myocardial infarctions (MI), 4 sudden cardiac deaths, 1 
ruptured abdominal aortic aneurysm and 1 bowel perforation.  Only 15/174 (9%) 
deaths appeared unrelated to systemic amyloidosis, 14 from unrelated 
malignancies and 1 from chronic obstructive pulmonary disease (COPD).   
Of the 240 individuals with systemic amyloidosis who were followed at 
the NAC but did not have amyloidosis stated on their death certificate, 179 (75%) 
had primary causes of death which were likely related to their amyloid.  Among 
the remaining 61/240 (25%) patients the primary cause of death was listed as 
follows: 26 ischaemic heart disease or heart failure, 13 ‘other’ malignancy, 10 
CVA, 3 COPD, 2 sepsis, and 1 each from drug overdose, end-stage renal failure, 
bowel obstruction, bowel ischaemia, pelvic abscess, peritonitis, and vasculitis.  
Taken together, these results suggest that amyloidosis contributed directly to 
death in more than 90% of patients with systemic amyloidosis. 
 
Estimate of Deaths Attributable to Amyloidosis in England 
 
According to death certificate data, 0.58 per thousand deaths were attributable to 
amyloidosis in England between 2000 and 2008.  Over the 9 year period, there 
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was a significant increase in the proportion of death certificates on which 
amyloidosis was included as a cause of death (Figure 3.2, R
2 
0.86, P=<0.001).  
Since 21% of patients who were known to the NAC with systemic amyloidosis 
did not have ‘amyloidosis’ mentioned on their death certificates, we estimated that 
at least the same proportion of cases may not be reported on death certificates in 
England generally.  Assuming 21% of deaths from systemic amyloidosis were not 
reported on English death certificates between 2000 and 2008, the total number of 
individuals who died from systemic amyloidosis in England during this time 
period was 3077 (2543 (79% reported) + 534 (21% unreported)), representing 
0.7 per 1000 deaths in the country.  Taking only the data for 2008 and using the 
same calculation (i.e., assuming 21% deaths from systemic amyloidosis were not 
reported as such), the total number of deaths from systemic amyloidosis in 
England in 2008 was 429, representing 0.9 per 1000 (429/475763) deaths.   
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Figure 3.2 Proportion of death certificates from England on which amyloidosis 
was included as a cause of death. 
 
 
Estimate of Incidence and Prevalence of Amyloidosis in England 
 
Referrals to NAC of patients with systemic amyloidosis (Table 3.4) doubled over 
the nine year study period (R
2
 0.8167, P=0.0008), from 0.29 per 100000 
population in 2001 to 0.51 per 100000 population in 2008.  The incidence 
increased with age and peaked between 60 and 79 years.  A proportion of patients 
with systemic amyloidosis are not referred to the NAC, and although this 
proportion appeared to fall substantially between 2000 and 2008 (Table 3.2), it is 
only possible to reliably estimate the minimum disease incidence from NAC data.  
The two-fold increase in referrals to the NAC between 2000 and 2008 is likely to 
reflect a combination of increased awareness of the disease and demand for NAC 
services, as well as improvement in diagnosis.  In 2008, 48.2% of the individuals 
in England in whom amyloidosis was recorded on their death certificate had been 
assessed at the NAC.  Extrapolation to the population of England generally 
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suggests an annual incidence in 2008 of 0.1/100000 persons.  Table 3.5 shows the 
number of patients in England diagnosed with different types of systemic 
amyloidosis at the NAC.  Systemic AL amyloidosis is the most prevalent, with a 
minimum overall incidence of 0.3 cases per 100000 population in 2008, which 
increases to 0.5 per 100000 when the estimated 51.8% of patients who were not 
seen at the NAC are included.   
According to NAC data, there were 435 individuals living in England with 
systemic amyloidosis in 2000 and 1051 individuals living with the disease in 
2008.  This apparent increase in prevalence is likely, in part, to reflect improved 
survival (median (CI) 27.6 (16.4 - 38.9) months in 2000 vs. median (CI) 45 (43.2 
– 46.7) months in 2008; log rank test for trend P=0.02) (Table 3.6) as well as 
changing referral patterns. 
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Table 3.4 Estimated incidence of systemic amyloidosis in England by age based purely on confirmed diagnoses among patients attending the 
National Amyloidosis Centre 
 
Year  0-19 years 20-29 
years 
30-39 
years 
40-49 
years 
50-59 
years 
60-69 
years 
70-79 
years 
80+ years Total newly 
diagnosed 
cases (Overall 
estimated 
 Incidence) 
Total alive at 
NAC/ 
Prevalence** 
(%) 
Total Pop 
2000 New cases at NAC 
(incidence*) 
0 (0) 1 (0.01) 2( 0.02) 22 (0.3) 31 (0.5) 48 (1.0) 20 (0.5) 5 (0.2) 129 (0.26) 435/0.88  
Population 12,357900 6,350000 7,736000 6,511400 6,083300 4,570300 3,626900 1,997300   49,233100 
2001 NAC 0 (0) 2 (0.03) 15 (0.2) 13 (0.2) 33 (0.5) 44 (0.9) 36 (1.0) 1 (0.05) 144 (0.29) 498/1.00  
Population 12,327700 6,307100 7,769600 6,616900 6,197600 4,555600 3,597600 2,077900   49,450000 
2002 NAC 0 (0) 0 (0) 9 (0.1) 10 (0.1) 44 (0.7) 62 (1.0) 44 (1.0) 6 (0.28) 175 (0.35) 581/1.17  
Population 12,334200 6,245000 7,759700 6,743000 6,280600 4,574000 3,577600 2,135000   49,649100 
2003 NAC 0 (0) 1 (0.01) 6 (0.07) 8 (0.1) 46 (0.7) 62 (1.0) 51 (1.0) 9 (0.41) 183 (0.36) 646/1.29  
Population 12,358000 6,232900 7,694600 6,890900 6,301500 4,657800 3,565300 2,172300   49,873300 
2004 NAC 0 (0) 6 (0.09) 4 (0.05) 20 (0.2) 41 (0.6) 61 (1.0) 41 (1.0) 12 (0.54) 185 (0.37) 710/1.41  
Population 12,365100 6,318600 7,575000 7,040800 6,309100 4,742600 3,555600 2,203000   50,109800 
2005 NAC 1 (0.008) 1 (0.01) 6 (0.08) 16 (0.2) 40 (0.6) 75 (1.0) 47 (1.0) 9 (0.40) 195 (0.38) 788/1.56  
Population 12,350400 6,488200 7,459400 7,217900 6,313100 4,836800 3,563900 2,236300   50,466000 
2006 NAC 0 (0) 3 (0.04) 11 (0.1) 15 (0.2) 34 (0.5) 62 (1.0) 62 (1.0) 13 (0.57) 200 (0.39) 853/1.68  
Population 12,337600 6,641400 7,313000 7,369200 6,319700 4,927200 3,579100 2,277000   50,764200 
2007 NAC 0 (0) 0 (0) 4 (0.05) 18 (0.2) 44 (0.7) 86 (1.0) 89 (2.0) 21 (0.90) 262  (0.51) 966/1.89  
Population 12,351800 6,826500 7,142600 7,501100 6,217700 5,138800 3,607600 2,320100   51,106200 
2008 NAC 3 (0.02) 3 (0.04) 10 (0.1) 17 (0.2) 50 (0.8) 83 (1.0) 82 (2.0) 19 (0.8) 267 (0.51) 1051/2.04  
Population 12,360600 6,988300 7,014300 7,588900 6,183100 5,323800 3,650400 2,355200   51,464600 
 
*Incidence per hundred thousand individuals of newly diagnosed cases per year, **prevalence; total number of people alive with the disease who 
have been seen at the NAC per hundred thousand population 
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Table 3.5 Estimated age-adjusted annual incidence in 2008 of each amyloid type 
per hundred thousand population in England assuming that all patients with 
amyloidosis are seen at the NAC 
 
 
 
Table 3.6 Kaplan Meier survival from the date of diagnosis among patients 
diagnosed with amyloidosis at the NAC by individual year of diagnosis 
 
Log Rank (Mantel Cox) for trend P = 0.023 
 
Number of patients (annual incidence per hundred thousand patients) 
Age Range 
AL 
Amyloidosis 
AA 
Amyloidosis 
Senile 
Systemic 
Amyloidosis 
Hereditary 
Amyloidosis 
and Other 
0-19 0 3 (0.03) 0 0 
20-29 0 3 (0.04) 0 0 
30-39 1 (0.01) 6 (0.08) 0 3 (0.04) 
40-49 11 (0.1) 5 (0.06) 0 1 (0.01) 
50-59 38 (0.6) 7 (0.1) 0 5 (0.08) 
60-69 59 (1.0) 14 (0.2) 1 (0.02) 8 (0.1) 
70-79 54 (1.0) 9 (0.2) 10 (0.3) 9 (0.2) 
80+ 11 (0.5) 1 (0.05) 7 (0.3) 0 
Total 174 (0.3) 48 (0.08) 18 (0.03) 26 (0.04) 
Median Survival (Months) 
Year of diagnosis Estimate 95% CI 
2000 27.7 16.4-38.9 
2001 33.2 16.7-49.7 
2002 17.4 11.3-23.5 
2003 32.3 20.5-44.1 
2004 27.5 16.2-38.8 
2005 29.2 18.5-39.8 
2006 36.0 20.5-51.6 
2007 33.9 23.1-44.7 
2008 45.0 43.2-46.7 
Overall 31.8 27.4-36.2 
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Regional Differences in Death Rates and Referrals to the NAC 
 
The regional differences across England in reported deaths from amyloidosis in 
2008 are shown in Table 3.7.  The proportion of deaths ranged from a minimum 
of 0.55/1000 in Yorkshire and the Humber to a maximum of 0.97/1000 in the 
South West.  There were significantly less deaths reported in Yorkshire and the 
Humber compared to the East of England, South Central and the South West 
(P<0.01).  There was no correlation between the proportion of deaths from 
amyloidosis and distance from the NAC.  The number of new referrals to the 
NAC did vary between strategic health authorities (SHAs) however, with a greater 
number of patients being referred from SHAs located closer to the NAC 
(Figure 3.3).  It would appear that nearly all patients who died from systemic 
amyloidosis in the London and the East of England regions had been seen at the 
NAC.  These regions are therefore likely to offer the greatest accuracy for 
estimating disease incidence. The minimum estimated disease incidence in these 
two regions respectively, based on new patient referrals to the NAC, is 0.73 and 
0.56/100000 population, corroborating earlier calculations of disease incidence. 
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Figure 3.3 Apparent incidence of amyloidosis in 2008 stratified by Strategic 
Health Authority, derived solely from new referrals to the National Amyloidosis 
Centre (NAC).  The incidence appears to fall as distance from the NAC increases. 
(R
2
 = 0.64, P = 0.005).  
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Table 3.7 Total Deaths and NAC Deaths from Amyloidosis and Incidence Based on New Referrals to the NAC in 2008 by Strategic Health 
Authority  
 
 
*Incidence of Amyloidosis – based on newly diagnosed NAC cases
Strategic Health 
Authority 
ONS total 
deaths 
ONS population 
estimates 
Amyloidosis 
on death 
certificate 
Proportion of 
Deaths due to 
Amyloidosis 
(per thousand) 
Deaths from 
Amyloidosis 
(per 100000 
population) 
New patients 
diagnosed 
with amyloid 
at NAC 
Incidence* of 
Amyloidosis 
per 100 000 
Number of 
deaths in 
NAC patients 
North east 27386 2,570600 20 0.73 0.77 2 0.07 4 
North west 70740 6,874100 45 0.63 0.65 24 0.35 24 
Yorkshire and the 
Humber 
50539 5,217500 28 0.55 0.54 22 0.42 13 
East midlands 42296 4,429400 25 0.59 0.56 21 0.47 8 
West midlands 52318 5,408400 33 0.63 0.61 35 0.64 13 
East of England 52689 5,717400 49 0.93 0.85 32 0.56 50 
London 50476 7,668300 42 0.83 0.54 56 0.73 38 
South east coast 42537 4,309400 26 0.61 0.6 24 0.55 16 
South central 33380 4,059100 33 0.98 0.81 26 0.64 24 
South west 53402 5,210400 52 0.97 0.99 25 0.47 27 
Total 475763 51,464600 353 0.74 0.68 267 0.52 217 
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Discussion 
 
Information regarding the epidemiology of systemic amyloidosis is scarce.  The 
most robust study by Kyle et al reported the incidence to be 8.9 per million person 
years.  This study used patient record data from Olmstead County, USA to 
identify patients diagnosed with the disease between 1950 and 1989, and 
incidence was extrapolated on the basis of population data for the whole of the 
USA.  The authors noted an increase in incidence across the time period.
25
 The 
findings from the Olmstead County study have not been validated or updated; 
furthermore, the epidemiology of systemic amyloidosis has not previously been 
studied in England.  A report from Boston University used death certificate data to 
estimate the number of deaths from systemic AL amyloidosis.  Although the 
diagnostic criteria for AL amyloidosis were somewhat unreliable in this study, the 
estimated incidence based on mortality data was 4.5/100000.
26
 Imaizumi et al 
used death certificates to estimate the rate of death from systemic amyloidosis in 
Japan, expressed as the number of cases with amyloid on death certificates per 
100000 population alive during that year.  They reported an increase in death rate 
from amyloid among males from 0.022/100000 in 1969 to 0.178/100000 in 
1992.
214
 
Death certificates have previously been used to estimate incidence in a 
number of rare diseases.
210
  Death certificate data is deemed a reliable way of 
estimating disease incidence only in conditions which are well defined, rarely 
misdiagnosed, and consistently fatal without changing survival.
210
  The sensitivity 
of mortality data for predicting disease incidence in systemic AL amyloidosis has 
not been systematically determined. On the one hand, there are well defined 
diagnostic criteria, it has a high mortality and short survival,
26
 whilst on the other 
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hand, it may be misdiagnosed
44
 and survival has steadily been improving,
213
 
introducing uncertainty into calculations of disease incidence.  In this study, 
amyloidosis was present on the death certificates of 79% of individuals with 
known systemic amyloidosis in England and 82.5% of individuals with known 
systemic AL amyloidosis.  Using the information from death certificates, an 
estimated 0.58/1000 deaths in England were attributable to amyloidosis, with a 
significant increase reported over the decade. Among those reviewed at the NAC 
who died, 80% had AL amyloidosis.  It is estimated therefore that ~0.46/1000 
deaths in England are attributable to AL amyloidosis.  Patient survival increased 
substantially between 2000 and 2008 meaning that estimates of disease incidence 
calculated from death certificate data alone may be invalid.  
Individual level data for patients reviewed at the NAC are likely to be 
extremely reliable particularly with respect to presence and type of amyloid.  Only 
48.2% of patients with systemic amyloidosis who died in 2008 had been seen at 
the NAC however, clearly suggesting that not all patients with systemic 
amyloidosis in England are seen at the centre.  An estimate of incidence of 
systemic amyloidosis which is calculated solely on the basis of NAC cases will 
undoubtedly be an underestimate; however, 0.51 per 100000 population in 2008 
can reliably be considered a minimum disease incidence.  The true incidence of 
systemic amyloidosis is likely to be approximately double this figure, ~1.0 per 
100000, although once again, this may be an underestimate since 21% of patients 
with systemic amyloidosis do not have amyloidosis on their death certificates.  
This estimate (10 per million population) is consistent with the reported incidence 
from Kyle et al of 8.9 per million person years.  
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The incidence, or perhaps more likely, recognition of systemic 
amyloidosis appears to be increasing.  Data from Olmstead County showed an 
apparent rise in incidence of AL amyloidosis during the last decade of their 
analyses.  In the present study, there was a significant rise each year in the number 
of individuals with amyloidosis on their death certificate, accompanied by a 
parallel rise in the number of patients with systemic amyloidosis assessed at the 
NAC throughout the study period.  This apparent rise may reflect an actual 
increase in disease incidence, but could equally well be contributed to through 
better awareness of the disease itself and/or existence of a national referral centre, 
as well as improved diagnostic techniques.   
The most rapidly advancing area for diagnostic imaging is in cardiology. 
Increasing numbers of patients are diagnosed through echocardiography and 
cardiac MRI, and this may have a significant impact on disease incidence. This 
theme is explored further in the next chapter which is focussed on patients with 
isolated cardiac disease. 
 
Study Limitations 
 
From a combination of NAC data and death certificate data one can robustly 
calculate the sensitivity of death certificates in reporting systemic amyloidosis.  
Unfortunately the specificity of death certificate data for reporting systemic 
amyloidosis cannot be calculated since further clinical information is not available 
on many of the relevant individuals, although since amyloid histology is required 
for diagnosis and is extremely specific. It is therefore assumed that specificity is 
likely to be very high.  The number of deaths among amyloidosis patients who 
were not seen at the centre has been used to make an estimate of the total number 
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of patients with amyloidosis in England. However, the proportion of patients who 
are diagnosed with amyloidosis but never seen at the NAC that have amyloidosis 
on their death certificates is not known.  It is conceivable that patients with 
systemic amyloidosis who attend the NAC are more likely to have amyloidosis on 
their death certificate than those with systemic amyloidosis who do not attend the 
NAC.  
 102 
 
 
Results Section Two: Cardiac Amyloidosis 
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Chapter Four: Senile Systemic Amyloidosis, 
Clinical Features at Presentation and Outcome 
Introduction 
 
ATTRwt amyloidosis is almost certainly under diagnosed
216
 and as the 
prevalence increases with age and the population demographic shifts towards the 
elderly, the burden of disease will become an increasing problem.
61, 62
 The results 
of chapter 3 showed an estimated incidence of ATTRwt in people over 80 years 
old to be 0.3 per hundred thousand population. In recent years sophisticated 
imaging techniques such as cardiac MRI have become increasingly used. This has 
resulted in higher detection rates of cardiac amyloidosis. The aging population 
and increased detection rate are likely to have a significant impact on the disease 
epidemiology and this is explored further in chapter 4. 
Without effective treatment cardiac AL amyloidosis is a fatal disease. Correctly 
identifying the amyloid type is vital as it has a major impact on prognosis and 
completely dictates treatment. Biopsy followed by Congo Red staining and 
immunohistochemistry is the gold standard for diagnosing and typing amyloid.
200
 
Correct diagnosis of isolated cardiac amyloidosis clinically is especially 
challenging as symptoms are often non specific.  The diagnosis of ATTRm is 
relatively straightforward if genetic screening of the TTR gene is performed but 
differentiating between ATTRwt and AL amyloidosis can be more problematic. 
ATTRwt invariably affects older patients who may well have an incidental 
MGUS. If the co-existence of amyloidosis and a plasma cell dyscrasia alone is 
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used as evidence of AL amyloidosis, chemotherapy based treatment may be given 
in error.
44
  
Detection of late gadolinium enhancement on cardiac MRI is reported to 
be characteristic of amyloidosis. Some features appear more characteristic of 
ATTR amyloid such as transmural late gadolinium enhancement (LGE) and right 
ventricular LGE, but currently MRI appearances cannot differentiate between 
amyloid types.
215
  
Currently there is no specific licensed treatment for ATTRwt amyloidosis, 
but new drugs are on the horizon with several clinical trials currently recruiting 
patients in transthyretin amyloidosis:   
http://clinicaltrials.gov/ct2/results?term=transthyretin.  
Defining the clinical course of the disease is important both for patient 
counselling in a disease for which there is currently limited literature and to 
identify clinical diagnostic and response criteria for further treatment trials.
70,144 
 The aims of this study were: firstly to characterise the disease natural 
history and identify factors which predict survival, and secondly to decipher 
whether baseline patient characteristics could be used to confidently diagnose the 
amyloid type thereby avoiding the need for cardiac biopsy. 
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Methods 
Patients 
 
One hundred and two patients with biopsy confirmed ATTRwt were analysed. 
Cases were diagnosed between 2002 and August 2011 at the NAC and compared 
to 36 patients with biopsy confirmed isolated cardiac AL amyloidosis diagnosed 
over the same time period. 
In the AL group, 20 patients were referred from cardiology and 16 patients 
were referred by haematologists, all AL patients had been seen by a cardiologist 
prior to initial assessment. In the ATTRwt group, 73 patients were referred from 
cardiology, 18 from haematology, 3 from general practice, 2 each from 
gastroenterology and urology and one each from elderly care, neurology, 
rheumatology and respiratory medicine. Ninety three of the 102 patients in the 
ATTRwt group had been seen prior to referral by a cardiologist.  
All patients had an initial diagnostic assessment. Onset of symptoms was 
defined on the basis of the history but a diagnosis of amyloidosis was dated from 
the biopsy, which provided histological proof of amyloid. Patients were then 
reviewed at 6-12 month intervals. Evidence of a plasma cell dyscrasia was defined 
as any of the following: detectable M-protein on plasma electrophoresis or 
immunofixation, Bence Jones proteins in urine or abnormal serum free light chain 
level (Kappa >19.4, Lambda >26.3) or abnormal ratio (0.26-1.65). 
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Diagnostic Procedures 
 
Amyloid deposition was confirmed histologically in all patients.
200
 All ATTRwt 
patients had immunohistochemical confirmation of transthyretin amyloidosis from 
a variety of tissues. All patients with transthyretin amyloidosis were confirmed to 
be wild type on genotyping.
208
  
All patients had amyloidotic cardiomyopathy defined by either 
endomyocardial biopsy proof of amyloid deposition or echocardiographic features 
consistent with amyloid deposition.
60
 Significant systemic amyloidosis was 
excluded by radiolabelled 
123
I-labelled SAP scitnigraphy.
51
 
 
Instrumental Definitions 
 
ECG measures were based on standard definitions.
217
 Echocardiographic 
measures of chamber quantification were based on standard recommendations.
218
 
In the survival analyses left ventricular wall thickness was graded as: mild 1.3-
1.5cm, moderate 1.6-1.9cm and severe >2.0cm. Ejection fraction was graded as: 
normal >55%, mild impairment 45-54%, moderate impairment 36-44% and 
severe impairment <35%.  
Classification of diastolic dysfunction on echocardiography was based on 
published data.
219
 Not all patients were included in the classification of diastolic 
dysfunction due to lack of measured parameters in patients diagnosed before 
2005. Patients who had AF with a rapid ventricular rate were excluded from 
grading of diastolic function. Patients with rate controlled AF were included when 
a combination of E/E’, MVdecT and IVRT were measured. 
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Statistical Analysis 
 
Results are expressed as mean (±SD), median (IQR) or percentage as appropriate. 
Patient follow-up was censored at the last clinic visit. Univariate analysis 
comparing the baseline data in the two groups used the unpaired t test (if the data 
were normally distributed) and the non-parametric Mann Whitney test for 
numerical variables, and Chi-square or Fisher’s exact test for categorical 
variables. Factors that achieved statistical significance (p<0.05) and deemed 
clinically relevant were included in a multivariable logistic regression model 
(SPSS Statistics Version 19). 
Patient survival was estimated by Kaplan-Meier analysis (Stata version 11: 
StataCorp LP). The log-rank test was used to compare differences in stratified 
Kaplan-Meier survival curves. Cox regression analysis using a backward stepwise 
approach was used to investigate factors associated with overall survival in 
ATTRwt patients, using IBM SPSS Statistics (Version 19) (Statistical significance 
was achieved if p < 0.05). 
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Results 
 
Referral Patterns and Diagnosis 
 
Of the 102 patients diagnosed with ATTRwt: 65 (63.7%) were diagnosed on 
endomyocardial biopsy, 24 (23.5%) on gastrointestinal biopsy, four (3.9%) from 
bladder biopsy, four (3.9%) on fat biopsy, one (0.9%) on carpal tunnel biopsy and 
one (0.9%) from fallopian tube tissue. Fifteen (41.6%) patients had amyloid 
proven on a biopsy prior to the initial assessment in the AL group and 46 (46.5%) 
in the ATTRwt group. The initial investigation which prompted the referral or 
biopsy in the AL group was: echocardiogram in 22 (61.1), CMR in 12 (33.35), 
one case each for bone marrow and CT scan. In the ATTRwt group the initial 
investigation which prompted referral or biopsy was echocardiogram in 55 
(55.5%), CMR in 37 (37.4%), cystoscopy in 2 cases and one case each for 
colonoscopy, gastroscopy and cardiomegaly on chest x-ray. Two cases were 
referred on the basis of evidence of a plasma cell dyscrasia and a history of 
breathlessness. The 36 out of a total of 1953 patients with AL amyloidosis 
diagnosed with isolated cardiac AL amyloidosis after comprehensive evaluation, 
represented 1.84% of AL patients. 
The number of diagnoses of ATTRwt has increased in the past five years 
with a doubling in the last 12 months. From 2007 to 2011 75-80% of referrals 
were from cardiologists each year. 
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Figure 4.1 Patients diagnosed with biopsy proven ATTRwt amyloidosis since 
2006 
 
Features in the History 
 
Three patients did not have evidence of cardiac amyloid on echocardiography. 
These were patients with amyloid in tissue from gastrointestinal tract, bladder and 
carpal tunnel; these patients were therefore removed from further analyses.  
Baseline (initial assessment) patient demographics of both groups is 
shown in Table 4.1. ATTRwt is a predominantly male disease; 88.8% of affected 
patients were men, significantly higher than the 69.4% of cardiac AL patients. 
The median age at presentation was 73 years, significantly older than 63 yrs in 
cardiac AL. Presenting symptoms were similar in both groups with the majority 
reporting breathlessness. The severity however was greater in the AL group with 
more patients describing NYHA class III/IV symptoms and over 50% of ATTRwt 
patients describing NHYA class I/II symptoms. The variety of presenting 
symptoms was much wider in the ATTRwt group than the AL patients. A history 
of arrhythmia was common, 43.4% had a history of AF which was the presenting 
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complaint in 10% of patients. AF was more common in the ATTRwt group than 
the AL patients. Eight percent of ATTRwt patients were found to have amyloid 
incidentally on routine testing or at the time of an operation for a different 
complaint, this feature was not seen in AL amyloidosis. TTR patients diagnosed 
by cardiac biopsy as opposed to other tissues were younger (median age at 
diagnosis of 72 vs. 77yrs (P=<0.01)) with a lower NT-proBNP (median 
295pmol/L vs. 540pmol/L, P=0.03). Although there was a higher mitral valve E/A 
ratio (median 2.7 vs. 1.6, P=0.01)) in the cardiac biopsy group, all other measures 
of diastolic dysfunction (IVRT, E/E’ and mitral valve deceleration time) were not 
significantly different, implying no real difference in overall diastolic function. 
A history of carpal tunnel syndrome was significantly more common in 
the ATTRwt group than the AL group (48.5% vs. 8.3%). In the AL group 2 
patients had symptoms of carpal tunnel at the time of diagnosis and one had a 
release a year prior to diagnosis. In the ATTRwt group 12 patients had symptoms 
of carpal tunnel syndrome at the time of diagnosis and 40 had previous release 
operations a median of 8 (IQR 3-10) years prior to diagnosis. 
 
Baseline Biochemical Evaluation 
 
On univariate analysis (Table 4.1) there were no major differences in biochemical 
markers of liver function consistent with the SAP scans which showed no cases of 
hepatic amyloid deposits in either group. There was significantly more proteinuria 
in the AL group perhaps due to renal amyloid involvement which was below the 
threshold of detection by SAP scintigraphy. Four AL patients had >1g of 
proteinuria. Of these patients, one had diabetes and one had a duplex kidney, the 
remaining two did not have any comorbidity which would explain proteinuria. 
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There was no difference in eGFR in patients with proteinuria compared to those 
without. Three patients with ATTRwt had underlying renal diseases associated 
with >1g of proteinuria, all other patients had <1g of proteinuria at baseline. Three 
ATTRwt patients had underlying diseases such as longstanding hypertension and 
diabetes which could explain proteinuria; however the cause for low level 
proteinuria was not explained by co-morbidities in the other patients.  
The most significant difference on univariate analysis was in NT pro-BNP 
measurements. This was a median of 714pmol/L in the AL group and 
317.5pmol/L in ATTRwt group (P<0.001). Evidence of a plasma cell dyscrasia 
was found in all patients with cardiac AL but also as an incidental finding  in 
24.1% of patients with ATTRwt (P<0.001). 
 
 
Baseline Cardiac Investigations 
 
On univariate analysis of ECG features, significantly more patients were in AF or 
atrial flutter in the ATTRwt group and more patients had AV conduction 
abnormalities (Table 4.2). Low QRS complexes were only seen in 27.3% of the 
AL patients and 12.9% of ATTRwt patients. There were significant differences in 
several echocardiographic features between the two groups (Table 4.3). On 
univariate analysis patients with ATTRwt had significantly thicker walled hearts 
than the AL group. Both groups had predominantly diastolic dysfunction, most 
commonly grade III/IV, indicating a restrictive filling pattern. The E/E’ was 
higher in the AL group (median (IQR) 21.76 (15.7, 26.06) vs. 15.81 (12.37, 
17.91); P = <0.001). The mitral valve deceleration time was higher in the 
ATTRwt group (mean; 191.2 ± 59.35 vs. 147.9 ± 42.46; P = <0.001, CI 20.42-
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66.26) and the IVRT was also higher in the ATTRwt group (mean ± SD 87.21 ± 
25.41 vs. 74.35 ± 20.74; P = 0.01, CI 2.68-23.03). Median left ventricular ejection 
fraction was 47% in both groups. 
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Table 4.1 Baseline Patient Characteristics in Patients with ATTRwt and Isolated 
Cardiac AL Amyloidosis (*Either a detectable paraprotein or an abnormal free 
light chain ratio). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AL (N= 36) ATTRwt (N=99) P value 
Male, n (%) 
Ethnicity, n (%) 
Caucasian –Northern European 
Caucasian – Southern European 
North American 
Indian Subcontinent 
Sub-Saharan African 
Afro-Caribbean 
25 (69.4) 
 
33 (92) 
0 (0) 
0 (0) 
1 (3) 
2 (5) 
0 (0) 
88 (88.8) 
 
92 (93) 
2 (2) 
1 (1) 
0 (0) 
1 (1) 
3 (3) 
0.01 
 
0.36 
Age at diagnosis, years (IQR) 63.0 (56.6, 65.8) 73.0 (69.5, 78.2) <0.001 
Age at symptom onset , years (IQR) 60.2 (53.8, 65.2) 70.9 (67.7, 74.1) <0.001 
Age at death (IQR) 63 (56, 67) 77 (74, 81) <0.001 
NT pro-BNP, pmol/L (IQR) 714.0 (427.5,1573.0) 317.5 (212.3, 909.3) <0.001 
NT pro-BNP (age 70 and under), pmol/L (IQR) 633 (412, 1073) 293 (227, 404)  
NT pro-BNP (age over 70), pmol/L (IQR) 2127 (1498, 2755) 440 (244, 794)  
Troponin T, ng/mL (IQR) 0.05 (0.02, 0.1) 0.04 (0.02, 0.05) 0.3 
Positive Troponin T, N (%) 19 (52.7) 51 (51.5)  
Hb, g/dL (IQR) 13 (12.4, 13.6) 14.8 (12.8, 14.8) 0.005 
Albumin, g/L (IQR) 41 (39, 43) 44 (41.3, 46.0) <0.001 
Bilirubin, µmol/L (IQR) 14 (11, 24) 15 (13, 28) 0.2 
ALP, U/L (IQR) 95 (72, 148) 106 (77, 138) 0.5 
GGT, U/L (IQR) 75.5 (41.0, 142.3) 111.0 (71.0, 162.3) 0.1 
eGFR, ml/min (IQR) 64 (48, 87) 63 (41, 69) 0.2 
24 hour urine protein, g (IQR) 0.39 (0.1, 0.8) 0.1 (0.1, 0.2) <0.001 
Lambda free light chain, mg/L (IQR) 255 (116, 468) 16 (13, 21) <0.001 
Missing, n (%) 0 (0) 8 (8)  
Kappa free light chain, mg/L 31 (7, 22) 18 (14, 24)  0.01 
Missing, n (%) 0 (0) 8 (8)  
Detectable paraprotein (%) 24  (66) 14/93 (15) <0.001 
Missing, n (%) 0 (0) 6 (6)  
Any detectable plasma cell dyscrasia* n (%) 36 (100) 22/91 (24%) <0.001 
Missing, n (%) 0 (0) 8 (8)  
Supine systolic Blood Pressure,  
mm Hg (IQR) 
107 (95, 118) 116, (107, 134) 0.006 
Supine diastolic Blood Pressure,  
mm Hg (IQR) 
72 (60, 76) 74 (66, 81) 0.1 
Orthostatic hypotension, n (%) 7 (19)  9 (9) 0.1 
Primary presenting symptom, n (%)    
Breathlessness 29 (80.5) 53 (53.5)  
Atrial fibrillation/Flutter 0 (0) 10 (10)  
Oedema 0 (0) 8 (8)  
Incidental finding 0 (0) 8 (8)  
Syncope 1 (3) 6 (6)  
Palpitations 0 (0) 3 (3)  
Chest pain 2 (5.5) 3 (3)  
Orthostatic hypotension 0 (0) 2 (2)  
Frank haematuria 0 (0) 2 (2)  
Carpal tunnel syndrome 0 (0) 1 (1)  
Cough 0 (0) 1 (1)  
Diarrhoea 0 (0) 1 (1)  
Dizziness 0 (0) 1 (1)  
Chest sepsis 1 (3) 0 (0)  
Lethargy 3 (8) 0 (0)  
NYHA Class, n (%)    
I 0 (0) 35  (35) <0.001 
II 14 (38) 26 (26)  
III 17 (47) 25 (25)  
IV 5 (13) 6 (6)  
missing 0 (0) 7 (7)  
Weight loss, n (%) 14 (38) 18 (18) 0.02 
History of atrial fibrillation, n (%) 6 (16) 43 (43) 0.004 
History of ischaemic heart disease, n (%) 4 (11) 27 (27) 0.06 
Pacemaker, n (%) 2 (5.5) 13 (13) 0.4 
Previous Normal Coronary Angiogram, n (%) 8 (22) 12 (12) 0.2 
Previous Coronary Artery Bypass Graft, n (%) 0 (0) 8 (8) 0.1 
History of chest pain, n (%) 3 (8) 14 (14) 0.6 
History of carpal tunnel syndrome, n (%) 3 (8) 48 (48) <0.01 
History of lower limb neuropathy, n (%) 3 (8) 9 (9) 1.00 
Macroglossia or bruising, n (%) 9 (25) 0 (0) <0.001 
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Table 4.2 Baseline Electrocardiographic Features in patients with ATTRwt and 
Isolated Cardiac AL amyloidosis (*Percentage of patients who were not paced are 
displayed) 
 AL   
(N = 34) 
ATTRwt  
(N= 93) 
P value 
Rhythm, n (%)    
Sinus 28 (82) 42 (45) 0.002 
Atrial Fibrillation 4 (11) 36 (38)  
Atrial Flutter 0 (0) 7 (7.5)  
Paced 2 (5) 8 (8)  
Mean voltage leads II/III/AVF (mm) 5.4 ± 3.6 2.9 ± 2.9 0.4 
Total QRS score leads II/III/AVF (mm) 14.9 ±10.2 17.5±8.6 0.1 
Mean voltage leads V4/V5/V6 (mm) 11.5 ± 5.5 13.5 ± 4.7 0.2 
Total QRS score leads V4/V5/V6 (mm) 30.7± 10.9 39.6±14.9 0.01 
Low QRS complexes* (N/%) 9 (27) 11 (13) 0.2 
Any AV conduction abnormality* n (%) 14 (43) 50 (58) 0.2 
Right Bundle Branch Block 1 (3) 14 (16)  
Left Bundle branch block 2 (6) 17 (20)  
First degree heart block 5 (15) 10 (11)  
Bi fascicular block 5 (15) 9 (10.5)  
Junctional rhythm 1 (3) 0 (0)  
QT interval (ms) 401 ± 71.5 430.1 ± 55.2 0.003 
QTcB (ms) 596.6 ± 745.0 478.7 ± 53.3 0.2 
T wave inversion, n (%) 18 (53) 37 (39) 0.2 
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Table 4.3 Baseline Echocardiographic Parameters in Patients with ATTRwt and 
Isolated Cardiac AL Amyloidosis 
 
(*Due to varying times at which echocardiography was performed not all 
measures were reported in all patients). 
 
 AL   ATTRwt  P value 
Interventricular septal thickness in 
diastole (IVSd), (cm) 
1.5 ± 0.2 
(n = 34) 
1.7 ± 0.3 
(n = 95) 
<0.001 
Left ventricular posterior wall 
thickness in diastole (LVPWd), 
(cm) 
1.5 ± 0.2 
(n = 34) 
1.7 ± 0.2 
(n = 95) 
<0.001 
Left ventricular internal dimension 
in diastole (LVIDd) (cm) 
4.2 ± 0.4 
(n = 34) 
4.4 ± 0.6 
(n = 95) 
0.1 
LV Ejection Fraction (%) 47.8 ± 12.6 
(n = 34) 
46.6 ± 12.8 
(n = 95) 
0.9 
E/A Ratio  2.6 ± 1.3 
(n = 26) 
2.4 ± 1.0 
(n = 66) 
0.9 
E/E
I 
(IQR)
 
21.8 (15.7, 26.1) 
(n = 31) 
15.8 (12.4, 17.9) 
(n  = 86) 
<0.001 
Mitral valve deceleration time 
(MVdecT) (ms) 
147.9 ± 42.5 
(n = 31) 
191.2 ± 59.4 
(n = 91) 
<0.001 
Iso-volumetric relaxation time 
(IVRT) (ms) 
74.4 ± 20.7 
(n = 31) 
87.2 ± 25.4 
(n = 79) 
0.01 
Tissue Doppler imaging lateral 
wall in diastole (TDIs wave lateral) 
(ms) 
0.06 ± 0.02 
(n = 20) 
0.06 ± 0.05 
(n = 70) 
0.4 
Grade of diastolic dysfunction, n 
(%) 
(n = 29) (n = 76)  
Normal 0  0.4 
I 2 (7) 10 (13)  
II 5 (17) 19 (25)  
III/IV 22 (76) 47 (62)  
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Distinguishing Between Patients with Isolated AL Amyloidosis and 
ATTRwt  
 
Baseline characteristics which could distinguish between the two diagnoses were 
identified. All patients in the AL amyloidosis group had a detectable underlying 
plasma cell dyscrasia, indicating that if no plasma cell dyscrasia could be 
identified in this cohort, the diagnosis was ATTRwt. No patient with ATTRwt had 
evidence of macroglossia which was purely an indicator of AL amyloidosis. A 
logistic regression model was used on the remaining 47 patients (25 patients with 
AL amyloidosis and 22 patients with ATTRwt) who had a detectable plasma cell 
dyscrasia and no macroglossia. There were no clinically relevant differences in 
baseline characteristics in the excluded patients when stratified by amyloid type.  
NT pro-BNP and the age at diagnosis were both associated with risk of ATTRwt. 
NT pro-BNP was higher in patients with AL amyloidosis. The odds of having 
ATTRwt reduced by 0.1% for every pmol/L unit increase in NT-pro BNP 
(P=0.04). Likewise patients with ATTRwt were older, the odds of ATTRwt 
increasing by 102% for every 1 year increase in age (P=0.02). A further logistic 
regression analysis which replaced actual age at diagnosis with age at diagnosis as 
a binary variable (27 patients aged ≤ 70 years and 20 patients aged > 70 years) 
indicated that both the binary age variable and NT pro-BNP at baseline were 
significantly associated with diagnosis (P=0.009 and P=0.03, respectively). Figure 
4.2 shows the probability of having ATTRwt amyloidosis in patients who have 
isolated cardiac amyloidosis without macroglossia or easy bruising, with a 
detectable plasma cell dyscrasia in patients above or below 70 years of age, 
according to the NT-proBNP at baseline. Patients less than or equal to 70 years 
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old were more likely (probability > 0.5) to have ATTRwt than AL if the NT pro-
BNP was <183pmol/L and patients over 70 years old with an NT-proBNP of 
<1420pmol/L were more likely to have ATTRwt. Using this combination of age 
and NT-proBNP, the positive predictive value was 90.0% and negative predictive 
value, 85.2%, with a positive likelihood ratio of 10.2 and negative likelihood ratio 
of 0.19. The area under the ROC curve was 0.98 (CI 0.95-1.0), sensitivity 83.3% 
and specificity 92%. 
 
Figure 4.2 Predicted probability of wild type transthyretin amyloidosis in patients 
aged 70 years and below or over 70 years with a detectable plasma cell dyscrasia 
by NT pro-BNP. 
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Patient Survival 
 
Survival from diagnosis in patients with ATTRwt was significantly longer than 
for the cardiac isolated AL group (log rank test P=0.001). Median survival for 
patients with ATTRwt was 2.71 years and in cardiac AL amyloidosis survival was 
0.87 years (Figure 4.3). Median survival from the onset of symptoms was much 
longer than from diagnosis in the ATTRwt group; 6.07 years compared to 1.7 
years in the cardiac AL group (log rank test P=<0.0001 (Figure 4.4). There was no 
difference in survival in ATTRwt patients with or without a detectable clone. 
A Cox proportional hazards multivariable survival analysis of the 
association of variables at diagnosis and death in patients with ATTRwt 
amyloidosis is shown in Table 4.4. A positive troponin T was strongly associated 
with death; hazard ratio (HR) 4.99 (95% CI 2.05-12.13: P=<0.001), as was having 
a pacemaker in situ; HR 4.90 (95% CI 1.74-13.80: P=0.003).  There was no 
significant difference in survival between patients with NYHA class II/ III 
symptoms and those with class I. NYHA class IV symptoms were however 
associated with a significantly higher risk of death, HR 15.14 (95% CI 3.59-63.80: 
P=<0.001). However the confidence limits are wide for this variable. Baseline 
factors entered into the model which showed no significant association with death 
were; age, NT-proBNP per unit increase, IVSd graded as mild, moderate or 
severe, grade of diastolic dysfunction, ejection fraction graded as normal, mild, 
moderate or severe, AV conduction abnormality or atrial fibrillation on ECG. 
Thirty two patients died in the ATTRwt group. The primary cause of death 
reported on the death certificates were as follows; 17 from congestive cardiac 
failure, and one each of: complete heart block, hypertensive heart disease, 
ischaemic heart disease, ischaemic stroke, old age, multi-organ failure, renal 
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failure, acute myeloid leukaemia, mesothelioma, metastatic lung cancer, urinary 
tract infection and pneumonia. The cause of death is unknown to us in three 
patients. Only two patients in the AL amyloidosis group developed extra-cardiac 
amyloid, one patient had symptoms of progressive peripheral neuropathy and one 
patient developed end stage renal failure. Twenty one patients (58%) died before 
their 6 month follow-up appointment. 
 
 
Table 4.4 Cox Regression model of survival outcome from diagnosis in patients 
with ATTRwt amyloidosis.  
 
Variable N Hazard Ratio 95% CI P value 
Positive Troponin T 51 4.9 2.1-12.1 < 0.001 
Pacemaker 13 4.9 1.7-13.8 0.003 
NYHA Class     
I 35 Reference   
II 26 2.5 0.8-2.5 0.14 
III 25 1.8 0.6-1.8 0.29 
IV 6 15.1 3.6-63.8 <0.001 
IVSd (cm)     
1.3-1.5 19 Reference   
1.6-1.9 52 0.4 0.2-1.1 0.09 
>2.0 15 0.4 0.1-1.1 0.08 
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Figure 4.3 Patient survival from diagnostic biopsy. Median survival in patients 
with wild type transthyretin amyloidosis from diagnostic biopsy is 2.71 years 
compared to 0.87 years in patients with isolated cardiac AL amyloidosis. Overall 
survival is significantly longer in the ATTRwt group (P=0.002 Log-rank (Mantel-
Cox) Test).  
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Figure 4.4 Patient survival from onset of symptoms. Median survival in patients 
with wild type transthyretin amyloidosis from onset of symptoms is 6.07 years 
compared to 1.7 years in patients with isolated cardiac AL amyloidosis. Overall 
survival from symptoms is significantly longer in the ATTRwt group (P=<0.0001 
Log-rank (Mantel-Cox) Test). 
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Discussion  
 
ATTRwt amyloidosis is a slowly progressive disease of the elderly whose true 
incidence is unknown. ATTRwt amyloid has been shown to deposit in the carpal 
tunnel.
142
 A recent series has reported ATTRwt deposits in 34% of patients with 
idiopathic carpal tunnel syndrome.
220
 Connors et al recently reported that carpal 
tunnel syndrome was rare in patients with ATTRwt cardiac amyloid.
221
 It has 
been suggested that systemic deposition of TTR occurs years before the onset of 
cardiac dysfunction.
222, 223
 In this series, 48% of ATTRwt patients gave a history 
of carpal tunnel syndrome which preceded the onset of clinical symptoms of heart 
failure in 77%, a median of 8 years prior to the diagnosis of amyloidosis being 
made, consistent with a slowly evolving disease. ATTRwt can be found in other 
tissues aside from the myocardium and wrist.
140, 224, 225
 Almost 4% of patients 
attending the NAC presented with frank haematuria or an incidental finding on 
bladder histology. No patients have had amyloid detectable on radiolabelled 
123
I 
SAP scintigraphy. 
The apparent increase in the disease over the last couple of years reflects 
an increase in the number of referrals to the NAC. Whilst the total number of 
amyloid referrals has risen the proportion referred from cardiologists has vastly 
increased. Thirty seven percent of cases had amyloid suspected on the basis of 
CMR findings. The use of sophisticated cardiac imaging techniques such as CMR 
in elderly patients are now more readily available and as the population ages the 
prevalence of the disease may well be increasing.  
Studies describing the natural history of the disease have been limited to 
small numbers.
70
 The largest study to date was reported this year by Rapezzi et al, 
it describes the long term follow-up of 186 patients with ATTRm and compares 
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them to 30 ATTRwt controls.
267 
This chapter described the long term follow-up of 
102 patients with ATTRwt amyloidosis. Patients predominantly presented with 
heart failure, although breathlessness was generally less severe than in cardiac AL 
amyloidosis despite greater LV wall thickness. Patients with ATTRwt 
amyloidosis had more arrhythmias than those with AL and were more likely to 
have required pacing before diagnosis. These findings are consistent with those 
reported by Rapezzi et al where patients with ATTRwt were found to have greater 
LV wall thicknesses than those with cardiac AL and a higher incidence of left 
bundle branch block.
70
 This area will be further explored in the next chapter 
which uses holter monitors to identify the prevalence of dysrhythmias in cardiac 
amyloidosis. 
Low QRS complexes are widely considered a marker of diagnosis of 
cardiac amyloidosis. In this study the prevalence of this is lower than previously 
described.
226
 Whilst low voltage QRS complexes on the ECG remain a potential 
indicator of cardiac amyloid, it is important to note that normal size complexes 
should not deter physicians from considering a diagnosis of amyloid. 
A marked survival difference between patients with ATTRwt and cardiac 
AL amyloidosis has been reported before.
70, 221
  Median survival in patients with 
ATTRwt was 2.71 years from diagnosis compared with 0.87 years in the AL 
group. This is even more striking when survival from symptom onset is 
considered; the median survival in the ATTRwt group was 6.07 years and this 
may be a more useful indicator for patients who have been picked up early on in 
the course of the disease or whose cardiac amyloid is an incidental finding. 
The presence of a pacemaker was associated with a nearly 5 fold increase risk of 
death by Cox regression. Clearly this does not necessarily imply that pacemaker 
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insertion is a bad idea; indeed it seems likely that patients with conduction 
abnormalities necessitating a pacemaker are at higher risk of sudden cardiac 
death. A recent study in FAP reported that prophylactic pacemakers prevented 
major cardiac events in 25% of patients.
227
 There is no specific literature on the 
role of implantable cardiac defibrillators in ATTRwt amyloidosis but in AL type it 
seems that very careful patient selection is required as most sudden cardiac death 
is reportedly due to pulseless electrical activity which is not amenable to 
cardioversion.
228
  
A positive troponin T at baseline was associated with an almost 5 fold 
increased risk of death. Suhr et al reported NT pro-BNP to be a sensitive marker 
for diagnosing ATTR cardiomyopathy in hereditary Val30Met patients.
229
 Recent 
data from Russo et al suggested that both troponin and BNP are prognostic 
indicators in ATTR amyloidosis. Troponin appeared to be a stronger predictor 
(HR 2.2 95% CI 1.4-3.5, p=<0.01) compared to BNP (HR 1.2 95% CI 1.1-1.4, 
P<0.01).
230
 Interestingly higher baseline NT pro-BNP in our cohort was not 
associated with death in ATTRwt. Functional impairment was only of 
significance at NYHA class IV symptoms which conferred a HR of death of 
15.14, however the confidence limits for this variable were wide indicating that 
this may not be a truly significant result. Although LV wall thickness has been 
reported to be associated with survival in patients with cardiac amyloidosis,
70
 it is 
not clear that this is the case in ATTRwt as these patients were a very small 
proportion and not separately analysed in the current published literature. In this 
study echocardiographic features such as wall thickness and degree of diastolic or 
systolic dysfunction did not predict survival. 
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The combination of transthyretin amyloid on endomyocardial biopsy and 
wild type TTR gene sequencing is the gold standard for diagnosing ATTRwt. 
Whilst endomyocardial biopsy carries a low reported risk of complications of 
between 1-2%,
231
 some elderly patients are not keen to undergo such an invasive 
investigation.  Tissue from screening biopsies such as abdominal fat and rectum 
can be helpful in diagnosing amyloid, however false negatives can occur due to 
patchy amyloid deposition and Connors et al recently reported that only 27% of 
fat aspirates in ATTRwt were positive.
221
 When histological confirmation is not 
possible clinicians must rely on a combination of clinical history, imaging and 
biochemical markers to come to a diagnosis. 99mTc- DPD scintigraphy has 
shown to be a sensitive imaging technique in diagnosing cardiac transthyretin 
amyloidosis.
65, 232, 233
 Studies are currently limited by small numbers but the 
technique appears to be highly specific for transthyretin amyloidosis
67
 and it is 
emerging as a helpful diagnostic tool; however the availability of the technique is 
currently limited to centres within Europe.  
The prevalence of MGUS in the general population is 5.3 percent among 
the over 70s, rising to 7.5 percent among those 85 years of age or older.
234
 Twenty 
four percent of patients with proven ATTRwt in this series were found to have a 
detectable plasma cell dyscrasia. This incidence is higher than expected and 
reflects the increased detection rates of incidental low grade clones through the 
use of the free light assay. It is also likely that there is referral bias with 
amyloidosis sought most diligently in patients with a detectable clonal excess. It is 
unlikely that this high incidence of abnormal clones have confounded the 
phenothype. Survival was no different in the ATTRwt group when comparing 
those with or without a detectable clone; all patients have biopsy proof of amyloid 
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fibril type, and in all cases the clonal abnormality was very subtle, with no patient 
diagnosed with overt myeloma. The cause of death in the ATTRwt group did not 
appear to be related to the underlying clonal disease in any case. 
The presence of a clone cannot be used to diagnose AL type amyloidosis 
without further tissue confirmation.   Clearly the converse is also a concern 
although in this series all of the patients with isolated cardiac AL amyloidosis did 
have a detectable plasma cell dyscrasia. Indeed at the NAC cardiac biopsy proven 
isolated cardiac amyloidosis accounts for only 1.84% of patients with systemic 
AL amyloidosis. Although it has been reported that 6% of patients with AL 
amyloidosis have no detectable clone,
76
 our recent experience from the 
prospective ALchemy cohort
77
 suggests that only one of 494 new patients with 
AL amyloidosis seen at our centre had no evidence of a plasma cell clone on 
serum and urine investigations. One would therefore predict that it is extremely 
rare for a patient with AL amyloidosis to present with isolated cardiac disease and 
no detectable clone, although this is theoretically possible.  
A much more frequent clinical problem is differentiating between 
ATTRwt and AL type in elderly patients who have isolated cardiac amyloid and 
an abnormal clone. Cardiac biopsy remains the only definitive method of 
distinction, and some patients are not prepared to undergo this invasive procedure. 
In this study, despite excluding patients with isolated cardiac amyloid and 
symptoms which are pathognomonic of AL amyloidosis such as macroglossia or 
easy bruising,
76
 it was possible to estimate the risk of ATTRwt amyloid in patients 
with a detectable monoclonal protein by using a combination of age and  NT pro-
BNP. NT pro-BNP is dependent on factors such as renal function, arrhythmias 
and fluid balance. Although these factors all display co-linearity with NT pro-
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BNP they were discarded on logistic regression analysis and NT pro-BNP 
remained a strong predictor of the diagnosis of either AL or ATTRwt assessment 
of a patient with amyloidosis. Figure 4.5 shows a flow diagram which outlines the 
diagnostic process in patients diagnosed with cardiac amyloid which uses age at 
diagnosis and level of NT-proBNP to help distinguish between ATTRwt and 
isolated cardiac AL amyloidosis in patients with a plasma cell dyscrasia. 
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Figure 4.5 Diagnostic flow diagram for patients presenting with suspected cardiac amyloidosis based on cardiac imaging. Initial investigations 
should include; a comprehensive patient history and examination; investigations for an abnormal clone and genotyping for hereditary 
transthyretin amyloidosis. 
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Chapter Five: Holter Monitoring in Systemic 
Amyloidosis 
 
Introduction 
 
Infiltration of the heart confers a poor prognosis in AL amyloidosis and is 
associated with sudden death.
123, 235
 Patients with cardiac AL amyloidosis (cAL) 
frequently have conduction disturbances on ECG and indeed, ECG abnormalities 
may indicate cardiac involvement.
60
 Previous small studies have described 
frequent complex ventricular arrhythmias in patients with AL amyloidosis.
236
 
There have been few studies in patients with cardiac transthyretin (cATTR) 
amyloidosis and data is scant. The results from chapter 4 showed that significantly 
more patients with isolated cardiac AL amyloidosis were in sinus rhythm on the 
ECG than those with ATTRwt (82% vs 45%, P = 0.02).  Atrial fibrillation was 
common in patients with ATTRwt (38%), but syncope was rarely the presenting 
symptom in either disease.  Of the thirty two patients who died in the ATTRwt 
cohort only one had complete heart block documented as the primary cause of 
death and no patients were described as dying from a sudden cardiac death or 
reported arrhythmia. These results could suggest that rhythm disturbances are 
common but the significance is relatively unknown in the ATTRwt phenotype. 
Data reported in patients with familial amyloid polyneuropathy show that patients 
frequently require pacemakers after liver transplantation suggesting that 
bradycardia and heart block may complicate cATTR.
227
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Histological analyses have shown that amyloid fibrils may have an affinity 
for the His-purkinje system, and prolongation of infra-His conduction times are 
common in cAL.
237,238
 Median left ventricular wall thickness at the time of 
diagnosis is greater in cATTR patients than those with cAL.
226
 One could 
therefore hypothesize that the greater cardiac mass could be associated with 
increased disruption of the His purkinje system and thus an increase in arrhythmic 
activity,  however, the prognosis is much better in cATTR than in cAL.
70
 This 
may indicate that arrhythmias are not the leading mode of death in these patients 
or that the pathological effects of these two amyloid fibril proteins are markedly 
different.  There is limited data regarding the mode of death in patients with 
cardiac amyloidosis.  Electromechanical dissociation was determined as the cause 
in the majority of AL patients in one study of prophylactic implantable 
defibrillators,
228
 and based on this data, there has been a general reluctance to 
implant defibrillators into patients with cardiac amyloidosis.  
The primary aims of chapter 5 are to determine the spectrum and 
frequency of rhythm disturbances in patients with cardiac amyloidosis and 
compare the two main amyloid types that affect the heart, AL and ATTR, and to 
determine whether there is an association between severity of cardiac amyloidosis 
by echocardiographic parameters and prevalence of dysrhythmias. 
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Methods 
 
Patient Selection and Characterisation 
 
This single UK centre prospective study was performed between May 2010 and 
June 2012.  All patients newly referred to the NAC with suspected systemic 
amyloidosis were eligible for 24 hour Holter monitoring.  Due to the limited 
availability of Holter equipment at the NAC, placement of monitors was 
prioritised to patients thought, on the basis of their referral letter, to have cardiac 
involvement by amyloid.   
All study patients were asked to record periods of strenuous activity and 
symptoms during the monitoring period by means of a diary card (Appendix 1).  
During the clinical consultation, doctors were required to complete a detailed case 
report form (Appendix 2), which included recording information on: previous 
cardiac history, current symptoms of syncope, palpitations, chest pain, 
breathlessness, NYHA class, exercise tolerance and medications. 
Investigation of all study patients included an electrocardiogram, 
echocardiogram and biochemical analysis of serum.  Biochemical analysis 
included the cardiac biomarkers troponin T and NT-proBNP, and serum 
potassium, calcium and magnesium concentration as well as thyroid function 
tests.  The assay for troponin T was replaced by a high sensitivity assay in 
November 2010.  A positive Troponin T was defined as >0.03 ng/mL for the low 
sensitivity assay and >0.014 ug/L for the high sensitivity assay. 
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Diagnosis 
 
Diagnosis of amyloidosis was based on histological proof of amyloid and was 
obtained from a variety of tissues, as previously described.
200
  Genotyping was 
performed in patients who were suspected of having hereditary amyloidosis from 
their clinical assessment.
208, 239
  Presence of cardiac amyloidosis was defined as a 
mean left ventricular wall thickness greater than 12 mm in the absence of 
hypertension or other potential causes of left ventricular hypertrophy, according to 
consensus criteria for AL amyloidosis.
60
  The same criteria were applied to 
patients with ATTR amyloidosis to define presence of cardiac amyloidosis since, 
to date, separate criteria have not been defined. 
 
Monitoring Procedures 
 
Continuous twenty-four hour electrocardiographic monitoring (Holter monitoring) 
was performed using a portable cassette recorder with three lead placements 
(Spacelabs Healthcare Lifecard CF).  Analysis of the 24 hour records was 
performed by an experienced electro physiologist using Pathfinder Digital 
Software V8.701 (Spacelabs).  Two consultant cardiologists reviewed the traces to 
verify the reported results. 
Ventricular arrhythmias were graded as previously described.
240
  To recap 
briefly, Grade 0, no ventricular premature depolarisations; Grade 1, occasional 
ventricular premature depolarisations, no more than 30 per hour; Grade 2, more 
than 30 ventricular polarisations per hour; Grade 3, multiform ventricular 
depolarisations; Grade 4, couplets (two consecutive ventricular depolarisations); 
Grade 5, non sustained ventricular tachycardia (three or more consecutive 
ventricular beats at a rate of ≥120 beats/min, lasting for <30seconds).  
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Statistical Analysis 
 
Patient survival was measured from the date of the Holter recording using Kaplan-
Meier analysis. The Log-rank test was used to compare survival using the 
Graphpad prism software, version 5. 
Continuous data were compared using a one-way analysis of variance 
(ANOVA) for parametric samples with Bonferroni post hoc analysis and Kruskal 
Wallis for non parametric variables.  P values were adjusted for multiple testing 
accordingly.  Differences in frequencies were compared using chi-square or 
Fisher’s exact tests where appropriate using SPSS software, version 20.  A P 
value <0.05 was considered significant. 
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Results 
 
In total 452 patients had 24 hour Holter monitors performed between May 2010 
and June 2012.  During the recruitment period a total of 956 patients were 
reviewed at the NAC with suspected systemic amyloidosis including 192 with 
cAL and 137 with cATTR.  Fifty eight of the 452 patients who had Holter 
monitoring were subsequently discovered not to have systemic amyloidosis and 
their data was not analysed as part of this study.  The 394 remaining ‘study 
patients’ were censored on 13th December 2012, 6 months after recruitment of the 
last individual.  Of 394 study patients, 156 had cAL, 94 had cATTR, and 144 had 
amyloidosis without cardiac involvement (non-cardiac).  Patients with cATTR 
were more often male (84%) and were significantly older than those in the other 
two groups. 
 
Baseline Characteristics 
 
Baseline biochemical characteristics are shown in Table 5.1. There were 
statistically significant differences in potassium and Hb but these were not 
clinically significant. NT-proBNP was significantly higher in the cAL group 
compared to the cATTR group which was in turn higher than the non-cardiac 
group.  The number of patients with a positive Troponin T was no different 
between the two cardiac groups but both cardiac groups had a greater proportion 
of patients with a positive Troponin T than the non-cardiac patients. Systolic 
blood pressure was higher among non-cardiac patients than those with cAL or 
cATTR. 
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Cardiac amyloidosis was defined according to consensus criteria which use 
echocardiography alone to define cardiac amyloidosis. In the non cardiac group a 
substantial proportion of patients had an elevated Troponin T and NT pro BNP 
(table 5.1). Fourteen patients (9.7%) had an NT-pro BNP greater than 332pMol/L 
(MAYO stage 2 or 3) of these 10 had an eGFR less than 30.  Of those patients 
with a positive troponin 33 (45%) had an eGFR <60 which could explain the 
result. Thirty nine patients however had a positive troponin which could not be 
explained by renal disease suggesting that they may have cardiac amyloid which 
is below the threshold for detection by echocardiography. 
Echocardiographic parameters varied between the three groups 
(Table 5.2), wall thickness was thickest in the cATTR patients followed by cAL. 
Systolic function characterised by EF was best in the non-cardiac patients and 
worst in the cATTR group. There was no difference in measures of diastolic 
function between the cAL and cATTR patients, but both cardiac groups showed 
significantly worse diastolic function than non-cardiac patients.  Small complexes 
were seen on the ECG in 50% of cAL patients significantly more than the cATTR 
cohort (25.3%) (P<0.001).  Small complexes were seen on the ECG in a 
significant proportion (30.4%) of patients in the non-cardiac group. 
Table 5.3 shows the frequency of cardiac symptoms and cardiac 
medications. A previous history of arrhythmia was present in a significantly 
greater proportion of cATTR patients (53%) than cAL (23%) (P<0.001) and non-
cardiac (13.5%)(P<0.001). Shortness of breath featured as a presenting symptom 
in 75.8% of cAL and 77.8% of cATTR patients, significantly more than non-
cardiac patients (34.8%) (P<0.001). The severity of breathlessness measured by 
NHYA class was not different between the cAL and cATTR groups.  In both 
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cardiac groups patients were described mostly as NYHA class II whilst the non-
cardiac patients were mostly described as having NYHA class I symptoms 
(55.9%).  The distribution of patients according to the MAYO staging system was 
no different in the two cardiac groups with most patients presenting as stage 3 
disease. 
Patients with cATTR were prescribed more anti-hypertensive medications 
than cAL and non-cardiac patients. Significantly more cATTR patients were 
taking B-blockers (cATTR 49.4% vs. cAL 28.7% (P=0.002) and non-cardiac 
18.7% (P<0.001)).  
Chapter 5 
 
137 
 
Table 5.1 Baseline Biochemical Characteristics in Patients who had Holter Monitoring 
 
 
 
 
 
 
Overall 
P value 
AL Cardiac 
N = 156 
Post Hoc P value 
Cardiac AL vs. 
Cardiac TTR 
Cardiac TTR 
N = 94 
Post Hoc P value 
Cardiac TTR vs. 
Non Cardiac 
Non Cardiac 
N = 144 
 
Post Hoc P value 
Cardiac AL vs. 
Non-cardiac 
 
Age, years (CI) <0.001 64 (63, 66) <0.001 74 (72, 75)
 
<0.001 67 (65, 68) 0.163 
Sex male (%) <0.001 103 (66) 0.006 79 (84) <0.001 82 (57) 0.366 
Ca, mmol/L  (CI) 0.013 2.3 (2.26, 2.30) 0.017 2.2 (2.21, 2.25)
 
0.41 2.3 (2.25, 2.30)
 
0.99 
K, mmol/L (CI) 0.006 4.4 (4.25, 4.45)  4.5 (4.39, 4.60)
 
 4.6 (4.47, 4.66)
 
 
Hb, g/dL  (CI) 0.001 12.7 (12.43, 13.04) 0.02 13.4 (13.07, 13.73)
 
<0.001 12.4 (12.12, 12.75) 0.470 
Mg mmol/L (CI) 0.062 0.83 (0.82, 0.85)  0.85 (0.83, 0.86)  0.82 (0.80, 0.84)  
Creatinine µmol/L  (IQR) 0.266 99 (75, 150)  105 (88, 137)  96 (69, 153)  
eGFR, ml/min (CI) 0.879 60 (56.2, 64.46)  59 (55.14, 63.33)  60 (56.35, 65.55)  
TSH mU/L  (CI) 0.064 3.4 (2.95, 3.86)  2.9 (2.29, 3.41)  2.7 (2.43, 3.07)
 
 
NT pro-BNP, pMol/L (IQR) <0.001 563 (222, 1271) 0.045 423 (222, 720) <0.001 51(17, 113)
 
<0.001 
Trop T positive N (%) <0.001 125 (80) 0.21 84 (89) <0.001 72 (50) <0.001 
Sys BP, mmHg  (CI) <0.001 114 (111, 117) 0.245 118 (115, 122)
 
<0.001 130 (127, 134)
 
<0.001 
Dias BP, mmHg  (CI) 0.003 70 (68, 72) 0.375 74 (70, 75)
 
0.411 75 (73, 77)
 
0.002 
BMI, kg/m
2
 (CI) 0.266 25 (25, 26)  25 (24, 26)  26 (25, 27)  
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Table 5.2 Baseline Echocardiographic Parameters in Patients who had Holter Monitoring 
 
 
Overall 
P value 
Cardiac AL 
P value Cardiac 
AL vs. Cardiac 
TTR 
Cardiac TTR 
P value 
Cardiac TTR 
vs. Non-
cardiac 
Non-cardiac 
 
P value 
Cardiac AL 
vs. Non-
cardiac 
 
Interventricular septal 
thickness in diastole (IVSd) 
cm (CI) 
<0.001 1.52 (1.48, 1.56) <0.001 1.67 (1.62, 1.72)
 
<0.001 1.09 (1.06, 1.12)
 
<0.001 
Left ventricular internal 
dimension in diastole 
(LVIDd) cm  (CI) 
0.001 4.13 (4.03, 4.22) 0.005 4.38 (4.26, 4.50)
 
0.99 4.36 (4.25, 4.46)
 
0.004 
Left ventricular posterior 
wall thickness in diastole 
(LVPWd) cm  (CI) 
<0.001 1.44 (1.39, 1.47) <0.001 1.61 (1.56, 1.64)
 
<0.001 1.04 (1.01, 1.07)
 
<0.001 
LV Ejection Fraction  %  (CI) 
 
<0.001 52 (50, 54) <0.001 45 (43, 48)
 
<0.001 60 (59, 61)
 
<0.001 
Mitral valve deceleration time 
(MVdecT) ms (CI) 
<0.001 189 (180, 199) 0.93 198 (186, 210)
 
<0.001 236 (224, 247)
 
<0.001 
E/E’  (CI) <0.001 
 
16.9 (15.7, 18.1) 
 
0.99 16.9 (15.7, 18.1)
 
<0.001 8.82 (8.2, 9.4)
 
<0.001 
E/A Ratio (IQR) <0.001 
 
1.48 (0.91, 2.36) 
 
0.045 2.17 (1.03, 2.70)
 
<0.001 0.85 (0.73, 1.06)
 
<0.001 
Iso-volumetric relaxation 
time (IVRT) ms (CI) 
<0.001 85.3 (80.54, 90.16) 0.99 85.3 (79.93, 90.82)
 
0.001 98.8 (94.55, 103.05)
 
<0.001 
Tissue Doppler imaging 
lateral wall (TDIs) m/s (CI) 
<0.001 0.07 (0.06, 0.07) 0.26 0.05(0.04, 0.06)
 
<0.001 0.09 (0.09, 0.10)
 
<0.001 
Small complexes on ECG,  N 
(%) 
<0.001 76 (50.7) <0.001 22 (25.3) 0.99 42 (30.4) <0.001 
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Table 5.3 Baseline Symptoms and Cardiac Medications in Patients who had Holter Monitoring 
History 
Overall P 
value 
Cardiac AL 
P value  
(cAL vs. cATTR) 
Cardiac ATTR 
P value (cATTR 
vs. Non cardiac) 
Non-cardiac AL 
P value  
(cAL vs. Non-cardiac) 
Ischaemic Heart Disease, N (%) 0.162 19 (12.4)  
16 (17.8) 
 
13 (9.2) 
 
Previous Arrhythmia, N (%)   <0.001 35 (23) <0.001 48 (53.3) <0.001 19 (13.5) 0.15 
Hypertension, N (%) 0.004 43 (28.1) 0.777 32 (36) 0.414 66 (46.8) 0.003 
 Palpitations, N (%) 0.328 20 (13.1)  
10 (11.1) 
 
11 (7.8) 
 
Shortness of Breath, N (%) <0.001 116 (75.8) 0.99 70 (77.8) <0.001 49 (34.8) <0.001 
Syncope, N (%) 0.498 11 (7.2)  
8 (8.9) 
 
7 (5.0) 
 
NYHA, N (%) 1 <0.001 25 (16.7) 0.99 15 (17.4) <0.001 76 (55.9) <0.001 
2  71 (47.3)  
52 (60.5) 
 
46 (33.8) 
 
3  49 (32.7)  
15 (17.4) 
 
12 (8.8) 
 
4  3 (2.0)  
4 (4.7) 
 
1 (0.7) 
 
 MAYO stage, N (%) <0.001  
0.99 
 
<0.001 
 
<0.001 
1  49 (34.5)  
38 (42.7) 
 
124 (89.9) 
 
2  4 (2.8)  
2 (2.2) 
 
1 (0.7) 
 
3  89 (62.7)  
49 (55.1) 
 
13 (9.4) 
 
Total Blood Pressure agents, N (%) 0 <0.001 73 (48) <0.001 20 (22.7) <0.001 67 (47.5) 0.99 
1  54 (35.5)  
29 (33) 
 
41 (29.1) 
 
2  22 (14.5)  
31 (35.2) 
 
25 (17.7) 
 
3  3 (2)  
7 (35.2) 
 
2 (1.4) 
 
4  0 (0)  
0 (0) 
 
4 (2.8) 
 
5  0 (0)  
1 (1.1) 
 
1 (0.7) 
 
6  0 (0)  
0 (0) 
 
1 (0.7) 
 
Beta Blocker, N (%) <0.001 43 (28.7) 0.002 44 (49.4) <0.001 26 (18.7) 0.195 
Digoxin, N (%) 0.024 4 (2.7) 0.057 9 (10.1) 0.258 5 (3.6) 0.99 
Amiodarone, N (%) 0.197 6 (4)  
2 (2.2) 
 
1 (0.7) 
 
Other anti-arrhythmic agents, N (%) 0.682 2 (1.3)  
0 (0) 
 
2 (1.4) 
 
Aspirin, N (%) 0.552 36 (24)  
27 (30.3) 
 
38 (27.3) 
 
Angiotensin II Receptor Blocker, N (%) 0.038 12 (8) 0.105 16 (18) 0.99 23 (16.5) 0.123 
Calcium Channel Blocker, N (%) 0.001 6 (4) 0.174 10 (11.2) 0.702 25 (18) <0.001 
Other Blood Pressure Medications, N (%) 0.012 0.99 (0.7) 0.441 3 (3.4) 0.99 10 (7.3) 0.027 
Loop diuretic, N (%) <0.001 99 (66) 0.363 68 (76.4) <0.001 59 (42.4) <0.001 
Thiazide diuretic, N (%) 0.575 7 (4.7)  
4 (4.5) 
 
10 (7.2) 
 
Other diuretic, N (%) <0.001 30 (20.1) 0.99 21 (23.6) <0.001 4 (2.9) <0.001 
Chapter 5 
 
140 
 
Frequency of Arrhythmias 
 
Ten percent of cATTR patients had a pacemaker at the initial assessment, 
significantly more than cAL (1.3%; P=0.009) and non-cardiac patients (0.7%; 
P=0.003) (Table 5.4). Supra-ventricular tachycardia was uncommon, occurring in 
only ~7% of all patients with no significant difference in prevalence between the 
three patient groups.  Arial fibrillation was present in 42.7% of cATTR patients, 
significantly more than cAL (18.3%; P<0.001) which was in turn more frequent 
than non-cardiac patients (7.8%; P=0.03). Significantly more complex ventricular 
arrhythmias (ventricular grading 3-5) were seen on Holter monitoring in cATTR 
patients (64.8%) compared to cAL (44.8%; P=0.003) and non-cardiac (25%; 
P=0.003). Non sustained VT (grade 5) was seen in 29.7% of cATTR, 23.7% of 
cAL and 8.3% of non-cardiac patients. No patient had sustained VT defined as 
lasting for more than 30 seconds and no patient reported syncope on their diary 
sheet. 
The mean IVSd was significantly higher among patients with complex 
ventricular arrhythmias compared to patients without complex ventricular 
arrhythmias (Mean IVSd 1.30cm (CI 1.26, 1.35) vs. 1.52cm (CI 1.46, 
1.57)(P<0.001). There was no significant difference in mean IVSd between cAL 
patients with and without complex ventricular arrhythmias (Mean (CI) 1.57cm 
(1.49, 1.65) vs. 1.48cm (1.43, 1.53), P=0.06), and similarly no difference in wall 
thickness among cATTR patients with and without complex ventricular 
arrhythmias (Mean (CI) 1.68cm (1.61, 1.71) vs. 1.65cm (1.56, 1.53), P=0.54).  
There was no correlation between severity of cardiac involvement as assessed by 
the MAYO staging system and frequency of complex ventricular arrhythmias.  It 
seems therefore, that the amyloid fibril type (more frequent in cATTR) is 
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potentially more important than disease severity in predicting risk of complex 
ventricular arrhythmias. 
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Table 5.4 Frequency of Arrhythmias on Holter Monitoring 
 
 
* Grade 0: No ventricular premature depolarisations. Grade 1: Occasional ventricular premature depolarisations no more than 30 per 
hour. Grade 2: More than 30 ventricular polarisations per hour. Grade 3: Multiform ventricular depolarisations. Grade 4: Couplets 
(two consecutive ventricular depolarisations). Grade 5: Non sustained ventricular tachycardia (three or more consecutive ventricular 
beats at a rate of ≥120 beats/min, lasting for <30 seconds). 
 
Overall P 
value 
Cardiac 
AL 
P value  
(cAL vs. 
cATTR) 
Cardiac 
ATTR 
P value 
(cATTR 
vs. non-
cardiac) 
Non-
cardiac AL 
P value  
(cAL vs. 
Non 
cardiac) 
Pacemaker, N (%) <0.001 2 (1.3) 0.009 9 (10) 0.003 1 (0.7) 1 
Supraventricular Tachycardia, N (%) 0.967 12 (7.8)  7 (7.8)  10 (7.1)  
Bradycardia, N (%) 0.249 9 (5.7)  10 (11.1)  8 (5.5)  
Complex Ventricular arrhythmia, N (%) <0.001 70 (44.8) 0.003 61 (64.8) <0.001 36 (25) 0.003 
Atrial Fibrillation, N (%) <0.001 28 (18.3) <0.001 38 (42.7) <0.001 11 (7.8) 0.039 
  Ventricular Grading*, N (%) <0.001  0.006  <0.001  0.003 
0  32 (20.5)  10 (10.6)  48 (33.1)  
1  50 (32.7)  19 (21.1)  57 (40.2)  
2  4 (2.6)  3 (3.3)  3 (2.1)  
3  2 (1.3)  2 (2.2)  3 (2.1)  
4  31 (20.3)  31 (34.4)  21 (14.9)  
5  37 (23.7)  28 (29.7)  12 (8.3)  
 Chapter 5 
143 
 
Patient Outcome 
 
Median follow-up from Holter monitoring for the whole study population was 14 
months (IQR 8.5, 21.8), during which there were 111 (28.9%) deaths; 73 (46.7%) 
cAL, 15 (15.9%) cATTR, and 23 (16.3%) non-cardiac.  Median Kaplan Meier 
survival was not reached in any group (Figure 5.1); however, survival estimates 
were significantly worse in cAL than in both cATTR (Mean (CI) 18.1 months 
(15.9, 20.2) vs. 25 months (22.9, 27); Log rank P<0.001) and non-cardiac patients 
(Mean (CI) 26.8 (25.2, 28.4); Log rank P<0.001).  There was no difference in 
estimated survival between cATTR and non-cardiac patients. 
One hundred and thirty four patients were taking anti-arrhythmic agents at 
their initial assessment.  There was no difference in overall survival between 
patients prescribed anti-arrhythmic agents and patients not taking anti-
arrhythmics. One hundred and thirteen patients were taking B-blockers; there was 
no difference in survival between patients on and off B-blockers.  None of a total 
of 9 patients taking amiodarone died during follow-up. 
On univariate analysis of the whole cohort the only arrhythmia associated 
with significantly worse survival was atrial fibrillation (18.0 months (CI 15.3, 
20.85) vs. 24.5 months (CI 23.2, 25.8); P<0.001).  Figure 5.2 shows Kaplan Meier 
survival in the whole cohort stratified by grading of ventricular arrhythmias, there 
was a significant trend towards worse survival as grade of ventricular arrhythmia 
increased, but no individual grading was associated with significantly worse 
survival than another. 
Atrial fibrillation remained associated with poorer survival in cAL (Mean 
(CI) 10.4 months (6.5, 14.4) vs. 20.1 months (17.7, 22.57) and non-cardiac 
patients (Mean (CI) 18.7 months (12.5, 23.9) vs. 27.4 months (25.8, 28.9); P = 
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0.015, but was not associated with a worse outcome in the cATTR patients (Mean 
(CI) 23.1 months (19.6, 26.6) vs. 26.6 months (25.8, 28.9).  Among cAL patients, 
as the grading of ventricular arrhythmias increased, survival appeared to reduce 
(Table 5.5).  Grading of ventricular arrhythmias did not correlate with survival in 
the cATTR patients; there were too few events in this cohort of patients to draw 
any definitive conclusions.  There was no difference in survival when the whole 
cohort was stratified for the following parameters: presence or absence of a 
pacemaker, and presence or absence of SVT/complex ventricular arrhythmia.  
Similarly, these parameters did not appear to influence survival even when those 
taking anti-arrhythmic medications were excluded from the analysis. 
 
Table 5.5 Survival Estimates in Patients with Cardiac AL Amyloidosis by 
Grading of Ventricular Arrhythmia 
 
Ventricular Arrhythmia 
Grading in patients with 
Cardiac AL Amyloidosis 
Mean Survival 
(months) 
Lower bound 
95% CI 
Upper Bound 
95% CI 
P value 
(Log Rank) 
0 21.8 17.1 26.4 0.049 
1 18.7 14.2 23.1  
2 17.7 11.7 23.8  
3 15.3 0.01 35.1  
4 15.5 11.3 19.8  
5 15.0 10.7 19.4  
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Figure 5.1 Patient Survival from Holter Monitoring Stratified by Cardiac 
Amyloid Type 
 
Log Rank test for trend P <0.0001 
 
 
Figure 5.2 Patient Survival in Total Cohort of Patients Stratified by Ventricular 
Grading 
 
Log Rank Test for trend P = 0.01 
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Non Sustained Ventricular Tachycardia 
 
A significant proportion of patients were discovered to have grade 5 ventricular 
arrhythmias. Table 5.6 outlines the proportion that had triplets, salvos or more 
than 5 beats of non-sustained ventricular tachycardia.  In the cATTR group 14.8% 
of patients had more than 5 beats of non-sustained VT, compared to only 8.3% of 
cAL patients, and 0.7% of non-cardiac patients.  In most cases only one run of >5 
beats of VT was identified during the 24 hours of monitoring.  Seven of 13 
(53.8%) of cAL patients who had >5 beats of non-sustained VT died, compared to 
only 1 of 14 (7.1%) cATTR patients and 1 patient in the non-cardiac group.  Only 
1 patient reportedly had a cardiac arrest; he was successfully resuscitated on two 
occasions and subsequently died in a hospice.  No other patient who had >5 beats 
of non-sustained VT on their Holter had a sudden cardiac death. 
 Eleven of 14 patients with cATTR amyloidosis who had >5 beats of VT 
were taking B-blockers at the time of their first 24 hour Holter monitor.  Based on 
the Holter findings, therapeutic alterations were recommended to the treating 
physician; namely either to increase the dose of B-blocker or to change to 
amiodarone.  Five such patients had their medications altered.  Among cAL 
patients, 3 of those with >5 beats of VT were already taking B-blockers at the 
time of Holter monitoring and 5 commenced B-blockers after the finding of 
non-sustained VT.  Three patients with cAL amyloidosis had repeat Holter 
monitoring during which no further episodes of non-sustained VT were identified.  
Five cATTR patients had repeat Holter monitoring; 4 of 5 showed further 
episodes of non-sustained VT. 
 
  
 Chapter 5 
147 
 
 
 
Table 5.6 Type of Non Sustained Ventricular Tachycardia and Frequency of 
Events 
*Triplets: three consecutive ventricular depolarisations, ** Salvos: four or five 
consecutive ventricular depolarisations. 
Discussion 
 
Complex ventricular arrhythmias are reportedly common in AL amyloidosis, 
occurring in 47% of cases in one study.
236
 Studies to date have involved small 
patient numbers and have focussed predominantly on AL amyloidosis.  
Non-sustained VT was the most frequently identified arrhythmia among 24 
patients who underwent autologous stem cell transplantation and were associated 
with a higher risk of death.
241
 Data in patients with ATTR amyloidosis is 
extremely limited.  Three of six patients in one study were shown to have 
ventricular tachycardia.
236
 Patients with ATTR commonly have first and second 
degree heart block on the ECG. Prophylactic pacemakers were reported to prevent 
major cardiac events in 25% of 262 patients followed up in a recent study.
227
  The 
results in chapter 4 showed that having a pacemaker was a poor prognostic feature 
in patients with ATTRwt possibly indicating that rhythm disturbances may be a 
potentially significant cause of death in this group.  This study of 394 patients has 
Ventricular Tachycardia 
breakdown 
Cardiac AL 
(N = 37) 
Cardiac TTR 
(N = 28) 
Non-Cardiac 
(N = 12) 
Triplets only 10 (6.4) 6 (6.3) 5 (3.4) 
Salvos only 4 (2.5) 4 (4.2) 1 (0.6) 
Salvos and triplets 10 (6.4) 4 (4.2) 5 (3.4) 
More than 5 beats of VT 13 (8.3) 14 (14.8) 1 (0.7) 
Number of episode of more than 5 beats 
1 6 (3.8) 11 (11.7) 1 (0.7) 
2 3 (1.9) 3 (3.1) 0 (0) 
3 3 (1.9) 0 (0) 0 (0) 
>3 1 (1.64)* 5 runs 0 (0) 0 (0) 
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shown that arrhythmias are a common feature in patients with both cATTR and 
cAL, especially in cATTR. Complex ventricular arrhythmias were the most 
common finding and were present in 65% of cATTR patients and 45% of cAL 
patients followed by atrial fibrillation which featured in 43% of cATTR and 18% 
of cAL patients. 
 The cause of rhythm disturbances in amyloidosis is not well understood.  
In one study the hypothesis for the development of ventricular arrhythmias and 
sudden death was that microvascular amyloid deposition and inflammation 
possibly results in focal adrenergic receptor up-regulation and catecholamine 
hypersensitivity.
241
 An alternative hypothesis is that infiltration of the His-
Purkinje system may give rise to conduction abnormalities. Histologic 
examination has shown that amyloid fibrils infiltrate the cardiac conduction 
system and may preferentially involve His-purkinje fibres.
237, 238
 Prolonged infra-
His conduction times were commonly seen in one study of AL amyloidosis 
patients and were reported to be associated with sudden death.
242
 One might 
therefore expect that patients with greater interstitial expansion and thicker 
myocardial walls may have greater infiltration of the His-purkinje system and that 
there may be an association with more frequent arrhythmias; however we could 
find no significant association between wall thickness and frequency of 
arrhythmias. Similarly the MAYO staging system is a very strong predictor of 
outcome in AL amyloidosis,
88
 and a positive troponin T (effectively consistent 
with MAYO stage 3 disease) was a predictor of poor outcome in ATTRwt 
patients described in chapter 4.  If rhythm disturbances are significantly associated 
with poor outcome one might expect that patients with a poorer prognosis by 
MAYO staging would have more frequent dysrhythmias.  There was no 
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association in this study of more frequent complex ventricular arrhythmias and 
MAYO staging indicating that severity of cardiac disease does not necessarily 
correlate with arrhythmias. 
The precise mode of death associated with cardiac amyloidosis is poorly 
understood.  Electromechanical dissociation was reported by Kristen et al to be 
the cause of death in 7 of 19 patients who received prophylactic defibrillators. In 
the same study, two patients were successfully DC cardioverted following 
episodes of sustained ventricular tachyarrhythmias. This study concluded that 
prophylactic defibrillators are not beneficial for patients, however better selection 
of patients to identify those at risk of sustained ventricular tachyarrhythmias 
would aid in distinguishing patients who may benefit from insertion of 
prophylactic defibrillators.
228
 Couplets, complex ventricular arrhythmias and 
ventricular tachycardia were all associated with worse survival in one study 
however, only couplets were predictive of sudden cardiac death in AL 
amyloidosis.
75
 Median survival was not reached in any of the three groups in the 
study presented here and therefore robust conclusions cannot be made about 
predictors of survival. However atrial fibrillation and increasing grade of 
ventricular arrhythmia did appear to be associated with worse outcome in the cAL 
group. 
Non sustained VT was more commonly seen in patients with cATTR. 
Runs of non-sustained VT were mostly isolated events and were not seen again on 
repeat Holter monitors. The subsequent management of patients was in line with 
current guidelines, most patients were started on a B-blocker or had the dose 
increased after non-sustained VT was identified, and this may have affected the 
frequency of events on repeat testing.  Deaths in patients who had non-sustained 
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VT did not appear to be due to sudden cardiac events, however no deaths were 
monitored at the point of death and so the mode of death remains unknown. 
Study Limitations 
 
Median survival was not reached in this prospective study and therefore robust 
conclusions regarding predictors of patient outcome cannot yet be made.  Patients 
were followed for a median of 14 months and analysis of results was performed 6 
months after recruitment of the last patient.  Among patients with cAL 
amyloidosis, we can be more confident of the findings since median survival in 
isolated cardiac AL amyloidosis patients was 10 months (see chapter 4) such that 
the follow up period was potentially adequate.  Median survival in the ATTRwt 
patients is more than 2.5 years (see chapter 4), so the follow-up in this study is 
insufficient to draw any firm conclusions on risk factors for death. 
Holter monitors were performed at the initial assessment and therefore it 
was not possible to stop anti-arrhythmic agents 48 hours prior to monitoring 
occurring. We do not know the degree to which agents such as B-blockers prevent 
arrhythmias and the baseline frequency of arrhythmias may well be greater when 
patients are not taking medications.  This study was designed as a pilot study to 
decipher the frequency of rhythm disturbances in the types of amyloidosis which 
commonly affect the heart. It was deemed unethical not to treat patients in line 
with current guidelines when potentially harmful arrhythmias were identified. 
Recommendations were therefore made to treating physicians to commence anti-
arrhythmic agents in patients who had non-sustained VT.  The degree to which 
such therapies may have affected outcome remains unknown; a further study is 
therefore needed to ascertain whether anti arrhythmic agents are effective in 
cardiac amyloidosis. 
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This study was designed to measure the baseline frequency of arrhythmias in 
patients with cardiac amyloidosis. Patients were therefore recruited on the basis of 
suspected cardiac disease, and due to limited availability of holter monitors not all 
newly referred patients had holter monitoring on their first visit. This recruitment 
bias may influence the results as patients who were not suspected to have cardiac 
disease were excluded. It is possible that some patients with less severe cardiac 
disease may not have been included and patients who had Holters who were 
subsequently found not to have cardiac amyloid may be more likely to have 
previous cardiac arrhythmias. There were significantly more patients in the non-
cardiac AL group with a history of hypertension. This is likely to reflect 
recruitment bias and is a confounding factor which may influence the frequency 
of arrhythmias seen in the non cardiac group. 
A substantial proportion of patients had a previous history of ischaemic heart 
disease, a potentially significant confounding factor. The proportion of patients 
however with ischaemic heart disease was comparable in each group (P=0.162) it 
is possible that this could influence the overall frequency of arrhythmias, however 
it is unlikely to influence the differences between the three groups and therefore 
these patients were not excluded from analyses.  
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Chapter Six: Outcome in Renal AL Amyloidosis 
following Chemotherapy 
Introduction 
 
The first half of the thesis has concentrated on the epidemiology of amyloidosis 
and the cardiac disease phenotype. Comparison has been made between ATTRwt 
and cardiac AL amyloidosis. The focus of the thesis will now turn to the renal 
phenotype. ATTRwt is a predominantly cardiac disease and significant renal 
dysfunction is not seen. In AL amyloidosis renal involvement which frequently 
progresses to ESRF, is the commonest clinical manifestation of the disease. The 
diagnosis of AL amyloidosis is commonly obtained through renal histology.
243
 
Over the past 20 years the use of cytotoxic chemotherapy to suppress production 
of amyloidogenic monoclonal immunoglobulin has improved outcomes
78, 131,244-246
 
such that median survival in AL amyloidosis now exceeds three years.
247,248
  
Features at presentation that predict renal response
249
 and progression to dialysis 
have recently been reported,
127
 but modifiable factors that may influence renal 
outcome have been little studied and findings in the small published series are 
conflicting.
103
 Furthermore, the few studies of renal replacement therapy in AL 
amyloidosis have mostly comprised small numbers opatients with dismal 
survival.
103,104,250 
The aims of chapter 6 are to identify factors at baseline 
presentation that are associated with patient survival and renal outcome, and to 
assess outcome on dialysis in patients with AL amyloidosis. 
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Methods 
Patients 
 
We included in this study all 923 patients who were diagnosed with renal AL 
amyloidosis and were assessed for the first time at the NAC between March 1987 
and May 2008.  Renal involvement in AL amyloidosis was defined as non-Bence 
Jones proteinuria of >0.5 g/day according to the amyloidosis international 
consensus criteria.
60
 The diagnosis of AL amyloidosis was confirmed 
histologically in 853 cases and through a series of non-invasive investigations in 
the remaining 70 cases.  In the absence of a histological diagnosis of AL 
amyloidosis, the following criteria were required for inclusion in the study: 
amyloid deposition in the bones and viscera on 
123
I-labeled SAP scintigraphy; 
renal dysfunction fulfilling the amyloidosis international consensus criteria; 
evidence of a clonal B cell dyscrasia; absence of amyloidogenic mutations
44 
and 
absence of a chronic inflammatory disorder, or acute phase response.   
Patients underwent prospective protocolized 6 monthly assessments at the 
NAC.  
 
Assessment of Hematologic Response 
 
For all patients whose baseline visit to the NAC was after December 2001, serial 
FLC concentration was prospectively monitored on blood samples scheduled 
monthly during periods of chemotherapy treatment and 1-3 monthly during 
subsequent follow up.  For patients who were first evaluated before this time, FLC 
concentration was determined retrospectively wherever possible using archived 
serum samples obtained at the baseline NAC assessment and first follow up visit 6 
months later.   
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 Healthy, polyclonal serum FLC concentrations rise progressively through 
advancing stages of CKD
206
 which impedes the monitoring of monoclonal light 
chain disorders.  In this study, the value of the FLC ‘monoclonal component’ was 
estimated by subtracting the concentration of the uninvolved light chain from that 
of the amyloidogenic light chain, the FLC difference (dFLC), a strategy that has 
been validated in myeloma.
207
 The FLC response to chemotherapy was defined 
throughout the study as the percentage of the dFLC at baseline that remained at 
the time of analysis.  In order to validate the method in AL amyloidosis, dFLC 
response was included as a covariate in the patient survival analysis.  
FLC response was ‘time updated’ in analyses of patient and renal survival 
and was defined at 6 months from baseline in analyses of renal outcome by 
amyloidosis international consensus criteria.
60
 
 
Assessment of Renal Outcome 
 
Risk factors for progression to dialysis were analyzed among the 752 patients with 
a baseline eGFR of ≥15 ml/min, but not among the remaining 171 patients 
(Table 6.1).   
A separate analysis of factors influencing change in renal function from 
baseline according to the amyloidosis international consensus criteria and 
including both ‘renal response’ and ‘renal progression’ was undertaken in all 429 
patients with follow up renal data.  Patients who died (n=226) or started dialysis 
(n=111) within 6 months of their baseline NAC visit and those in whom there was 
no creatinine or proteinuria measurement recorded after 6 months from baseline 
(n=157) were excluded from this analysis (Table 6.1).  A 6 month time point from 
baseline was chosen because it corresponded to the first follow up visit during 
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which FLC response was routinely determined, and also allowed sufficient time 
for occurrence of a potential change in renal function.  Renal progression was 
defined as the earliest of: (i) starting dialysis; (ii) 50% increase in proteinuria 
AND increase by ≥1 g/day; or (iii) 25% increase in serum creatinine AND follow 
up creatinine >120 μmol/L.60 Renal response was defined as the earliest of: (i) 
50% decrease in proteinuria AND decrease by ≥0.5 g/day as long as creatinine 
had not increased by 25%; or (ii) 25% reduction in serum creatinine as long as 
proteinuria had not increased by 50%.
60
 
 
Survival Analyses and Statistical Methods 
 
Patient follow up was censored at date of last clinic visit before May 2008.  
Kaplan-Meier analyses and Cox regression were used to investigate factors 
associated with overall survival of all patients in the cohort.  Cox regression 
models were also used to: identify independent predictors of progression to 
dialysis-dependence among 752 patients with eGFR ≥15 ml/min at baseline, 
indentify predictors of either a ‘renal response’ or a ‘renal progression’ among 
429 patients; and define survival from commencement of dialysis among 
221 patients (Table 6.1).  All factors which were of statistical and/or clinical 
significance (P<0.20) in univariate analyses were included in multivariate 
analyses.  Cut points were chosen by their clinical relevance (ALP, bilirubin, 
albumin, CKD stage, and proteinuria) or on the basis of previously published 
work in amyloidosis (NT-proBNP, FLC concentration).  The log rank test was 
used to compare difference in stratified Kaplan-Meier survival analyses. 
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Table 6.1 Summary of Cohort and Sub Group Analysis in Patients with Renal AL Amyloidosis 
 
Analyses Patients Included and Excluded from Analysis Patient No. 
Factors influencing patient survival Exclusion    None  0 
Inclusion     All patients in the study 923 
Factors influencing progression to 
dialysis 
Exclusion    All patients with eGFR <15 ml/min at baseline 171 
Inclusion     All patients with eGFR ≥15 ml/min at baseline 752 
Factors influencing change in renal 
function  
Exclusion     Patients who died before 6 months follow up 
                      Patients who progressed to dialysis before 6 months follow up 
                      Patients without follow up renal data at or after 6 months 
226 
111 
157 
Inclusion      All patients with follow up renal data at or after 6 months 429 
Factors influencing patient survival 
from dialysis 
Exclusion     Non-dialysis patients 702 
Inclusion     All dialysis patients 221 
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Results 
 
Baseline Characteristics and Patient Survival 
 
Baseline characteristics of the patients are listed in Table 6.2.  The cohort of 923 
patients were followed for a median (IQR) of 22.4 (7.3, 49.0) months after 
diagnosis.  A total of 530 (57.4%) patients died.  The Kaplan-Meier median 
survival from diagnosis for the whole cohort was 35.2 (95% CI: 28.0, 42.0) 
months (Figure 6.1).  Median (IQR) time from diagnosis to baseline NAC visit 
was 2.8 (1.4, 5.8) months. 
NT-proBNP concentration at baseline was strongly associated with 
survival (Figure 6.2) and NT-proBNP >150 pmol/L remained significantly 
associated with mortality in multivariate analyses (P<0.0001).  There was a clear 
decreasing trend between risk of death and magnitude of FLC response to 
chemotherapy, with a hazard ratio for death of 0.73 (95% CI: 0.57, 0.92, P=0.01) 
for patients achieving a 50-90% FLC response, and 0.27 (95% CI: 0.18, 0.39, 
P<0.0001) for those achieving >90% FLC response compared to patients 
achieving <50% FLC response.  Other baseline factors associated with increased 
mortality were older age, lower urine protein, bilirubin >21 μmol/L, 
ALP >130 u/L, systolic blood pressure <120 mmHg, lower serum albumin and 
higher amyloidogenic serum FLC concentration (Table 6.3).  
Chapter 6 
 
159 
 
Table 6.2 Baseline Characteristics of Patients with Renal AL Amyloidosis (N=923) 
  N (%) 
Sex Male 524 (56.8) 
Age (years) Median (IQR) 62 (55, 70) 
Time from diagnosis to baseline evaluation (months) Median (IQR) 2.8 (1.4, 5.8) 
Year of amyloid diagnosis <2000 312 (33.8) 
 2001-2004 377 (40.9) 
 2005-2008 234 (25.4) 
Amyloid load by SAP scan Small 434 (47.1) 
 Moderate 222 (24.1) 
 Large 216 (23.4) 
 Missing 51 (5.5) 
Pre-treatment with chemotherapy Yes 329 (35.7) 
Chronic kidney disease stage 1 141 (15.3) 
 2 263 (28.5) 
 3 256 (27.7) 
 4 92 (10.0) 
 5 146 (15.8) 
 Missing  25 (2.7) 
Started dialysis before first visit   94 (42.5) 
Started dialysis within 6 months of first visit   42 (19.0) 
Started dialysis after 6 months from first visit  85 (38.5) 
Serum albumin (g/L) <25 332 (36.0) 
 26-35 354 (38.4) 
 >35 221 (23.9) 
 Missing  16 (1.7) 
24 hour urine protein (g) 0.5-3 264 (28.6) 
(BJP not included) 3.1-10 520 (56.3) 
 >10 109 (11.8) 
 Missing 30 (3.3) 
NT-proBNP (pmol/L) 0-35 97 (10.5) 
 36-150 95 (10.5) 
 151-400 76 (8.2) 
 >400 145 (15.7) 
 Missing 510 (55.3) 
Amyloidogenic light chain Lambda (%) / Kappa (%) 77.3% / 22.7% 
Laboratory markers at first visit  Median (IQR) 
Haemoglobin (g/dL)  12.5 (11.1, 14.0) 
Serum creatinine (μmol/L)  106 (78, 192) 
Creatinine clearance (ml/min)  54.4 (28.5, 81.6) 
eGFR (ml/min)  56 (27, 79) 
24 hour urine protein (g)  5.1 (2.5, 7.6) 
Serum albumin (g/L)  28 (23, 35) 
Bilirubin (u/L)  7 (5, 11) 
Alkaline phosphatase (u/L)  107 (76, 175) 
Systolic blood pressure (mmHg)  125 (110, 145) 
Diastolic blood pressure (mmHg)  76 (68, 85) 
Standing systolic blood pressure (mmHg)  123 (109, 140) 
Standing diastolic blood pressure (mmHg)  76 (66, 86) 
Lambda light chain in lambda patients (mg/L)  99.1 (37.5, 283.5) 
Kappa light chain in kappa patients (mg/L)  18.7 (9.7, 52.7) 
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Figure 6.1 Kaplan-Meier survival from diagnosis in systemic AL amyloidosis.  
Median (IQR) survival among 923 patients was 35.2 (28.0, 42.2) months.   
 
 
 
N  923   439      233      124         61          32 16   9 
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Figure 6.2 Survival from diagnosis stratified by NT-proBNP.  Survival was 
significantly better among patients with baseline NT-proBNP <150 pmol/L (black 
line) compared to those with NT-proBNP >150 pmol/L (grey line) (median 97.0 
vs 35.9 months; P<0.0001, log rank test).  
 
 
N   197         145              77              48        20               7 
N   223          97     46              19          7               3 
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Table 6.3 Factors Associated with Death in 923 Patients with Renal AL 
Amyloidosis 
 
   Univariate 
 
Multivariate 
  Died/Total (%) HR (95% CI) 
 
P-value HR (95% CI) P-value 
Dialysis (time-
updated) 
No 476/829 (57.4)1 1 0.02 1 0.06 
Yes 54/94 (57.4) 1.29 (1.04, 1.59)  0.77 (0.58, 1.01)  
Sex Male  314/524 (59.9) 1.27 (1.07, 1.51) 0.01 1.20 (1.00, 1.43) 0.05 
 Female 216/399 (54.1) 1  1  
FLC response <50% N/A
2 1 - 1 - 
(time updated) 50-90%  0.70 (0.55, 0.88) 0.05 0.73 (0.57, 0.92) 0.01 
 >90%  0.31 (0.21, 0.44) 0.003 0.27 (0.18, 0.39) <0.0001 
 Missing   1.27 (1.00, 1.62) <0.0001 0.82 (0.63, 1.08) 0.16 
Yr of baseline 
evaluation 
<2002 255/356 (71.6) 1.15 (0.96, 1.37) 0.12 0.60 (0.48, 0.76) <0.0001 
>2002 275/567 (48.5) 1  1  
Age at diagnosis Per 10 yr  
Higher 
 1.22 (1.12, 1.33) <0.0001 1.22 (1.11, 1.33) <0.0001 
NT-proBNP at 0-35 25/101 (24.8) 0.22 (0.14, 0.35) <0.0001 0.33 (0.20, 0.53) <0.0001 
baseline  36-150 34/96 (35.4) 0.39 (0.26, 0.58)  0.40 (0.26, 0.61)  
(pmol/L) 151-400 32/78 (41.0) 0.49 (0.33, 0.74)  0.56 (0.37, 0.85)  
 >400 83/148 (56.1) 1  1  
 Missing
3 356/500 (71.2) 1.22 (0.96, 1.56)  1.15 (0.88, 1.51)  
Baseline FLC 
concentration 
0-150 116/291 (39.9) 1 <0.0001 1 <0.0001 
151-500 155/273 (56.8) 1.96 (1.54, 2.49)  1.79 (1.39, 2.30)  
(mg/L) >500 123/190 (64.7) 2.27 (1.76, 2.93)  2.30 (1.76, 3.01)  
 Missing 136/169 (80.5) 3.99 (3.10, 5.12)  3.04 (2.27, 4.07)  
CKD Stage at 1-3 375/660 (56.8) 1 0.005 1 0.002 
baseline 4-5 140/242 (57.9) 1.26 (1.04, 1.53)  0.87 (0.68, 1.12)  
 Missing  15/21 (71.4) 1.96 (1.17, 3.28)  2.47 (1.42, 4.30)  
24 hr urine 
protein at  
0-3 166/264 (62.9) 1.37 (1.13, 1.65) <0.0001 1.34 (1.08, 1.66) <0.0001 
3-10 289/520 (55.6) 1  1  
baseline  >10 56/109 (51.4) 0.78 (0.59, 1.04)  0.60 (0.44, 0.82)  
(g/24 hr) Missing  19/30 (63.3) 1.94 (1.22, 3.08)  1.76 (1.03, 3.00)  
Bilirubin at  0-21 472/836 (56.5) 1 <0.0001 1 0.004 
baseline  >21 46/65 (70.8) 2.16 (1.59, 2.92)  1.52 (1.08, 2.13)  
(u/L) Missing 12/22 (54.5) 1.12 (0.63, 1.98)  4.09 (1.26, 13.24)  
Albumin at  <20 90/129 (68.8) 1.49 (1.16, 1.90) 0.01 2.73 (2.04, 3.63) <0.0001 
baseline  20-29 212/363 (58.4) 1.22 (1.01, 1.48)  1.56 (1.27, 1.92)  
(g/L) >30 221/419 (52.7) 1  1  
 Missing 7/12 (58.3) 1.08 (0.51, 2.30)  0.62 (0.14, 2.75)  
ALP at baseline 0-130 307/581 (52.8) 1 <0.0001 1 <0.0001 
(u/L) >130 214/326 (65.6) 1.81 (1.52, 2.16)  1.76 (1.45, 2.14)  
 Missing 9/16 (56.3) 1.03 (0.53, 2.01)  0.33 (0.06, 1.89)  
Systolic BP at <120 140/243 (57.6) 1 <0.0001 1 <0.0001 
baseline  >120 132/323 (40.9) 0.63 (0.49, 0.79)  0.72 (0.56, 0.93)  
(mmHg) Missing 258/357 (72.3) 1.55 (1.26, 1.91)  1.48 (1.18, 1.86)  
 
1
Numbers refer to dialysis at any time during follow up.  
2Not applicable since ‘time-updated’ 
and patients may move from one FLC response category to another.  
3
Despite missing NT-
proBNP data in 500 patients, there was no statistical difference in survival between ‘missing’ 
and <35 pmol/L categories. 
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Renal Outcome: Factors Influencing Progression to Dialysis 
 
Among 752 patients with an eGFR of ≥15 ml/min at baseline, 98 (13.0%) 
progressed to ESRF and received dialysis after a median of 26.8 months.  
Independent factors at baseline associated with progression to dialysis were higher 
CKD stage (HR for CKD stage 3: 2.06 (1.22, 3.49), and CKD stage 4: 7.07 (4.01, 
12.47) compared to CKD stage 2; P<0.0001) and lower serum albumin (3.04 
(1.57, 5.88) for albumin <20 g/L compared with >30 g/L; P=0.003).  FLC 
response was also significantly associated with progression to dialysis; patients 
with a 50-90% response (0.63 (0.39, 1.00), P=0.05) and those with a >90% 
response (0.24 (0.12, 0.49), P=0.0001) were less likely to progress to dialysis 
compared to patients with <50% response.   
 
Renal Outcome: Factors Influencing Change in Renal Function 
 
Among 429 patients evaluable for renal outcome by amyloidosis international 
consensus criteria, progression of renal disease from baseline occurred in 235 
(54.8%) patients and renal responses occurred in 140 (32.6%) cases.  
Interestingly, CKD stage at baseline did not significantly influence the chance of 
renal response with 27.3%, 33.5%, 33.6%, and 27.8% of patients with CKD 
stages 1, 2, 3 and 4 respectively achieving a renal response.  The median time 
from baseline NAC visit to renal progression was 23.8 (95% CI: 18.8, 33.5) 
months.  In univariate analyses, FLC response at 6 months from baseline 
(HR=0.32 (95% CI: 0.20, 0.52) for >90% response compared to <50% response), 
24hr urine protein (1.62 (1.15, 2.27) for urine >10 g compared with <3 g) and 
serum albumin (2.47 (1.71, 3.58) for albumin <20 g/L compared with >30 g/L) 
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were associated with an increased risk of renal progression.  Factors significantly 
associated with renal response and renal progression in multivariate analyses are 
shown in Table 6.4.  Importantly, achieving >90% FLC response at 6 months was 
associated with a near four-fold increase in the chance of renal response 
(P<0.0001) and a 68% reduction in the chance of renal progression (P<0.0001) 
when compared to an FLC response of 0-50%.  In sensitivity analyses, renal 
outcome was significantly better among patients with a >90% FLC response 
compared to those with 50-90% FLC response (P=0.0004 for renal progression; 
P<0.0001 for renal response).   
Among 253 non pre-treated patients, HR for renal progression among 50-
90% FLC responders was 0.67 (0.44, 1.02) and for >90% FLC responders was 
0.26 (0.14, 0.50) compared to <50% FLC responders (P=0.0002).  HR for renal 
response among non pre-treated patients who were 50-90% FLC responders was 
1.56 (0.77, 3.13) and for >90% FLC responders was 4.29 (2.15, 8.57) compared to 
<50% FLC responders (P<0.0001). 
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Table 6.4 Independent Factors Significantly Associated with Renal Progression and Renal Response among 429 Evaluable Patients 
 
  Renal Progression  Renal Response 
N (%) HR (95% CI) P-value N (%) HR (95% CI) P-value 
FLC response at 0-49% 77/120 (64.2) 1 <0.0001  23/120 (19.2) 1 <0.0001 
6 months 50-90% 97/163 (59.5) 0.76 (0.56, 1.04)   48/163 (29.4) 1.64 (0.99, 2.71)   
 >90% 21/65 (32.3) 0.32 (0.19, 0.52)   41/46 (89.1) 3.95 (2.36, 6.63)  
 Missing 40/81 (49.4) 0.52 (0.35, 0.78)   28/81 (34.6) 1.76 (0.98, 3.16)  
CKD stage 1 39/88 (44.3) 0.68 (0.47, 1.01) 0.003  Excluded from multivariate analyses
1
 
 2 88/164 (53.7) 1      
 3 71/119 (59.7) 1.24 (0.90, 1.71)      
 4 23/37 (62.2) 1.76 (1.09, 2.84)      
 5 9/14 (64.3) 1.71 (0.84, 3.45)      
 Missing 5/7 (71.4) 2.27 (0.91, 5.69)      
Serum albumin <20 g/L 42/54 (77.8) 2.74 (1.76, 4.27) <0.0001  9/54 (16.7) 0.33 (0.16, 0.69) 0.01 
 20-29 g/L 101/169 (59.8) 1.90 (1.37, 2.63)   43/169 (25.4) 0.57 (0.38, 0.85)  
 ≥30 g/L 88/202 (43.6) 1   86/202 (42.6) 1  
 Missing 
 
4/4 (100) 2.11 (0.72, 6.16)   2/4 (50.0) 0.58 (0.08, 3.99)  
 
235/429 (54.8%) experienced renal progression and 140/429 (32.6%) experienced renal response 
1
P=0.67 in univariate analyses 
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Dialysis Outcome 
 
Two hundred and twenty-one of 923 (23.9%) patients with renal AL amyloidosis 
received dialysis during the course of their disease, 127 only after their first visit 
to the NAC.  One hundred and fourteen of 221 (51.6%) dialysis dependent 
patients died and median survival from commencement of dialysis, which was 
unaltered by censoring at renal transplantation, was 39.0 (95% CI: 29.8, 
43.9) months (Figure 6.3).  Survival stratified by year of commencement of 
dialysis is shown in Figure 6.4.  Serum albumin <25 g/L (P=0.04) and alkaline 
phosphatase >130 u/L at commencement of dialysis (P=0.02) were significantly 
associated with mortality in multivariate analyses.   
 
Figure 6.3 Kaplan-Meier survival from commencement of dialysis in systemic 
AL amyloidosis. Median survival among all (n=221) patients from start of dialysis 
was 39.0 months.   
 
 
N   221  152 97      63       33      20      12        8        7        4 
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Figure 6.4 Patients who started dialysis after 2002 (black line) survived for 
significantly longer than those starting dialysis before 2002 (grey line) (median 
43.6 vs 29.8 months; P=0.05).   
 
 
N     85           59      45   33        19     17 
N   136           93      52   29        15               3 
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Discussion 
 
This study, comprising long-term follow up of a uniquely large cohort of 923 
patients with renal AL amyloidosis, demonstrates prolonged survival and superior 
renal outcomes among patients who achieved greater than 90% reduction in their 
dFLC value following chemotherapy.  The substantial survival advantage 
associated with an FLC response demonstrated here is completely consistent with 
previous studies in AL amyloidosis,
78, 125
 and the present series therefore validates 
the use of the dFLC method in this disease.  As CKD progresses, the 
concentration of healthy polyclonal and abnormal monoclonal FLCs increase 
progressively, reflecting reduced renal clearance and metabolism, invalidating the 
use of absolute FLC measurements for tracking hematologic response in patients 
with renal disease.  In contrast, the validity of dFLC measurements throughout all 
stages of CKD enabled estimation of the proportion of the amyloidogenic 
monoclonal light chain present at baseline that remained after chemotherapy. This 
has demonstrated for the first time a compelling and substantial relationship 
between magnitude of FLC response to chemotherapy and renal outcome.  FLC 
response at 6 months from baseline was independently associated with both 
improvement in renal function and renal progression among evaluable patients in 
this series with a >90% response conferring a near fourfold chance of renal 
response and a greater than 3 fold reduction in chance of renal progression 
compared to <50% FLC response (P<0.0001).  Other factors independently 
associated with renal progression and/or requirement for dialysis included lower 
eGFR, lower serum albumin and heavier proteinuria at presentation, consistent 
with previous reports.
127
 It is however important to recognize that management 
and outcome of individual patients is also governed by tolerability and toxicity of 
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treatment, and that the design of the present study did not ascertain renal 
progression or deaths that may have resulted from counterproductive attempts to 
translate a clonal PR to CR with additional chemotherapy.  It is also important to 
appreciate that the degree to which monoclonal light chain concentration needs to 
be suppressed in order to facilitate improvement in amyloidotic organ dysfunction 
differs not only between individuals but also between different organs within the 
same individual.  The present findings therefore do not imply that chemotherapy 
should necessarily target a >90% FLC response in all patients with renal AL 
amyloidosis, but, subject to prospective validation, the present findings support 
this general objective in the absence of undue toxicity from chemotherapy, guided 
by serial FLC measurements using the simple dFLC method.  The low proportion 
of patients reaching dialysis in this cohort in comparison to other series is likely to 
reflect the markedly different inclusion criteria; one cannot directly compare 
patients with renal AL amyloidosis according to amyloidosis international 
consensus criteria with patients who present with dominant renal AL amyloidosis.   
Independent factors associated with death in this series, along with <50% 
FLC response to chemotherapy, were older age, higher absolute baseline 
amyloidogenic FLC concentration and lower serum albumin at presentation.  In 
addition, systolic blood pressure <120 mmHg, higher NT-proBNP, and alkaline 
phosphatase and bilirubin outside the normal range at presentation, which are 
likely to reflect amyloidotic involvement of the autonomic nerves, heart and liver 
respectively, were associated with poorer survival.   
 Median survival from commencement of dialysis among 221 patients was 
>3 years, considerably longer than previously reported,
103,104,127,250
 and was 
43.6 months for patients starting after 2002.  The reasons for the prolonged 
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survival on dialysis in comparison to other series as well as the improved survival 
on dialysis among those commencing after 2002 remain unclear but, in the 
absence of evidence that the criteria for instituting dialysis differ or have changed 
over time respectively, are likely to reflect a combination of improved supportive 
management, improved dialysis techniques and better chemotherapy treatments 
for AL amyloidosis. 
Median survival from dialysis was not changed when censoring for 
transplantation. This may suggest that transplantation does not confer a survival 
benefit over dialysis, or too few patients may have been transplanted for a modest 
survival benefit to have an impact on the results. The results following 
transplantation will be described further in the next chapter. 
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Chapter Seven: Renal Transplantation in Systemic 
Amyloidosis – Importance of Amyloid Fibril Type 
and Precursor Protein Abundance 
Introduction 
 
The results of chapter 6 highlight the importance of suppression of the 
amyloid fibril precursor protein on patient outcome in AL amyloidosis. 
Progression to ESRF is common, in more recent years patients were shown to be 
surviving longer on dialysis. This has led to an increasing number of patients who 
may benefit from renal transplantation.  
There are 7 types of systemic amyloidosis which commonly affect the 
kidneys and cause progressive renal dysfunction and ESRF. Disease natural 
history and organ involvement vary widely according to amyloid type.  AA 
amyloidosis confers a better overall prognosis but is also typically associated with 
progression to ESRF which can be rapid.
86
 AFib, which presents universally with 
proteinuria, is also characterized by a progressive decline in kidney function to 
ESRF within 5 years of diagnosis.
45
  AApoAI is phenotypically heterogeneous but 
CKD is common and typically progresses more slowly to ESRF than AL, AA and 
AFib.
177
  Likewise, ALys usually causes slowly progressive CKD.
180, 252
 
The results of chapter 6 highlight the importance of suppression of the 
fibril precursor protein in AL amyloidosis with respect to altering disease natural 
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history and improving renal outcome. Similarly, suppression of SAA levels with 
anti-inflammatory therapy affects disease outcome in AA amyloidosis.
86
  
Fibrinogen A ∝-chain is synthesized by the liver alone253 and approximately 50% 
of plasma apolipoprotein A-I is liver derived.
176
 Orthotopic Liver Transplantation 
(OLT) therefore results in complete replacement of variant amyloidogenic 
fibrinogen in AFib and partial replacement of variant apoAI in AApoAI by the 
respective normal protein, and thus halts or slows amyloid accumulation.
165, 177, 254
  
It is not currently possible to alter the natural history of ALys. 
Renal transplantation remains a contentious issue in patients with systemic 
amyloidosis.  This is predominantly due to fears of early allograft loss from 
recurrent amyloid and poor outcomes related to progressive extra-renal 
amyloidosis.  Concerns that immunosuppression could increase the malignant 
potential of low grade plasma cell dyscrasias have also been expressed although 
remain largely unfounded.  Patient survival in AL amyloidosis has improved in 
association with an ever increasing armamentarium of available chemotherapeutic 
agents
130
 and similarly, there are new therapeutic options for patients with chronic 
inflammatory diseases.
255
 These advances mean that there are more ESRF patients 
with stable extra-renal AL and AA amyloid deposits.  A recent study of renal 
transplantation in AA amyloidosis found that 14% of patients developed recurrent 
disease in their graft which was associated with an increased risk of death. It was 
therefore hypothesized that there may be an association between SAA 
concentration and recurrent disease, this has yet to be systematically tested.
105
 
The aim of this chapter is to characterize outcome following renal 
transplantation in the different forms of renal amyloidosis and ascertain whether 
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suppression of the precursor protein prior to transplantation confers a benefit to 
graft outcome. 
 
Materials and Methods 
 
Patients 
 
All patients who received either a renal transplant (RTx) or combined liver kidney 
transplantation (CLKT) between January 1978 and May 2011 were identified 
from the NAC database.  The amyloid type was confirmed in each patient by 
review of histology
200
 and where appropriate, by additional genetic analysis, as 
previously described.
208
 The diagnosis of amyloidosis had been established prior 
to renal transplantation in 91 patients and only after renal transplantation in 13 
cases. 
Patients with AL amyloidosis were reviewed at the NAC every 6 months 
and those with AA and hereditary amyloidosis were reviewed annually.   
 
Assessment of Fibril Precursor Protein Abundance 
 
The clonal response was defined according to the minimum response achieved 
after renal transplantation (e.g. a complete clonal response must have been 
achieved throughout follow-up) by previously published criteria
60
 adapted for use 
in CKD
256
 as follows: CR was a normal FLC ratio and no detectable serum 
paraprotein or BJP, no response (NR) was a dFLC concentration  of >50% of the 
pre-treatment value, and partial response (PR) was a dFLC concentration of <50% 
the pre-treatment value in the absence of CR.   
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Among patients with AA amyloidosis response was defined according to 
serial SAA concentration, measured at each NAC appointment and at monthly 
intervals in between.
86
 Median SAA concentration was calculated for each year 
after renal transplantation and response was defined according to the minimum 
response after renal transplantation as follows: CR was a median SAA <10 mg/L, 
PR was defined as median SAA from 10-50 mg/L and NR >50 mg/L, as 
previously described.
85
 
Fibrinogen is made exclusively by the liver and the amyloidogenic variant protein 
disappears from the plasma after liver transplantation.
253
 Liver transplantation in 
AApoAI results in a 50% reduction in the plasma concentration of the 
amyloidogenic apoAI variant.
176
  
Serum lysozyme concentration changes with GFR and is associated with 
allograft function following renal transplantation.
257
 It is not known what 
proportion of variant lysozyme remains in the plasma after solid organ 
transplantation.  Patients with ALys were therefore excluded from the analysis of 
outcome by precursor protein response. 
 
Assessment of Recurrent Disease 
 
Recurrent amyloid in the graft was defined by abnormal uptake of tracer in the 
transplant on SAP scintigraphy (23 cases) and was corroborated by histology 
showing amyloid in 7 such cases.  Patients underwent renal biopsies where 
clinically indicated.  All cases that had recurrent amyloid on biopsy were 
associated with abnormal uptake of tracer within the allograft on SAP 
scintigraphy.  
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Assessment of Organ Function 
 
Renal allograft function was assessed at each NAC appointment by measurement 
of serum creatinine, MDRD eGFR, measured creatinine clearance and 24 hour 
urine protein.  Graft failure was defined as the date of recommencement of renal 
replacement therapy (RRT). 
 
Statistical Analysis 
 
Results are expressed as median and IQR or percentage.  Patients were 
censored at their last NAC clinic visit and patient and graft survival were 
estimated by Kaplan-Meier analyses.  Graft survival was non-censored for death; 
whereby death with a functioning graft was classified as graft loss.  The log rank 
test was used to compare the difference in stratified Kaplan-Meier survival 
analyses.  Statistical analysis was with the Man Whitney U test as all data 
analyzed was non-parametric (Graph pad prism version 5, Graph Pad, San Diego, 
Calif., USA). 
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Results 
 
One hundred and four patients with systemic amyloidosis received a total of 111 
renal transplants including 10 CLKTs and one combined cardiac and renal 
transplant.  Sixty patients (58%) were male and 29 (28%) patients received grafts 
from live donors.  A small proportion (12%) of patients received pre-emptive 
renal transplants; most commonly those with ALys where the rate of renal decline 
is typically slow (Table 7.1).  A variety of immunosuppression regimens were 
used in accordance with local protocols (Table 7.1).  Transplant survival differed 
between the different amyloid types and there appeared to be an association 
between natural history of disease and transplant survival, such that the 
amyloidosis syndromes associated with gradual loss of native eGFR, ALys and 
AApoAI, were associated with longer transplant survival than those known to 
cause rapid eGFR loss, AL, AA and AFib (Figure 7.1, log rank P=0.03).  Amyloid 
did not recur in the renal allograft of any patient who achieved complete 
suppression of the precursor protein throughout the duration of their follow up 
despite prolonged follow up after transplantation in certain patients (Figure 7.2).  
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Figure 7.1 Renal transplant survival in years, non-censored for death stratified by 
disease natural history.  Median survival in apolipoprotein A-I and lysozyme 
amyloidosis (slow natural history) was significantly longer than AL, AA and 
fibrinogen amyloidosis (fast natural history)  (Median survival 13.1 years vs. 8.3 
years; P = 0.03). 
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Figure 7.2 Time to recurrent amyloid in all patients by precursor protein 
abundance. 
 
 
 
*Patients with combined liver kidney transplant in Fibrinogen amyloid are defined 
as CR and those with renal transplant NR and patients with Apolipoprotein AI 
amyloidosis are defined as PR 
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Table 7.1 Baseline Characteristics and Outcome of Patients who Underwent Renal Transplantation (N=104).   
  No. of AL Patients 
N     (%) 
No. of AA Patients 
N      (%) 
No. of AFib Patients 
N       (%) 
No. of AApo AI Patients 
N     (%) 
No. of ALys Patients 
N       (%) 
Total Number of Patients  25 43 19 14 3 
Total number of grafts  25 46 21 16 3 
Total Number of Combined liver kidney transplants 0 0 9 2 0 
Sex Male 9 (36) 27 (62) 12 (63) 10 (71) 2 (66) 
Age a transplant (years) Median (IQR) 60 (52-63) 37 (29-48) 59 (56-61) 49 (37-56) 45 (32-62) 
Donors Live 5 (20) 16 (35) 2 (9.5) 3 (14) 3 (100) 
Pre-emptive Yes 1 (4) 3 (6.5) 5 (24) 1 (6.25) 2 (66) 
Time from diagnosis to ESRF (years) Median (IQR) 1.1 (0.0-3.6) 1.4 (0-5.8) 1.06 (0.03-1.6) 0.99 (0-27.4) 10.6 (0-14.6) 
Time from ESRF to first transplant 
(years) 
Median (IQR) 2.3 (1.1-5.0) 1.5 (0.9-3.0) 1.3 (0-2.8) 2.5(0.5-3.2) 0 (0-0.2) 
Amyloid load at presentation 
 
Small 
Moderate 
Large 
Missing2 
7 (28) 
8 (32) 
7 (28) 
3 (12) 
7 (16) 
26 (60) 
10 (23) 
0 (0) 
12 (63) 
6 (31.5) 
1 (5.5)) 
0 (0) 
2 (14.5) 
4 (28.5) 
8 (57) 
0 (0) 
0 (0) 
1 (33) 
2 (67) 
0 (0) 
Other organ involvement at 
presentation 
 
Cardiac 
Liver 
Spleen 
Adrenals 
5 (20) 
12 (48) 
21 (87.5) 
1 (4) 
0 (0) 
11 (25.5) 
43 (100) 
7 (16.2) 
0 (0) 
1 (5.2) 
17 (89.4) 
1 (5.2) 
1 (7.1) 
12 (85.7) 
14 (100) 
0 (0) 
0 (0) 
3 (100) 
2 (66.6) 
0 (0) 
3Underlying disease Hereditary fever syndrome 
Inflammatory bowel disease 
Inflammatory arthritis 
Recurrent infection 
Castleman’s 
Unknown 
 10 (23.2) 
9 (20.9) 
16 37.2) 
5 (11.6) 
2 (4.65) 
1 (2.32) 
   
4Number of lines of treatment 0 
1 
2 
3 
4 
3 (12) 
12 (48) 
6 (24) 
2 (8) 
2 (8) 
    
Immunosuppression regimen CNI/Pred/MMF 
CNI/Pred 
CNI/MMF 
Aza/Pred 
MMF/Pred 
CNI only 
Sirolimus/Pred/MMF 
Sirolimus only 
Pred only 
Unknown  
7 (28) 
5 (20) 
2 (8) 
1 (4) 
0 (0) 
2 (8) 
2 (8) 
1 (4) 
0 (0) 
5 (20) 
9 (20.9) 
9 (20.9) 
2 (4.6) 
7 (16.2) 
1 (2.3) 
3 (6.9) 
3 (6.9) 
0 (0) 
0 (0) 
9 (20.9) 
5 (26.3) 
3 (15.7) 
1 (5.2) 
2 (10.5) 
0 (0) 
0 (0) 
1 (5.2) 
0 (0) 
0 (0) 
7 (36.8) 
6 (42.8) 
3 (21.4) 
1 (7.1) 
1 (7.1) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
1 (7.1) 
2 (14.2) 
2 (66.6) 
0 (0) 
1 (33.3) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Grafts with recurrent amyloid Number 
Missing 
7 (28) 
2 (8) 
9 (19.5) 
4 (8.6) 
7 (33.3) 
0 (0) 
3(18.75) 
2 (12.5) 
0 (0) 
0 (0) 
Follow-up post transplant (years) Median (IQR) 4.6 (2.6-6.9) 5.1 (3.4-11.6) 3.3 (0.5-6.5) 9.8 (3-13.7) 2.9 (0.9-6.8) 
Number of deaths  13 (52) 16 (37.2) 7 (36.8) 1 (7.1) 0 (0) 
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AL Amyloidosis 
 
Twenty five of 246 (10.2%) patients with AL amyloidosis who received RRT 
underwent renal transplantation, among whom median time to ESRF from 
diagnosis of amyloidosis was 1.1 (IQR 0.0-3.6) years, and median time to 
transplantation from ESRF was 2.3 (IQR 1.1-5.0) years.  Median follow-up from 
transplantation was 4.6 (IQR 2.6-6.9) years.  Thirteen (52%) patients died, most 
commonly from infection (6 patients), with 1 patient each dying from GI blood 
loss and cardiac decompensation.  The remainder (5 patients) died from unknown 
causes.  No patient who died from infection was receiving chemotherapy at the 
time.  At the time of transplantation, amyloid was present in the spleen, liver and 
autonomic nerves in 21, 12 and 2 patients respectively.  Five patients had cardiac 
amyloidosis deemed ‘mild’ on the basis of their echocardiogram.  ECOG 
performance status was <2 in every case.  Presence of extra-renal involvement by 
amyloid did not significantly influence patient survival.  
Median graft survival was 5.8 years, 5 and 10 year graft survival was 74% 
and 25% respectively.  Two patients lost their grafts, one to chronic allograft 
nephropathy (CAN) after 2.9 years and one from recurrent transplant 
pyelonephritis and obstructive nephropathy after 0.9 years.  No grafts failed from 
recurrent amyloid, despite presence in 7 (28%) patients of renal allograft amyloid, 
diagnosed a median of 5.9 (IQR 3.8-6.3) years after transplantation.   
Twenty two patients (88%) received chemotherapy in total.  Clonal 
response at the time of transplantation was variable; 5 (20%) patients were in a 
clonal CR, 13 (52%) were in a PR and 3 (12%) cases had not achieved any clonal 
response or had not been treated prior to renal transplantation (Table 8.2).  Among 
21 patients who were evaluable for clonal response, 2 died within one year of 
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RTx, 18 were followed for more than one year post-RTx, and one was lost to 
follow-up (Table 7.3). There was no significant difference in renal allograft 
survival between patients who were in CR at the time of transplantation and those 
in PR although patients who had not achieved at least a PR prior to transplantation 
had significantly worse graft survival (5.3 vs 8.9 years; P = 0.02) (Figure 7.3).  
Five patients (28%) had a clonal relapse following transplantation after a median 
of 2.0 years for which 4 patients received further chemotherapy, 3 achieving a 
subsequent CR and 1 a PR. No patient developed symptomatic myeloma during 
follow-up. 
 
Table 7.2 Fibril Precursor Protein Response Prior to Renal Transplantation 
 
 
*In patients with AL amyloidosis; complete response (CR) is defined as normal 
free light chain ratio, no paraprotein or Bence Jones proteins, partial response 
(PR) is defined as dFLC response of >50% and no response (NR) a dFLC of 
<50%. (dFLC:  the difference between the involved and uninvolved light chain). 
 
Type of amyloid (precursor protein) 
 
Abundance of 
precursor protein 
 
No. (%) 
*AL (serum free light 
chain) 
Clonal response at 
transplantation 
CR 
PR 
NR 
unknown 
5 (20) 
13 (52) 
3 (12) 
4 (16) 
AA (Serum amyloid 
A protein) 
Median SAA (mg/L) 
during  6 months prior 
to transplantation 
<10 
10-50 
>50 
unknown 
13 (30.2) 
14 (32.5) 
4 (9.3) 
12 (27.9) 
AFib (variant 
fibrinogen) 
CLKT 
Kidney only 
Complete removal  
No reduction 
9 (47.3) 
10 (52.6) 
AApoAI (variant 
ApoAI) 
CLKT 
Kidney only 
50% reduction 
No reduction 
2 (12.5) 
14 (87.5) 
ALys (variant 
lysozyme) 
Kidney only No reduction 3 (100%) 
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Table 7.3 Response to Chemotherapy in 18 Evaluable Patients with AL Amyloidosis 
 
 
 
Patient 
no. 
 
 
Response at Tx 
Number 
of years 
followed-
up after 
transplant 
 
 
Dead/Alive 
 
Graft 
loss/ 
eGFR at 
last visit 
Relapse 
Y/N (year 
after Tx 
patient 
relapsed 
 
Chemotherapy after 
relapse 
Clonal  
response 
after 
further 
treatment 
 
Last known clonal 
response 
 
Recurrent amyloid 
in graft at last visit 
(yes/no) 
1  VGPR 6 Dead 33 No   VGPR Yes 
2  CR 8 Dead 18 No   CR No 
3  VGPR 8 Alive 49 Yes (2) Intermediate dose 
Melphalan  4 cycles 
CR CR No 
4  VGPR 12 Alive 37 Yes (3) CVAD 3 cycles CR CR Yes 
5  CR 6 Alive 39 No   CR No 
6  VGPR 2 Alive 55 Yes (1) Bortezomib/ 
Dexamethasone   
3 cycles 
CR CR No 
7  NR 5 Dead 30 No (*7) Melphalan/ 
Dexamethasone  
8 cycles 
PR PR Yes 
8  CR 4 Alive 41 No   CR No 
9  VGPR 4 Dead 78 No   VGPR Yes 
10  PR 3 Dead 48 Yes (1) nil  NR No 
11  NR 3 Dead 42 No   VGPR No 
12  VGPR 1 Dead 58 Yes (2) Cyclophosphamide 
/Dexamethasone  
5 cycles 
VGPR VGPR No 
13  NR 4 Alive 45 No   VGPR No 
14  VGPR 4 Alive 48 No   VGPR No 
15  PR 8 Alive 33 No   VGPR No 
16  VGPR 5 Dead 37 No   VGPR No 
17  CR 4 Alive 45 No   CR No 
18  CR 5 Alive 26 No   CR No 
*Patient 7 wasn’t treated with chemotherapy until progressive disease and recurrence in the graft was established 7 years after transplantation. 
CVAD - cyclophosphamide, vincristine, doxorubicin and dexamethasone, CR - complete response, VGPR - very good partial response, PR – 
partial response, NR – no response 
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Figure 7.3 Graft survival, non-censored for death in patients with AL amyloidosis 
according to clonal response at the time of transplantation. 
 
AA Amyloidosis 
 
Forty three of 128 (33.6%) patients with AA amyloidosis who required RRT 
underwent renal transplantation, receiving a total of 46 grafts.  The inflammatory 
diseases underlying AA amyloidosis included inflammatory arthritis in 16 
(37.2%) patients, hereditary periodic fever syndromes in 10 (23.2%), 
inflammatory bowel disease in 9 (20.9%), recurrent infection in 5 (11.6%), 
Castleman’s disease in 2 (4.7%) and was undefined in one patient.  Median time 
from diagnosis to ESRF was 1.4 (IQR 0-5.8) years, and median time from ESRF 
to transplantation was 1.5 (IQR 0.9-3) years.  Median follow-up from 
transplantation was 5.1 (IQR 3.4-11.6) years.  Sixteen (37.2%) patients died, most 
commonly from infection (6 cases).  One case each died from post transplant 
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lymphoproliferative disorder (PTLD), cervical malignancy, infarction of the 
transplant and bowel perforation and 6 from unknown causes.   
Median estimated graft survival non-censored for death was 10.3 years 
and 8 (18.6%) grafts had failed at censor.  Five and 10 year graft survival was 
86% and 59% respectively.  There was no significant difference in renal allograft 
survival between patients stratified by amyloid load or involvement of the liver, 
the latter being a measure of advanced AA amyloidosis.
258
 Nine patients (19.5%) 
had recurrent amyloid in their renal allograft diagnosed a median of 5.3 (IQR 2.0-
7.5) years after transplantation; 2 such cases lost their grafts due to recurrent 
amyloid.  Three patients received a second RTx after failure of the first: one from 
primary non function whose second renal allograft lasted 17 years; one after 24 
years from CAN whose second transplant is functioning well after one year; and 
one from recurrent amyloid after 8 years (six years after amyloid was first 
identified in the renal allograft) who died from sepsis one month after the second 
RTx.  
Twenty-nine patients had serial SAA monitoring in the 6 months prior to 
transplantation.  Graft survival non-censored for death was 14.5 years in patients 
with a median SAA value of <10 mg/L, and 7.8 years in those with a median SAA 
of >10 mg/L (P=ns).  Median SAA concentration was significantly higher among 
those with recurrent amyloid in their graft compared to those in whom amyloid 
did not recur (P=0.04) (Figure 7.4). 
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Figure 7.4 Median serum amyloid A protein concentration measured during the 6 
months prior to diagnosis of recurrent amyloid compared to the last 6 months of 
follow-up in patients without recurrent amyloid. 
 
 
Hereditary Fibrinogen A∝-Chain Amyloidosis (AFib) 
 
Nineteen of 51 (37.2%) patients with AFib who required RRT underwent renal 
transplantation receiving a total of 21 renal allografts including 9 patients who 
received CLKT.  One patient received CLKT following failure of an initial 
isolated renal transplant after 5.6 years; CLKT was the initial transplant procedure 
among the remainder.  Median time to ESRF from clinical presentation was 3.16 
(IQR 1.5-7.8) years and median time from ESRF to transplantation was 1.4 (IQR 
0-2.8) years.  Four of 10 patients with RTx died, two from malignancy, one 
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following a GI bleed and one from an unknown cause.  Among 9 patients who 
received CLKT, 3 (33.3%) died in the early post-operative course from peri-
operative complications.   
Median graft survival among patients who received isolated RTx (defined 
as NR) was 7.3 years compared to 6.4 years in those who received CLKT (defined 
as CR) (P=ns).  Five and 10 year graft survival was 85% and 30% in patients with 
an isolated RTx, and 63% and 31% in those with CLKT.  Recurrent amyloid was 
identified in the renal allografts of 7 patients, all of whom had isolated RTx, after 
a median of 4.9 (IQR 4.3-6.0) years.  No patient with CLKT developed renal 
allograft amyloid.  Four isolated RTx failed, 3 from recurrent amyloid and another 
from primary non function.  One patient was discovered to have renal allograft 
amyloid at the time of graft failure, and graft loss occurred 1.2 and 2.5 years after 
discovery of amyloid in the remaining 2 cases.  One CLKT patient lost their renal 
allograft after 6.5 years from CAN; none developed recurrent amyloid.   
 
Hereditary Apolipoprotein A-I Amyloidosis (AApoAI) 
 
Fourteen of 16 (87.5%) patients with AApoAI who required RRT underwent renal 
transplantation receiving a total of 16 renal allografts including 2 patients who 
received CLKT, one who was planned for CLKT but received the liver transplant 
alone due to intra-operative donor complications followed by a RTx 3 years later, 
and one who received a combined heart and renal transplant.  Median time from 
clinical presentation to ESRF was 5.9 (IQR 4.2-10.8) years.  Median time to 
transplantation from ESRF was 2.5 (IQR 0.5-3.2) years.  One patient died during 
follow-up from an unknown cause 13 years after renal transplantation. 
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Median graft survival non-censored for death was 13.1 years, significantly 
longer than patients with AA, AL, and AFib amyloidosis (P=0.02).  Five and 10 
year graft survival was 100% and 77% respectively.  Three patients (18.8%) all of 
whom had received isolated RTx, were found to have recurrent amyloid in their 
grafts after a median of 3.5 (IQR 2.8-17) years but this only caused graft loss in 1 
case after a further 2 years of follow up with the other 2 cases losing their grafts 
after 8.8 and 12.5 years from chronic allograft nephropathy.   
 
Hereditary Lysozyme Amyloidosis (ALys) 
 
Three of 3 patients with ALys who required RRT received renal transplants, all 
from living donors.  Two renal transplants were pre-emptive and the third patient 
only received dialysis for 2 months prior to RTx.  Decline in native renal function 
was very slow; the median time from diagnosis to ESRF was 10.6 (IQR 0-14.6) 
years.  All three grafts were functioning well 0.9, 2.9 and 6.2 years after RTx 
without evidence in any case of amyloid recurrence. 
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Discussion 
 
This study details outcome associated with RTx in different types of renal 
amyloidosis and in particular, highlights the importance of the natural history of 
particular types of amyloidosis disease on outcome.  The slowly progressive 
nature of ALys
252
 and AApoAI
177
 is well established and corroborated by a mean 
rate of eGFR loss among those with nephropathy visiting the NAC of only 
4.7 ml/min/yr (95% CI 0.9-8.6 ml/min/yr).  Despite the presence of extensive liver 
amyloid in most patients with these types of hereditary amyloidosis at the time of 
renal transplantation, and the persistent and undiminished production of the 
amyloid fibril precursor protein after the RTx procedure in all but 2 CLKT 
recipients, median estimated graft survival was 13.1 years with only 1/19 grafts 
lost to recurrent amyloid.  There was only one death after median follow-up from 
transplantation of 8.8 (IQR 1.9-12.5) years.  Furthermore, nearly all (17 of 19) 
patients with these types of amyloidosis who reached ESRF actually underwent 
renal transplantation.   
These findings contrast AL, AA and AFib which are known to be 
associated with a more rapid disease natural history reflected by greater rates of 
eGFR loss.
45, 256
  Until relatively recently there was a reluctance amongst 
nephrologists to proceed with renal transplantation in AA and AL amyloidosis 
due to the well documented risk of allograft failure from recurrent amyloid 
combined with the risk of death from progressive extra-renal amyloidosis.
259-261
  
Furthermore, amyloid typically recurs within renal transplants in AFib leading to 
graft failure between 5 and 12 years after RTx.
45
 The natural history of AA, AL 
and AFib are modifiable however. Suppression of the precursor protein (dFLC) 
was shown in chapter 6 to be associated with improved patient and renal outcome. 
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Similarly in AA amyloidosis the SAA level is associated with renal outcome.
86
 It 
stands to reason therefore, that the concentration of the fibril precursor protein is 
also likely to influence outcomes following renal transplantation.  In AFib the 
precursor protein is made in the liver and liver transplantation therefore removes 
the amyloidogenic protein thus preventing ongoing amyloid accumulation.
262, 263
 
This study demonstrates good transplant outcomes among carefully selected 
patients with AA and AL amyloidosis such that only about one third of ESRF 
patients with AA amyloidosis and ~10% of ESRF patients with AL amyloidosis 
underwent renal transplantation.  Median graft survival was 10.3 and 5.8 years in 
AA and AL patients in this series respectively.  Amyloid was detected in the renal 
allografts of 9/43 (21%) and 7/25 (28%) patients with AA and AL amyloidosis 
respectively, but only 2 of these 68 grafts failed from recurrent amyloid despite up 
to 25 years of follow up.  Graft outcomes were better among patients with 
suppression of the fibril precursor protein concentration prior to renal 
transplantation, and risk of amyloid recurrence in AA amyloidosis was higher 
among patients with elevated SAA levels.  To what extent the fibril precursor 
protein needs to be suppressed in any particular individual in order to prevent 
recurrence in the renal allograft is not known.  In this series there was no 
difference in renal allograft survival between AL amyloidosis patients who had 
achieved a clonal CR or clonal PR, although outcomes were poorer among those 
who had not achieved any clonal response prior to renal transplantation.  Five 
(28%) patients experienced a clonal relapse following renal transplantation, and 
all 4 of those who received chemotherapy achieved at least a partial clonal 
response following further treatment, with no detrimental effect on renal allograft 
function.  Based on this data, the recommendations would be to try and achieve at 
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least a partial clonal response in AL amyloidosis prior to listing for renal 
transplantation but that the absence of a complete clonal response should not 
preclude listing, particularly since it is usually possible to achieve a deeper clonal 
response with further chemotherapy once a patient has received a RTx.  Current 
practice is to list patients immediately once a clonal response has been obtained.   
The different amyloid types are associated with different patterns of organ 
involvement.
264
 Furthermore, there is considerable heterogeneity in organ 
involvement, even within the same amyloid type.  In this series, no relationship 
could be identified between patient survival and pattern of extra-renal organ 
involvement, nor total body amyloid burden.  Presence of extra-renal amyloid 
should not therefore exclude patients from being listed for RTx.  On the basis of 
this study the recommendation would be that as long as ECOG performance status 
and exercise tolerance are preserved, (thereby excluding patients with substantial 
cardiac and autonomic nerve involvement by amyloid), RTx should be 
considered, particularly if the extra-renal disease is stable in the context of a 
clonal response.  It is notable however, that very few patients had cardiac 
amyloidosis which is known to confer a poor prognosis in AL amyloidosis
265
 and 
is a rare complication of advanced AA amyloidosis.
266
  Acute cardiovascular 
events were recently reported to be a significant cause of death among renal 
transplant recipients with AA amyloidosis.
105
  There is little doubt that all patients 
with systemic amyloidosis should undergo an extensive cardiovascular assessment 
including specialized tests for presence and degree of cardiac amyloidosis prior to 
renal transplantation. 
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Chapter 8: General Conclusions 
 
The studies described in this thesis outline several novel findings concerning the 
incidence, prognosis and management of systemic amyloidosis.  
The epidemiology of amyloidosis in the UK has not previously been 
described, and there is historically only one publication from the US. Death 
certificates were shown here to be a reasonably sensitive method for detecting 
deaths attributable to systemic amyloidosis in England. Patients are being 
diagnosed with amyloidosis throughout England but there is a referral bias with 
significantly less patients from the North East, North West and Yorkshire seen at 
the NAC.  The proportion of individuals diagnosed with systemic amyloidosis 
who are seen at the NAC is increasing year on year. The annual incidence of 
systemic amyloidosis in 2008 was estimated to be 10 per million population 
which is comparable to the historical estimate of disease incidence from the US. 
ATTRwt is increasingly diagnosed in elderly patients attending cardiology 
clinics and the number of patients with the disease seen at the NAC is increasing 
dramatically. Accurately diagnosing fibril type in patients with isolated cardiac 
amyloidosis is paramount. Cardiac AL amyloidosis and ATTRwt are separate 
diseases with very different outcomes and management. Survival in ATTRwt is 
far superior to that in cardiac AL amyloidosis and chemotherapy is inappropriate 
in ATTRwt.  Troponin T, the need for a pacemaker and severe functional 
impairment (NYHA class IV symptoms) are associated with poor outcome in 
ATTRwt. Age at diagnosis and level of NT-proBNP can help to distinguish 
between patients with ATTRwt and isolated cardiac AL amyloidosis when there is 
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an underlying clonal disorder. In patients with isolated cardiac amyloidosis and no 
clonal disease the chance of the amyloid type being AL is less than 1%. 
Arrhythmic activity was frequently detected by 24 hour Holter monitoring 
among patients with cardiac amyloidosis. The most common abnormalities are 
complex ventricular arrhythmias and AF. There is a higher frequency of 
arrhythmic activity in cardiac ATTR amyloidosis than cardiac AL amyloidosis. 
Given that survival in AL amyloidosis is much shorter this may indicate that 
arrhythmic activity may not necessarily precipitate death in amyloidosis. The 
results of this Holter monitoring study could not determine a relationship between 
wall thickness or MAYO staging and frequency of complex ventricular 
arrhythmias, indicating that these two factors may not be a helpful way of 
identifying those who would benefit most from ICDs. Atrial fibrillation did appear 
to be associated with worse outcome; however median survival in this study was 
not reached. A further analysis after prolonged follow-up is necessary to 
determine outcomes and risk factors for death in cardiac amyloidosis. 
The dFLC method is an appropriate way of evaluating haematologic 
response in patients with varying degrees of renal dysfunction in AL amyloidosis. 
Patients who achieve a >90% dFLC response have prolonged survival and better 
renal outcomes. The results presented in this thesis have changed current 
management of patients with AL amyloidosis in the UK. The dFLC method has 
routinely been incorporated into the response assessment. The target of 
chemotherapy remains a CR however this is often not achievable without 
precipitating major toxicity in patients with AL amyloidosis, and a 90% dFLC 
response is now deemed sufficient in the vast majority of cases to allow treatment 
to be discontinued. Similarly during relapse further chemotherapy is now 
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frequently instituted when the light chain levels have risen to a <90% dFLC 
response (in those who achieved this initially) rather than waiting for a doubling 
of the serum free light chain as was historically recommended. 
Survival on dialysis has improved in recent years. Overall survival 
outcomes on dialysis among patients with AL amyloidosis were vastly superior to 
previous reports. This is likely to reflect a combination of more appropriate 
patient selection and improvements in supportive care, dialysis technique and 
advances in treatment with chemotherapy.  
Progression of extra-renal amyloid and risk of recurrent disease in the 
renal allograft have, until recently, been major barriers to renal transplantation in 
systemic amyloidosis.  No patient whose precursor protein was completely 
suppressed, regardless of amyloid type, developed recurrent disease in their graft.  
In diseases such as AL and AA amyloidosis where the precursor protein 
concentration can be modified by therapeutic intervention, it is important to 
monitor precursor protein concentration before and after renal transplantation.  In 
AFib the only currently available treatment to suppress precursor protein 
concentration is liver transplantation, and the high risk of peri-operative mortality 
with CLKT must be balanced against elimination of risk of recurrent amyloid 
disease in the allograft further down the line; current recommended practice is to 
consider CLKT in younger, AFib patients.
45
  In the hereditary amyloidoses with a 
slow natural history such as ALys and AApoAI, there is no need to suppress the 
precursor protein supply in order to prevent amyloid recurrence in the renal 
allograft since, in keeping with the disease natural history, this occurs extremely 
slowly.
177,252
 When considering any patient with systemic amyloidosis for renal 
transplantation, a search for presence of cardiac amyloidosis is mandatory. 
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Future Studies 
The results of chapter 4 described the presenting features and survival in ATTRwt 
amyloidosis. This is the largest retrospective study to date, and whilst it provides 
an initial insight into the disease there is much to learn about the natural history 
and long term follow-up. A prospective study of patients diagnosed with ATTRwt 
and hereditary TTR amyloidosis is planned. The aims of this study are to 
characterize the phenotype and clinical course of the disease in detail. Patients 
will be reviewed every six months and undergo serial CMR and 
99m
Tc-DPD 
scintigraphy, as well as quality of life assessments.  
The NAC has seen a massive increase in the number of patients with 
ATTRwt referred from cardiology clinics in the last 2 years. The true prevalence 
of the disease in the elderly population remains to be determined. 
99m
Tc-DPD 
scintigraphy has proven to be a useful tool for diagnosing transthyretin 
amyloidosis, and uptake into the myocardium appears to be very sensitive. 
Patients who present currently with cardiac amyloidosis, routinely have both SAP 
and 
99m
Tc-DPD scintigraphy as part of their initial assessment at the NAC. A 
further study is planned to estimate the prevalence of the disease in the elderly 
(over 80s). Subjects will be recruited from two groups; firstly 
99m
Tc-DPD 
scintigraphy will be performed in 150 subjects from the general population with 
no prior diagnosis of IHD or CCF, and secondly a further 150 will be recruited 
from open access echocardiography and cardiology clinics at the Royal Free 
Hospital. Patients who have positive 
99m
Tc-DPD scintigraphy will then be offered 
definitive investigations to diagnose the amyloid type and offered follow-up. 
The model in chapter 4 utilizes age and NT-proBNP to give a probability 
of either ATTRwt or AL amyloidosis. 
99m
Tc-DPD scintigraphy was not performed 
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in the majority of the cohort as it was not available. Now that 
99m
Tc-DPD 
scintigraphy is a routine test it would be interesting to develop a model which 
utilizes all three measures in order to increase the sensitivity and specificity of the 
model, and to prospectively assess the predictive power of these basic tools, in 
order to reduce the need for biopsies. 
In chapter 5 it was determined that arrhythmias are a common occurrence 
in cardiac amyloidosis, especially in ATTR type. The length of follow-up was 
insufficient to determine whether this has a significant impact on patient outcome, 
and more specifically sudden cardiac death. Further analysis is planned after 
prolonged follow-up to determine whether complex ventricular arrhythmias are 
associated with worse outcome. 
Little is known about the mode of death in patients with cardiac 
amyloidosis. Implantation of REVEAL devices into patients with a poor 
prognosis i.e. MAYO stage 3 in AL patients, and patients with a positive 
Troponin T and NYHA class IV in ATTRwt could potentially identify the cardiac 
rhythm at the time of death. These devices could also determine whether 
malignant arrhythmias predate sudden cardiac death, and therefore identify 
patients who might benefit from an ICD. 
The results of chapter 6 validated the dFLC method in AL amyloidosis and 
showed that a 90% reduction in dFLC conferred a greater chance of renal 
response. Since this data was published this target has been used in clinical 
practice. A prospective AL chemotherapy (Alchemy) study at the NAC has 
subsequently recruited 500 patients with systemic AL amyloidosis; this 
longitudinal observational study will determine the amount of treatment required 
and the toxicity associated with achieving this clonal response. It will also identify 
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the clonal responses that are actually achieved given this target and the rates of 
organ responses.  
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